WO2013173337A2 - Self-stabilizing linker conjugates - Google Patents
Self-stabilizing linker conjugates Download PDFInfo
- Publication number
- WO2013173337A2 WO2013173337A2 PCT/US2013/040951 US2013040951W WO2013173337A2 WO 2013173337 A2 WO2013173337 A2 WO 2013173337A2 US 2013040951 W US2013040951 W US 2013040951W WO 2013173337 A2 WO2013173337 A2 WO 2013173337A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- unit
- ligand
- drug
- linker
- conjugate
- Prior art date
Links
- 239000003814 drug Substances 0.000 claims abstract description 366
- 229940079593 drug Drugs 0.000 claims abstract description 362
- 125000005647 linker group Chemical group 0.000 claims description 328
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical group O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims description 258
- 239000003446 ligand Substances 0.000 claims description 167
- 238000006460 hydrolysis reaction Methods 0.000 claims description 148
- 230000007062 hydrolysis Effects 0.000 claims description 137
- 239000003795 chemical substances by application Substances 0.000 claims description 93
- 150000003839 salts Chemical class 0.000 claims description 93
- 229960002317 succinimide Drugs 0.000 claims description 90
- 125000006575 electron-withdrawing group Chemical group 0.000 claims description 83
- 206010028980 Neoplasm Diseases 0.000 claims description 82
- 125000002947 alkylene group Chemical group 0.000 claims description 77
- 125000006850 spacer group Chemical group 0.000 claims description 76
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 66
- -1 phosphoryl moiety Chemical group 0.000 claims description 61
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 60
- 238000000034 method Methods 0.000 claims description 57
- 229910052757 nitrogen Inorganic materials 0.000 claims description 57
- 201000011510 cancer Diseases 0.000 claims description 51
- 125000004429 atom Chemical group 0.000 claims description 49
- 239000000427 antigen Substances 0.000 claims description 45
- 108091007433 antigens Proteins 0.000 claims description 45
- 102000036639 antigens Human genes 0.000 claims description 45
- 125000000732 arylene group Chemical group 0.000 claims description 44
- 125000005549 heteroarylene group Chemical group 0.000 claims description 42
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims description 42
- 230000021615 conjugation Effects 0.000 claims description 41
- 238000001514 detection method Methods 0.000 claims description 39
- 125000000217 alkyl group Chemical group 0.000 claims description 37
- 229910052739 hydrogen Inorganic materials 0.000 claims description 34
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 32
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 29
- 239000001257 hydrogen Substances 0.000 claims description 27
- 150000003573 thiols Chemical group 0.000 claims description 24
- 239000003623 enhancer Substances 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 20
- 230000000087 stabilizing effect Effects 0.000 claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 19
- 208000023275 Autoimmune disease Diseases 0.000 claims description 17
- 150000003568 thioethers Chemical class 0.000 claims description 17
- 125000002393 azetidinyl group Chemical group 0.000 claims description 16
- 125000003386 piperidinyl group Chemical group 0.000 claims description 16
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 229910017711 NHRa Inorganic materials 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- 208000035473 Communicable disease Diseases 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 12
- 238000003379 elimination reaction Methods 0.000 claims description 12
- 150000002431 hydrogen Chemical class 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 10
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 9
- 125000001188 haloalkyl group Chemical group 0.000 claims description 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 5
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 5
- 108010016626 Dipeptides Proteins 0.000 claims description 4
- 238000009877 rendering Methods 0.000 claims description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 4
- 238000012546 transfer Methods 0.000 claims description 4
- 150000003335 secondary amines Chemical class 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 150000003923 2,5-pyrrolediones Chemical class 0.000 claims 1
- 150000003951 lactams Chemical class 0.000 claims 1
- 229920002857 polybutadiene Polymers 0.000 claims 1
- 239000000562 conjugate Substances 0.000 description 211
- 235000013350 formula milk Nutrition 0.000 description 83
- 235000002639 sodium chloride Nutrition 0.000 description 83
- 229940049595 antibody-drug conjugate Drugs 0.000 description 81
- 210000004027 cell Anatomy 0.000 description 63
- 239000000611 antibody drug conjugate Substances 0.000 description 41
- 102100031408 Acidic amino acid decarboxylase GADL1 Human genes 0.000 description 40
- 108091022873 acetoacetate decarboxylase Proteins 0.000 description 40
- 241000282414 Homo sapiens Species 0.000 description 36
- 150000001413 amino acids Chemical group 0.000 description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 29
- 229940024606 amino acid Drugs 0.000 description 28
- 235000001014 amino acid Nutrition 0.000 description 28
- 238000011282 treatment Methods 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 26
- 150000001875 compounds Chemical class 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 24
- 239000000203 mixture Substances 0.000 description 22
- 230000002829 reductive effect Effects 0.000 description 20
- 239000002253 acid Substances 0.000 description 19
- 125000003118 aryl group Chemical group 0.000 description 19
- 0 *CSC(CC(CO)=O)C(NC(CN)C(N*)=O)=O Chemical compound *CSC(CC(CO)=O)C(NC(CN)C(N*)=O)=O 0.000 description 18
- 229940127089 cytotoxic agent Drugs 0.000 description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 16
- 241000700159 Rattus Species 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 230000001472 cytotoxic effect Effects 0.000 description 15
- 208000035475 disorder Diseases 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 125000004432 carbon atom Chemical group C* 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 125000000524 functional group Chemical group 0.000 description 14
- 210000004881 tumor cell Anatomy 0.000 description 14
- 231100000433 cytotoxic Toxicity 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 150000001412 amines Chemical class 0.000 description 12
- 230000027455 binding Effects 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 230000037396 body weight Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 125000004434 sulfur atom Chemical group 0.000 description 11
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 10
- 230000001154 acute effect Effects 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 238000003776 cleavage reaction Methods 0.000 description 10
- 230000001085 cytostatic effect Effects 0.000 description 10
- 239000002254 cytotoxic agent Substances 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 125000005842 heteroatom Chemical group 0.000 description 10
- 238000011068 loading method Methods 0.000 description 10
- 238000004949 mass spectrometry Methods 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 150000003141 primary amines Chemical class 0.000 description 10
- 229910052717 sulfur Inorganic materials 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 125000003277 amino group Chemical group 0.000 description 9
- 239000002246 antineoplastic agent Substances 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 235000018417 cysteine Nutrition 0.000 description 9
- 125000000623 heterocyclic group Chemical group 0.000 description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 9
- 230000007017 scission Effects 0.000 description 9
- 208000011580 syndromic disease Diseases 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000004472 Lysine Substances 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 150000003857 carboxamides Chemical class 0.000 description 8
- 239000000824 cytostatic agent Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 125000001072 heteroaryl group Chemical group 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 208000032839 leukemia Diseases 0.000 description 8
- 229960003646 lysine Drugs 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- 238000004007 reversed phase HPLC Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- WZEAGSMYTVSXQA-XZZQEHRXSA-N [4-[[(2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]phenyl]methyl n-[(2s)-1-[[(2s)-1-[[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methox Chemical group C1([C@H](O)[C@@H](C)NC(=O)[C@H](C)[C@@H](OC)[C@@H]2CCCN2C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCC=2C=CC(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](N)C(C)C)=CC=2)C(C)C)OC)=CC=CC=C1 WZEAGSMYTVSXQA-XZZQEHRXSA-N 0.000 description 7
- 230000008030 elimination Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 239000004471 Glycine Substances 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
- 238000000429 assembly Methods 0.000 description 6
- 230000000712 assembly Effects 0.000 description 6
- 230000001363 autoimmune Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
- 229960002433 cysteine Drugs 0.000 description 6
- 231100000599 cytotoxic agent Toxicity 0.000 description 6
- 150000002019 disulfides Chemical class 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 229960002449 glycine Drugs 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 201000006747 infectious mononucleosis Diseases 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 6
- 235000018977 lysine Nutrition 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 238000001959 radiotherapy Methods 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
- AXKGIPZJYUNAIW-UHFFFAOYSA-N (4-aminophenyl)methanol Chemical compound NC1=CC=C(CO)C=C1 AXKGIPZJYUNAIW-UHFFFAOYSA-N 0.000 description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
- 239000004473 Threonine Substances 0.000 description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 229960003767 alanine Drugs 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- 229960003121 arginine Drugs 0.000 description 5
- 235000009697 arginine Nutrition 0.000 description 5
- 229960001230 asparagine Drugs 0.000 description 5
- 235000009582 asparagine Nutrition 0.000 description 5
- 229940049706 benzodiazepine Drugs 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 235000013922 glutamic acid Nutrition 0.000 description 5
- 229960002989 glutamic acid Drugs 0.000 description 5
- 239000004220 glutamic acid Substances 0.000 description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 5
- 229960002743 glutamine Drugs 0.000 description 5
- 229940127121 immunoconjugate Drugs 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 229960000310 isoleucine Drugs 0.000 description 5
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 5
- 229960003136 leucine Drugs 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 5
- 229960005190 phenylalanine Drugs 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 229960001153 serine Drugs 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 229960002898 threonine Drugs 0.000 description 5
- 229960004799 tryptophan Drugs 0.000 description 5
- 229960004441 tyrosine Drugs 0.000 description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
- 229960004295 valine Drugs 0.000 description 5
- 239000004474 valine Substances 0.000 description 5
- 235000014393 valine Nutrition 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 4
- 108090001090 Lectins Proteins 0.000 description 4
- 102000004856 Lectins Human genes 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 229940123237 Taxane Drugs 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 108010044540 auristatin Proteins 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 238000006210 cyclodehydration reaction Methods 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 239000003018 immunosuppressive agent Substances 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 239000002523 lectin Substances 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- FSQQTNAZHBEJLS-UPHRSURJSA-N maleamic acid Chemical compound NC(=O)\C=C/C(O)=O FSQQTNAZHBEJLS-UPHRSURJSA-N 0.000 description 4
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 3
- WJQDJDVDXAAXSB-UHFFFAOYSA-N 5-sulfanylidenepyrrolidin-2-one Chemical compound O=C1CCC(=S)N1 WJQDJDVDXAAXSB-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 239000012626 DNA minor groove binder Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940122803 Vinca alkaloid Drugs 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 229960005261 aspartic acid Drugs 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- 238000005815 base catalysis Methods 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000001268 conjugating effect Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 150000001945 cysteines Chemical class 0.000 description 3
- 229960003668 docetaxel Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 229940125721 immunosuppressive agent Drugs 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 150000002688 maleic acid derivatives Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229960002429 proline Drugs 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 231100000027 toxicology Toxicity 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
- WGMMKWFUXPMTRW-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[(2-bromoacetyl)amino]propanoate Chemical compound BrCC(=O)NCCC(=O)ON1C(=O)CCC1=O WGMMKWFUXPMTRW-UHFFFAOYSA-N 0.000 description 2
- PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 description 2
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 2
- XSAKVDNHFRWJKS-IIZANFQQSA-N (2s)-n-benzyl-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC=2C=CC=CC=2)CCC1 XSAKVDNHFRWJKS-IIZANFQQSA-N 0.000 description 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 206010001257 Adenoviral conjunctivitis Diseases 0.000 description 2
- 102100034452 Alternative prion protein Human genes 0.000 description 2
- 206010001935 American trypanosomiasis Diseases 0.000 description 2
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 2
- 201000002909 Aspergillosis Diseases 0.000 description 2
- 208000036641 Aspergillus infections Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
- 229960005532 CC-1065 Drugs 0.000 description 2
- RHQGFVOXIOMBMC-UUMMFNFXSA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)OCC2c3ccccc3-c3ccccc23)C(C)C)cc1)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)OCC2c3ccccc3-c3ccccc23)C(C)C)cc1)C(C)C RHQGFVOXIOMBMC-UUMMFNFXSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 208000024699 Chagas disease Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 201000003808 Cystic echinococcosis Diseases 0.000 description 2
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- LQKSHSFQQRCAFW-UHFFFAOYSA-N Dolastatin 15 Natural products COC1=CC(=O)N(C(=O)C(OC(=O)C2N(CCC2)C(=O)C2N(CCC2)C(=O)C(C(C)C)N(C)C(=O)C(NC(=O)C(C(C)C)N(C)C)C(C)C)C(C)C)C1CC1=CC=CC=C1 LQKSHSFQQRCAFW-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010014096 Echinococciasis Diseases 0.000 description 2
- 208000009366 Echinococcosis Diseases 0.000 description 2
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 208000005577 Gastroenteritis Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000007465 Giant cell arteritis Diseases 0.000 description 2
- 108010060309 Glucuronidase Proteins 0.000 description 2
- 102000053187 Glucuronidase Human genes 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930126263 Maytansine Natural products 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical class C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- OWPCHSCAPHNHAV-UHFFFAOYSA-N Rhizoxin Natural products C1C(O)C2(C)OC2C=CC(C)C(OC(=O)C2)CC2CC2OC2C(=O)OC1C(C)C(OC)C(C)=CC=CC(C)=CC1=COC(C)=N1 OWPCHSCAPHNHAV-UHFFFAOYSA-N 0.000 description 2
- 229910007161 Si(CH3)3 Inorganic materials 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 101800003344 Vaccinia growth factor Proteins 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical class C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 201000009361 ascariasis Diseases 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 108010046713 cemadotin Proteins 0.000 description 2
- 229950009017 cemadotin Drugs 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 229960005501 duocarmycin Drugs 0.000 description 2
- 229930184221 duocarmycin Natural products 0.000 description 2
- XOPYFXBZMVTEJF-PDACKIITSA-N eleutherobin Chemical compound C(/[C@H]1[C@H](C(=CC[C@@H]1C(C)C)C)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1OC(C)=O XOPYFXBZMVTEJF-PDACKIITSA-N 0.000 description 2
- XOPYFXBZMVTEJF-UHFFFAOYSA-N eleutherobin Natural products C1=CC2(OC)OC1(C)C(OC(=O)C=CC=1N=CN(C)C=1)CC(C(=CCC1C(C)C)C)C1C=C2COC1OCC(O)C(O)C1OC(C)=O XOPYFXBZMVTEJF-UHFFFAOYSA-N 0.000 description 2
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 2
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 2
- 229960001842 estramustine Drugs 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 238000005710 macrocyclization reaction Methods 0.000 description 2
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical group CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 2
- XMYQHJDBLRZMLW-UHFFFAOYSA-N methanolamine Chemical compound NCO XMYQHJDBLRZMLW-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 235000006109 methionine Nutrition 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- IDBIFFKSXLYUOT-UHFFFAOYSA-N netropsin Chemical compound C1=C(C(=O)NCCC(N)=N)N(C)C=C1NC(=O)C1=CC(NC(=O)CN=C(N)N)=CN1C IDBIFFKSXLYUOT-UHFFFAOYSA-N 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 150000003057 platinum Chemical class 0.000 description 2
- 229960003171 plicamycin Drugs 0.000 description 2
- 239000003880 polar aprotic solvent Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 2
- OWPCHSCAPHNHAV-LMONGJCWSA-N rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 201000004409 schistosomiasis Diseases 0.000 description 2
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 2
- 229940055619 selenocysteine Drugs 0.000 description 2
- 235000016491 selenocysteine Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000006379 syphilis Diseases 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 206010043207 temporal arteritis Diseases 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- HOFQVRTUGATRFI-XQKSVPLYSA-N vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- FKBHRUQOROFRGD-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2[C]3C=CC=CC3=NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC FKBHRUQOROFRGD-IELIFDKJSA-N 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- FLCQLSRLQIPNLM-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-acetylsulfanylacetate Chemical compound CC(=O)SCC(=O)ON1C(=O)CCC1=O FLCQLSRLQIPNLM-UHFFFAOYSA-N 0.000 description 1
- VRDGQQTWSGDXCU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-iodoacetate Chemical compound ICC(=O)ON1C(=O)CCC1=O VRDGQQTWSGDXCU-UHFFFAOYSA-N 0.000 description 1
- JSHOVKSMJRQOGY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCSSC1=CC=CC=N1 JSHOVKSMJRQOGY-UHFFFAOYSA-N 0.000 description 1
- GKSPIZSKQWTXQG-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[1-(pyridin-2-yldisulfanyl)ethyl]benzoate Chemical compound C=1C=C(C(=O)ON2C(CCC2=O)=O)C=CC=1C(C)SSC1=CC=CC=N1 GKSPIZSKQWTXQG-UHFFFAOYSA-N 0.000 description 1
- LGNCNVVZCUVPOT-FUVGGWJZSA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 LGNCNVVZCUVPOT-FUVGGWJZSA-N 0.000 description 1
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 1
- WOWDZACBATWTAU-FEFUEGSOSA-N (2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-n-[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 WOWDZACBATWTAU-FEFUEGSOSA-N 0.000 description 1
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 description 1
- IHUKVJKKTBLTEE-QMMMGPOBSA-N (2s)-2-acetamido-5-[[amino-(methylcarbamoylamino)methylidene]amino]-n-methylpentanamide Chemical compound CNC(=O)NC(N)=NCCC[C@H](NC(C)=O)C(=O)NC IHUKVJKKTBLTEE-QMMMGPOBSA-N 0.000 description 1
- VVQIIIAZJXTLRE-QMMMGPOBSA-N (2s)-2-amino-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound CC(C)(C)OC(=O)NCCCC[C@H](N)C(O)=O VVQIIIAZJXTLRE-QMMMGPOBSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- INAUWOVKEZHHDM-PEDBPRJASA-N (7s,9s)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7-[(2r,4s,5s,6s)-5-hydroxy-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1 INAUWOVKEZHHDM-PEDBPRJASA-N 0.000 description 1
- 125000006585 (C6-C10) arylene group Chemical group 0.000 description 1
- 125000006736 (C6-C20) aryl group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- FSQQTNAZHBEJLS-OWOJBTEDSA-N (e)-4-amino-4-oxobut-2-enoic acid Chemical group NC(=O)\C=C\C(O)=O FSQQTNAZHBEJLS-OWOJBTEDSA-N 0.000 description 1
- VYEWZWBILJHHCU-OMQUDAQFSA-N (e)-n-[(2s,3r,4r,5r,6r)-2-[(2r,3r,4s,5s,6s)-3-acetamido-5-amino-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)C(O)C[C@@H]2[C@H](O)[C@H](O)[C@H]([C@@H](O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O2)NC(C)=O)NC(=O)/C=C/CC(C)C)C=CC(=O)NC1=O VYEWZWBILJHHCU-OMQUDAQFSA-N 0.000 description 1
- OJQSISYVGFJJBY-UHFFFAOYSA-N 1-(4-isocyanatophenyl)pyrrole-2,5-dione Chemical compound C1=CC(N=C=O)=CC=C1N1C(=O)C=CC1=O OJQSISYVGFJJBY-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- WTTBAQAXSWGSLB-UHFFFAOYSA-N 2-(2,5-dioxopyrrolidin-1-yl)-6-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]hexanoic acid Chemical compound O=C1CCC(=O)N1C(C(=O)O)CCCCNC(=O)CCN1C(=O)C=CC1=O WTTBAQAXSWGSLB-UHFFFAOYSA-N 0.000 description 1
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 1
- DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical group SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 description 1
- YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical compound [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 description 1
- YIMDLWDNDGKDTJ-QLKYHASDSA-N 3'-deamino-3'-(3-cyanomorpholin-4-yl)doxorubicin Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1C#N YIMDLWDNDGKDTJ-QLKYHASDSA-N 0.000 description 1
- BBLXURZYMFSIKP-UHFFFAOYSA-N 3-(3,3-diaminopropanoyl)pyrrole-2,5-dione Chemical compound NC(N)CC(=O)C1=CC(=O)NC1=O BBLXURZYMFSIKP-UHFFFAOYSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical class C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- AUDYZXNUHIIGRB-UHFFFAOYSA-N 3-thiophen-2-ylpyrrole-2,5-dione Chemical compound O=C1NC(=O)C(C=2SC=CC=2)=C1 AUDYZXNUHIIGRB-UHFFFAOYSA-N 0.000 description 1
- QXZBMSIDSOZZHK-DOPDSADYSA-N 31362-50-2 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CNC=N1 QXZBMSIDSOZZHK-DOPDSADYSA-N 0.000 description 1
- UPMLOUAZCHDJJD-UHFFFAOYSA-N 4,4'-Diphenylmethane Diisocyanate Chemical compound C1=CC(N=C=O)=CC=C1CC1=CC=C(N=C=O)C=C1 UPMLOUAZCHDJJD-UHFFFAOYSA-N 0.000 description 1
- ROMPPAWVATWIKR-UHFFFAOYSA-N 4-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]butanoic acid Chemical compound O1C(CCCC(=O)O)=NC(C=2C=CC(Cl)=CC=2)=N1 ROMPPAWVATWIKR-UHFFFAOYSA-N 0.000 description 1
- WCVPFJVXEXJFLB-UHFFFAOYSA-N 4-aminobutanamide Chemical class NCCCC(N)=O WCVPFJVXEXJFLB-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- HBEDKBRARKFPIC-UHFFFAOYSA-N 6-(2,5-dioxopyrrol-1-yl)hexanoic acid;1-hydroxypyrrolidine-2,5-dione Chemical compound ON1C(=O)CCC1=O.OC(=O)CCCCCN1C(=O)C=CC1=O HBEDKBRARKFPIC-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 description 1
- VGGWNGWXGFWLRK-UHFFFAOYSA-N 8,9-dihydro-1H-[1,3]oxazolo[4,5-i][1,2]benzodiazepine Chemical class C1=CC=NNC2=C(OCN3)C3=CC=C21 VGGWNGWXGFWLRK-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 206010001324 Adrenal atrophy Diseases 0.000 description 1
- 208000000230 African Trypanosomiasis Diseases 0.000 description 1
- 208000008190 Agammaglobulinemia Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- FBEHFRAORPEGFH-UHFFFAOYSA-N Allyxycarb Chemical compound CNC(=O)OC1=CC(C)=C(N(CC=C)CC=C)C(C)=C1 FBEHFRAORPEGFH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024985 Alport syndrome Diseases 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- 208000035939 Alveolitis allergic Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000002045 Ancylostomiasis Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 208000033211 Ankylostomiasis Diseases 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 241001523209 Antissa Species 0.000 description 1
- 108010083590 Apoproteins Proteins 0.000 description 1
- 102000006410 Apoproteins Human genes 0.000 description 1
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- 208000006740 Aseptic Meningitis Diseases 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 1
- 108020003591 B-Form DNA Proteins 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 229930190007 Baccatin Natural products 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010044583 Bartonella Infections Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005098 Blastomycosis Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 208000031638 Body Weight Diseases 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- XNHJVZBXKLTKFO-UHFFFAOYSA-N CC(C)=[N](C)(C)=C Chemical compound CC(C)=[N](C)(C)=C XNHJVZBXKLTKFO-UHFFFAOYSA-N 0.000 description 1
- HPNODJVICKSGPQ-UHFFFAOYSA-N CCC(C)CNI Chemical compound CCC(C)CNI HPNODJVICKSGPQ-UHFFFAOYSA-N 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N CN1CCNCC1 Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- 201000002829 CREST Syndrome Diseases 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 101100217502 Caenorhabditis elegans lgg-3 gene Proteins 0.000 description 1
- 208000008889 California Encephalitis Diseases 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000020119 Caplan syndrome Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 102000003902 Cathepsin C Human genes 0.000 description 1
- 108090000267 Cathepsin C Proteins 0.000 description 1
- 102000003908 Cathepsin D Human genes 0.000 description 1
- 108090000258 Cathepsin D Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000026368 Cestode infections Diseases 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 208000000362 Chlamydial Pneumonia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 206010008761 Choriomeningitis lymphocytic Diseases 0.000 description 1
- 206010008803 Chromoblastomycosis Diseases 0.000 description 1
- 208000015116 Chromomycosis Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 241001327965 Clonorchis sinensis Species 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 208000010007 Cogan syndrome Diseases 0.000 description 1
- 208000011038 Cold agglutinin disease Diseases 0.000 description 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 101710184994 Complement control protein Proteins 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 206010010619 Congenital rubella infection Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010011416 Croup infectious Diseases 0.000 description 1
- 102100021906 Cyclin-O Human genes 0.000 description 1
- 206010011715 Cyclitis Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 239000012624 DNA alkylating agent Substances 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 241001050985 Disco Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010066486 EGF Family of Proteins Proteins 0.000 description 1
- 102000018386 EGF Family of Proteins Human genes 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 208000005235 Echovirus Infections Diseases 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014584 Encephalitis california Diseases 0.000 description 1
- 206010014614 Encephalitis western equine Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 206010014978 Epidemic pleurodynia Diseases 0.000 description 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
- 208000007985 Erythema Infectiosum Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000004332 Evans syndrome Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 201000005866 Exanthema Subitum Diseases 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000028387 Felty syndrome Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 201000006353 Filariasis Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 102000004862 Gastrin releasing peptide Human genes 0.000 description 1
- 108090001053 Gastrin releasing peptide Proteins 0.000 description 1
- 102100036519 Gastrin-releasing peptide Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 235000005612 Grewia tenax Nutrition 0.000 description 1
- 244000041633 Grewia tenax Species 0.000 description 1
- 208000012766 Growth delay Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 208000020061 Hand, Foot and Mouth Disease Diseases 0.000 description 1
- 208000025713 Hand-foot-and-mouth disease Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 201000006219 Herpangina Diseases 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 description 1
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 1
- 101000994378 Homo sapiens Integrin alpha-3 Proteins 0.000 description 1
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 1
- 101000994369 Homo sapiens Integrin alpha-5 Proteins 0.000 description 1
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101001090860 Homo sapiens Myeloblastin Proteins 0.000 description 1
- 101001099381 Homo sapiens Peroxisomal biogenesis factor 19 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 1
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 1
- 101000610602 Homo sapiens Tumor necrosis factor receptor superfamily member 10C Proteins 0.000 description 1
- 101000610609 Homo sapiens Tumor necrosis factor receptor superfamily member 10D Proteins 0.000 description 1
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 description 1
- 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 206010020376 Hookworm infection Diseases 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102100025323 Integrin alpha-1 Human genes 0.000 description 1
- 102100025305 Integrin alpha-2 Human genes 0.000 description 1
- 102100032819 Integrin alpha-3 Human genes 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- 102100032817 Integrin alpha-5 Human genes 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010023076 Isosporiasis Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- KJQFBVYMGADDTQ-CVSPRKDYSA-N L-buthionine-(S,R)-sulfoximine Chemical compound CCCCS(=N)(=O)CC[C@H](N)C(O)=O KJQFBVYMGADDTQ-CVSPRKDYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 201000009908 La Crosse encephalitis Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000004204 Larva Migrans Diseases 0.000 description 1
- 206010023927 Lassa fever Diseases 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 206010024641 Listeriosis Diseases 0.000 description 1
- 208000002041 Loiasis Diseases 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 208000030156 Marburg disease Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 206010027201 Meningitis aseptic Diseases 0.000 description 1
- 241000002163 Mesapamea fractilinea Species 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 201000000090 Microsporidiosis Diseases 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 206010028424 Myasthenic syndrome Diseases 0.000 description 1
- 241000041810 Mycetoma Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 102100034681 Myeloblastin Human genes 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 108010042309 Netropsin Proteins 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010029443 Nocardia Infections Diseases 0.000 description 1
- 206010029444 Nocardiosis Diseases 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000010505 Nose Neoplasms Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 241000243985 Onchocerca volvulus Species 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- 241000842783 Orna Species 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108010035042 Osteoprotegerin Proteins 0.000 description 1
- 102000008108 Osteoprotegerin Human genes 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910018828 PO3H2 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241000935974 Paralichthys dentatus Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 102100038883 Peroxisomal biogenesis factor 19 Human genes 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 206010035673 Pneumonia chlamydial Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010036631 Presenile dementia Diseases 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 206010037688 Q fever Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 201000007981 Reye syndrome Diseases 0.000 description 1
- 208000034712 Rickettsia Infections Diseases 0.000 description 1
- 241000606723 Rickettsia akari Species 0.000 description 1
- 201000004282 Rickettsialpox Diseases 0.000 description 1
- 206010061495 Rickettsiosis Diseases 0.000 description 1
- 206010039207 Rocky Mountain Spotted Fever Diseases 0.000 description 1
- 208000036485 Roseola Diseases 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 208000007893 Salpingitis Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 206010041736 Sporotrichosis Diseases 0.000 description 1
- 206010041896 St. Louis Encephalitis Diseases 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042938 Systemic candida Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 description 1
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 208000004938 Trematode Infections Diseases 0.000 description 1
- 206010044608 Trichiniasis Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010044696 Tropical spastic paresis Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 1
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 1
- 102100040115 Tumor necrosis factor receptor superfamily member 10C Human genes 0.000 description 1
- 102100040110 Tumor necrosis factor receptor superfamily member 10D Human genes 0.000 description 1
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 description 1
- 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 206010047505 Visceral leishmaniasis Diseases 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000005466 Western Equine Encephalomyelitis Diseases 0.000 description 1
- 201000005806 Western equine encephalitis Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 206010061418 Zygomycosis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 201000007691 actinomycosis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
- 208000036676 acute undifferentiated leukemia Diseases 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 201000003462 adenoid hypertrophy Diseases 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 230000003429 anti-cardiolipin effect Effects 0.000 description 1
- 230000003476 anti-centromere Effects 0.000 description 1
- 230000002583 anti-histone Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000002529 anti-mitochondrial effect Effects 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 201000008680 babesiosis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 206010004145 bartonellosis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 description 1
- 201000007180 bile duct carcinoma Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Chemical class 0.000 description 1
- 208000015440 bird fancier lung Diseases 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- KDPAWGWELVVRCH-UHFFFAOYSA-M bromoacetate Chemical compound [O-]C(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-M 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 201000006824 bubonic plague Diseases 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
- 229930195731 calicheamicin Natural products 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000005587 carbonate group Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 description 1
- 150000004814 combretastatins Chemical class 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 201000010549 croup Diseases 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 150000003950 cyclic amides Chemical class 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 201000008167 cystoisosporiasis Diseases 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 208000008576 dracunculiasis Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000010582 ecthyma Diseases 0.000 description 1
- 208000000292 ehrlichiosis Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 206010014881 enterobiasis Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 208000021373 epidemic keratoconjunctivitis Diseases 0.000 description 1
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 208000001606 epiglottitis Diseases 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 208000024711 extrinsic asthma Diseases 0.000 description 1
- 208000006275 fascioliasis Diseases 0.000 description 1
- 206010016235 fasciolopsiasis Diseases 0.000 description 1
- 201000006061 fatal familial insomnia Diseases 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 description 1
- 201000005298 gastrointestinal allergy Diseases 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 239000003168 generic drug Substances 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 201000006592 giardiasis Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 150000008134 glucuronides Chemical group 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 125000005179 haloacetyl group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000025750 heavy chain disease Diseases 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 208000003215 hereditary nephritis Diseases 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000029080 human African trypanosomiasis Diseases 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000005462 imide group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 125000003010 ionic group Chemical group 0.000 description 1
- 238000000752 ionisation method Methods 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 208000001419 lymphocytic choriomeningitis Diseases 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 239000012516 mab select resin Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 201000011475 meningoencephalitis Diseases 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- AUHZEENZYGFFBQ-UHFFFAOYSA-N mesitylene Substances CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 1
- 125000001827 mesitylenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical group C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 201000007524 mucormycosis Diseases 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000001167 myeloblast Anatomy 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- 208000037830 nasal cancer Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 208000037931 necrotizing enteritis Diseases 0.000 description 1
- 230000007524 negative regulation of DNA replication Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229950006344 nocodazole Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 1
- 208000003177 ocular onchocerciasis Diseases 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 208000003692 opisthorchiasis Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- CWODDUGJZSCNGB-HQNRRURTSA-N palytoxin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CCCCC[C@H](C)C[C@@H]2[C@@]3(C)C[C@H](C)C[C@@](O3)(CCCCCCC[C@H](O)C[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@](O)(C[C@H](O)[C@@H](C)\C=C\[C@@H](O)CC[C@@H](O)[C@@H](O)[C@H]4O[C@H](C[C@@H](O)[C@H](O)C[C@@H]5[C@H]([C@H](O)[C@@H](O)[C@H](C[C@H](O)\C=C/C=C/C[C@@H](O)[C@H](O)[C@H](O)C\C=C/C(=C)CC[C@H](O)[C@@H](O)[C@H](O)[C@H](C)C[C@@H]6[C@@H]([C@@H](O)[C@H](O)[C@@H](\C=C/[C@@H](O)[C@H](O)C[C@H]7O[C@H]8C[C@H](O[C@@H]8CC[C@@H]8[C@@H](C[C@@H](CN)O8)O)C7)O6)O)O5)O)[C@@H](O)[C@H](O)C4)O3)O)O2)[C@H](C[C@H](O)[C@H](O)C(\C)=C\[C@H](O)C[C@@H](C)[C@H](O)C(=O)N\C=C\C(=O)NCCCO)[C@H](O)[C@@H](O)[C@@H]1O CWODDUGJZSCNGB-HQNRRURTSA-N 0.000 description 1
- 229960005548 palytoxin Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 201000001369 pharyngoconjunctival fever Diseases 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 208000030773 pneumonia caused by chlamydia Diseases 0.000 description 1
- 229920000889 poly(m-phenylene isophthalamide) Polymers 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Chemical group 0.000 description 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
- 210000004765 promyelocyte Anatomy 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000018883 protein targeting Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- IFOHPTVCEBWEEQ-UHFFFAOYSA-N pyrrolo[2,3-i][1,4]benzodiazepine Chemical class N1=CC=NC2=C3C=CN=C3C=CC2=C1 IFOHPTVCEBWEEQ-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000002534 radiation-sensitizing agent Substances 0.000 description 1
- 208000010563 rat-bite fever Diseases 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000002407 reforming Methods 0.000 description 1
- 208000007865 relapsing fever Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000030925 respiratory syncytial virus infectious disease Diseases 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 201000006476 shipyard eye Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000002612 sleeping sickness Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- DFVFTMTWCUHJBL-BQBZGAKWSA-N statine Chemical compound CC(C)C[C@H](N)[C@@H](O)CC(O)=O DFVFTMTWCUHJBL-BQBZGAKWSA-N 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 208000005057 thyrotoxicosis Diseases 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 208000003982 trichinellosis Diseases 0.000 description 1
- 201000007588 trichinosis Diseases 0.000 description 1
- 208000009920 trichuriasis Diseases 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 208000006961 tropical spastic paraparesis Diseases 0.000 description 1
- 239000003744 tubulin modulator Substances 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 206010061393 typhus Diseases 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-M valerate Chemical compound CCCCC([O-])=O NQPDZGIKBAWPEJ-UHFFFAOYSA-M 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229920003169 water-soluble polymer Chemical group 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Definitions
- ADC antibody-drug conjugate
- the invention provides inter alia, Linkers, Drug-Linkers, Ligand-Drug Conjugates, Ligand-Linker Conjugates, Ligand-Functional Agent Conjugates, and Functional Agent-Linkers, and methods of preparing and using them.
- the Ligand-Drug Conjugates are stable in circulation, yet capable of inflicting cell death once released in the vicinity or within tumor cells.
- Figure 1 provides a reaction scheme illustrating the reduction of the interchain disulfides of a human IgGl , followed by conjugation of the resulting thiols with a self-stabilizing linker and subsequent hydrolysis of the succinimide ring (Top); and the use of mass spectrometry to monitor the change in the molecular weight of the antibody conjugates due to hydrolysis (Bottom).
- FIG. 2 illustrates the timecourse of succinimide ring hydrolysis of a self-stabilizing antibody conjugate by electrospray mass spectrometry.
- Conjugation of fully reduced cACI O with maieimido-DPR-val-cit-PAB-MMAE was performed at pH 7.2 and 22°C, then samples were subjected to analysis by LC-MS at the indicated times (Top).
- the resulting data of % hydrolysis was plotted versus time and fit to an exponential equation to determine kinetic parameters (Bottom).
- Figure 3 provides the hydrolysis kinetic profiles for bioconjugates prepared with an IgGl antibody and self-stabilizing linkers with varying spacing between the maleimide and the basic group (a primary amine). Conjugation was performed at pH 8 and 37°C, then hydrolysis of the IgGl light chain conjugate was immediately monitored by mass spectrometry, plotted as a function of time, and fit to an exponential equation.
- Figure 4 provides kinetic profiles of the hydrolysis of bioconjugates prepared with an IgG l antibody and self-stabilizing maleimide linkers with varying spacing between the maleimide and the basic group (a primary amine). Conjugation was performed at pH 8 and 37°C, then hydrolysis of the IgG l light chain conjugate was immediately monitored by mass spectrometry, plotted as a function of time, and fit to an exponential equation.
- Figure 5 provides hydrolysis kinetic profiles for bioconjugates prepared with an IgGl antibody and various N-substituted maieirnides. Conjugation was performed at pH 7.4 and 22°C, then hydrolysis of the IgG l light chain conjugate was immediately monitored by mass spectrometry, plotted as a function of time, and fit to an exponential equation. Hydrolysis of the maleimido-caproyl conjugate (bottom structure) is too slow to produce any detectable hydrolysis in 24 hours under these conditions.
- Figure 6 provides hydrolysis kinetic profiles for self-stabilizing maleimido drug- linkers prepared with et-diaminopropionic acid (a-DPR, open circles) and with ⁇ - diaminopropionic acid ( ⁇ -DPR, filled circles). Although isomers of each other, the positioning of the basic amino group and the electron withdrawing carboxamide relative to the succinimide results in a 17-fold difference in the rate of succinimide hydrolysis.
- Figure 7 illustrates the change in drug loading over time for an ADC prepared with a self-stabilizing maleimido-DPR drug-linker versus one prepared with a maieimido-caproyl drug linker when incubated in a buffer containing excess thiol.
- the reversed -phase chromatograms of the two ADCs at lime zero and time 14 days after incubation is shown in the top panel.
- Chromatographic peak assignments L0, LI , HO, HI, H2, and H3 correspond to unconjugated light chain, light chain with one drug, unconjugated heavy chain, and heavy chain with 1 , 2, or 3 drugs, respectively.
- the self-stabilizing maleimido-DPR drug-linker is represented with open circles versus one prepared with a maieimido-caproyl drug linker (open squares). Drug loading remains constant at 8 per antibody for the self-stabilizing drug-linker (open circles), but falls to 4 drugs per antibody over 14 days for the maieimido-caproyl drug linker (open squares), reflecting loss of drug by maleimide elimination.
- ADC samples at each timepoint were purified by Ig Select affinity resin and their drug loading evaluated by reversed-phase HPLC analysis of the ADCs.
- ADCs were captured on Protein A affinity resin at each timepoint and the drug released enzymatically via its protease-cleavable linker. The released drug was then quantified by LC- MS/MS and normalized to the initial value. Each timepoint reflects the percent of the conj ugated drug that was observed at tO.
- ADCs were dosed i.v. and plasma samples from each timepoint were purified by Ig Select affinity resin and their drug loading evaluated by reversed-phase HPLC analysis of the ADCs.
- FIG 11 illustrates the antitumor activity of ADCs in a murine xenograft model of ALCL (Karpas-299 cell line).
- ADCs were prepared with the anti-CD3G antibody cACl O and drug linkers containing the val-cit-PAB-MMAE cytotoxic payload linked to the antibody via either a maleimido-caproyl group (closed circles) or a self-stabilizing maleimido-DPR group (open circles).
- Tumors were allowed to reach a volume of approximately 250 mm J before dosing at 1 mg/kg weekly for three doses (six mice per dose group).
- the self-stabilizing ADC dose group experienced complete responses (no detectable tumor) in all six animals, with five animals experiencing durable regressions, while the maleimido-caproyl ADC experienced no complete responses.
- trade name includes the product formulation, the generic drug, and the active pharmaceutical ingredient(s) of the trade name product, unless otherwise indicated by context.
- electron-withdrawing group refers to a functional group that draws electrons away from a reaction center.
- electron withdrawing groups can also include aryl groups (e.g., phenyl) and certain heteroaryj groups (e.g., pyridine).
- electron withdrawing groups includes aryls or heteroaryls further substitued with electron withdrawing groups.
- base refers to a functional group that deprotonates water to produce a hydroxide ion.
- exemplary bases are amines and nitrogen containing heterocycles.
- Representative bases include -N(R 3 )(R 4 ) wherein R 3 and R 4 are independently selected from H or Ci-6 alkyl, preferably H or methyl,
- R 5 , R & , R 7 and R 8 are, at each occurrence, independently selected from hydrogen or Ci-g alky], preferably H or methyl, and e is 0-4.
- the base is a nitrogenous base.
- antibody herein is used in the broadest sense and specifically covers intact monoclonal antibodies, polyclonal antibodies, monospecific antibodies, muitispecific antibodies (e.g., bispecific antibodies), and antibody fragments that exhibit the desired biological activity.
- An intact antibody has primarily two regions: a variable region and a constant region.
- the variable region binds to and interacts with a target antigen.
- the variable region includes a complementary determining region (CDR.) that recognizes and binds to a specific binding site on a particular antigen.
- CDR. complementary determining region
- the constant region may be recognized by and interact with the immune system (see, e.g., Janeway et al, 2001, Immuno, Biology, 5th Ed., Garland Publishing, New York).
- An antibody can be of any type (e.g. , IgG, IgE, IgM, IgD, and IgA), class (e.g., IgGl, IgG2, lgG3, IgG4, IgAl and IgA2) or subclass.
- the antibody can be derived from any suitable species.
- the antibody is of human or murine origin,
- An antibody can be, for example, human, humanized or chimeric,
- the term "monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site.
- an "intact antibody” is one which comprises an antigen-binding variable region as well as a light chain constant domain (CL) and heavy chain constant domains, C H 1 , C H 2, Q arid C H , as appropriate for the antibody class.
- the constant domains may be native sequence constant domains (e.g., human native sequence constant domains) or amino acid sequence variant thereof.
- an "antibody fragment” comprises a portion of an intact antibody, comprising the antigen-binding or variable region thereof.
- antibody fragments include Fab, Fab', F(ab') 2 , and Fv fragments, diabodies, triabodies, tetrabodies, linear antibodies, single-chain antibody molecules, scFv, scFv-Fc, multispecific antibody fragments formed from antibody fragment(s), a fragments) produced by a Fab expression library, or an epitope-binding fragments of any of the above which immunospecificaily bind to a target antigen (e.g., a cancer ceil antigen, a viral antigen or a microbial antigen).
- a target antigen e.g., a cancer ceil antigen, a viral antigen or a microbial antigen.
- An "antigen” is an entity to which an antibody specifically binds.
- the terms “specific binding” and “specifically binds” mean that the antibody or antibody derivative will bind, in a highly selective manner, with its corresponding target antigen and not with the multitude of other antigens.
- the antibody or antibody derivative binds with an affinity of at least about IxlO "7 M, and preferably 10 "8 M to iO "9 M, 10 "10 M, 10 ⁇ n M, or 10 "!2 M and binds to the predetermined antigen with an affinity that is at least two-fold greater than its affinity for binding to a non-specific antigen (e.g., BSA, casein) other than the predetermined antigen or a closely-related antigen.
- the term “inhibit” or “inhibition of means to a reduce by a measurable amount, or to prevent entirely.
- the term "therapeutically effective amount” refers to an amount of a drug effective to treat a disease or disorder in a mammal.
- the therapeutically effective amount of the drug may reduce the number of cancer ceils; reduce the tumor size; inhibit (i.e., slow to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (i.e., slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the cancer.
- the drug may inhibit growth and/or kill existing cancer ceils, it may be cytostatic and/or cytotoxic.
- efficacy can, for example, be measured by assessing the time to disease progression (TTP) and/or determining the response rate (RR).
- substantially refers to a majority, / ' , e. >50% of a population, of a mixture or a sample, preferably more than 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98%, or 99% of a population.
- intracellulariy cleaved and “intracellular cleavage” refer to a metabolic process or reaction inside a ceil on a Ligand Drug conjugate (e.g., an Antibody Drug Conjugate (ADC) or the like), whereby the covalent attachment, e.g., the linker, between the Drug moiety (D) and the Ligand unit (e.g., an antibody (Ab)) is broken, resulting in the free Drug, or other metabolite of the conjugate dissociated from the antibody inside the cell.
- ADC Antibody Drug Conjugate
- the cleaved moieties of the Drug-Linker-Ligand conjugate are thus intracellular metabolites.
- cytotoxic activity refers to a cell-killing, a cytostatic or an anti-proliferative effect of a Drug-Linker-Ligand con jugate compound or an intracellular metabolite of a Drug- Linker-Ligand conjugate. Cytotoxic activity may be expressed as the IC50 value, which is the concentration (molar or mass) per unit volume at which half the cells survive.
- cytotoxic agent refers to a substance that inhibits or inhibits the function of cells and/or causes destruction of cells.
- the term is intended to include radioactive isotopes (e.g., 211 At, 13i I, 125 1, 90 Y, f 86 Re, 188 Re, 1S3 Sm, 2i2 Bi, 32 P, 60 C, and radioactive isotopes of Lu), chemotherapeutic agents, and toxins such as small molecule toxins or enz raatically active toxins of bacterial fungal, plant or animal origin, including synthetic analogs and derivatives thereof.
- radioactive isotopes e.g., 211 At, 13i I, 125 1, 90 Y, f 86 Re, 188 Re, 1S3 Sm, 2i2 Bi, 32 P, 60 C, and radioactive isotopes of Lu
- chemotherapeutic agents e.g., chemotherapeutic agents, and toxins such as small molecule toxins or enz
- cancer and “cancerous” refer to or describe the physiological condition or disorder in mammals that is typically characterized by unregulated cell growth.
- a “tumor” comprises one or more cancerous cells.
- autoimmune disease herein is a disease or disorder arising from and directed against an individual's own tissues or proteins.
- Examples of a "patient” include, but are not limited to, a human, rat, mouse, guinea pig, monkey, pig, goat, cow, horse, dog, cat, bird and fowl.
- the patient is a human.
- beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., no worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable.
- Treatment can also mean prolonging survival as compared to expected survival if not receiving treatment.
- treating includes any or all of: inhibiting growth of tumor cells, cancer cells, or of a tumor; inhibiting replication of tumor cells or cancer cells, lessening of overall tumor burden or decreasing the number of cancerous cells, and ameliorating one or more symptoms associated with the disease.
- the term “treating” includes any or all of: inhibiting replication of cells associated with an autoimmune disease state including, but not limited to, cells that produce an autoimmune antibody, lessening the autoimmune-antibody burden and ameliorating one or more symptoms of an autoimmune disease.
- the term "Detection unit” refers to refers to any molecule which produces, or can be induced to produce, a detectable signal. Detection units having reporter molecules that can be detected by imaging equipment include, but are not limited to, radioactive, paramagnetic, fluorescent or radtoopaque chemical entities. In some embodiments, the
- Detection unit will be a radioactive compound, a chemilummescent agent, a fluorescent agent, or a chromogen. In some embodiments, the Detection unit will be a fluorescent molecule such as a fluorophore.
- Stability unit refers to a compound that promotes the stability of the conjugate, e.g., by increasing systemic retention of the Ligand when administered to a patient.
- a Stability unit can also increase the water solubility of the conjugate.
- An exemplary Stability unit is polyethylene glycol
- Th compound can contain at least one amino group, and accordingly acid addition salts can be formed with the amino group.
- Exemplary salts include, but are not limited to, sulfate, trifluoroacetate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tarmate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate (i.e., 1 ,1 '-methyl ene-bis - (2-hydroxy-3- naphthoate)) salts.
- pamoate i.e., 1 ,
- a pharmaceutically acceptable salt may involve the inclusion of another molecule such as an acetate ion, a succinate ion or other counterion.
- the counterfoil may be any organic or inorganic moiety that stabilizes the charge on the parent compound.
- a pharmaceutically acceptable salt may have more than one charged atom in its structure. Instances where multiple charged atoms are part of the pharmaceutically acceptable salt can have multiple counter ions. " Hence, a pharmaceutically acceptable salt can have one or more charged atoms and/or one or more counterion.
- alkyl by itself or as part of another term refers to a substituted or unsubstituted straight chain or branched, saturated or unsaturated hydrocarbon having the indicated number of carbon atoms (e.g., "-CfCg alkyl” or “-Cf-Cio alkyl refer to an aikyl group having from I to 8 or 1 to 10 carbon atoms, respectively). When the number of carbon atoms is not indicated, the aikyl group has from 1 to 8 carbon atoms.
- Representative straight chain "-Cj -Cg aikyl” groups include, but are not limited to, -methyl, -ethyl, -n-propyl, - n-butyl, -n-pentyl, -n-hexyl, -n-heptyi and -n-octyl; while branched -Ci-Cg alkyis include, but are not limited to, -isopropyl, -sec-butyl, -isobutyl, -fert-butyl, -isopent l, and -2-methylbutyl;
- unsaturated -C 2 -C 8 alkyis include, but are not limited to, -vinyl, -allyl, -1 -butenyl, -2-butenyl, -isobutyienyl, -1-pentenyl, -2-pentenyl, -3-methyI- 1 -butenyl, -2-methyl-2 ⁇ butenyl,
- an aikyl group is unsubstituted.
- An aikyl group can be substituted with one or more groups.
- an aikyl group will be saturated,
- alkylene by itself of as part of another term, refers to a substituted or unsubstituted saturated, branched or straight chain or cyclic hydrocarbon radical of the stated number of carbon atoms, typically 1-10 carbon atoms, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent, alkane.
- Typical alkylene radicals include, but are not limited to:
- an alkylene is a branched or straight chain hydrocarbon (i.e., it is not a cyclic hydrocarbon).
- aryl by itself or as part of another term, means a substituted or unsubstituted monovalent carbocyclic aromatic hydrocarbon radical of 6-20 carbon atoms derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system.
- Some aryl groups are represented in the exemplary structures as "Ar".
- Typical aryl groups include, but are not limited to, radicals derived from benzene, substituted benzene, naphthalene, anthracene, biphenyl, and the like.
- An exemplary aryl group is a phenyl group as follows:
- an "arylene,” by itself or as part of another term, is an aryl group as defined above which has two covalent bonds (i.e., it is divalent) and can be in the ortho, meta, or para configurations as shown in the following structures, with phenyl as the exemplary group:
- a C 3 -C S heterocycle refers to a monovalent substituted or unsubstiiuted aromatic or non-aromatic monocyclic or bicyclic ring system having from 3 to 8 carbon atoms (also referred to as ring members) and one to four heteroatom ring members independently selected from N, O, P or S, and derived by removal of one hydrogen atom from a ring atom of a parent ring system.
- One or more N, C or S atoms in the heterocycle can be oxidized.
- the ring that includes the heteroatom can be aromatic or nonaromatic.
- the heterocycle is attached to its pendant group at any heteroatom or carbon atom that results in a stable structure.
- Representative examples of a C Cg heterocycle include, but are not limited to, pyrrolidinyl, azetidinyl, piperidinyl, morpbolinyl, tetrahydrofuranyl, tetrahydropyranyl, benzofuranyl, benzothiophene, inclolyl, benzopyrazolyl, pyrrolyl, thiophenyl (thiophene), furanyl, thiazoiyl, imidazolyl, pyrazoiyl, pyrimidinyl, pyridinyl, pvrazinyl, pyridazinyl. isothiazolyi, and isoxazolyl.
- A"C 3 -Cs Iieteroaryi is an aromatic C 3 -C 8 heterocycle.
- C 3 -Q heterocyclo refers to a C 3 -Cg heterocycle group defined above wherein one of the heterocycle group's hydrogen atoms is replaced with a bond (i.e., it is divalent).
- C 3 -C 3 carbocycle by itself or as part of another term, is a 3-, 4-, 5-, 6-, 7- or 8-menibered monovalent, substituted or unsubstituted, saturated or unsaturated non-aromatic monocyclic or bicyclic carbocyclic ring derived by the removal of one hydrogen atom from a ring atom of a parent ring system.
- 32 include, but are not limited to, cyclopropyi, cydobutyl, cyelopentyl, cydopentadienyl, cyelohexyl, cyelohexenyi, 1 ,3-cyclohexadienyl, 1,4-cyclohexadienyl, eyeloheptyl, 1,3- cycioheptadienyl, 1 ,3,5-cydoheptatrieny I, cyciooctyl, and cyclooctadienyl.
- C 3 -Cg carbocyclo refers to a Q Cs carbocycle group defined above wherein another of the carbocycle groups' hydrogen atoms is replaced with a bond (i.e., it is divalent),
- heteroalkyi by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain hydrocarbon, or combinations thereof, fully saturated or containing from 3 to 3 degrees of unsaturation, consisting of the stated number of carbon atoms and from one to ten, preferably one to three, heteroatoms selected from the group consisting of O, N, Si and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized.
- the heteroatom(s) O, N and S may be placed at any interior position of the heteroalkyi group or at the position at which the alky! group is attached to the remainder of the molecule.
- a Cj to C 4 heteroalkyi or heteroaikylene has 1 to 4 carbon atoms and 1 or 2 heteroatoms and a Q to C 3 heteroalkyi or heteroaikylene has 1 to 3 carbon atoms and 2 or 2 heteroatoms.
- a heteroalkyi or heteroaikylene is saturated.
- heteroaikylene by itself or as part of another subsiituent means a divalent group derived from heteroalkyi (as discussed above), as exemplified by -CH 2 -CH 2 -S-CH 2 -CH 2 - and - H2-S-CH2-CH2-NH-CH2-.
- heteroaikylene groups heteroatoms can also occupy either or both of the chain termini.
- alkylene and heteroaikylene linking groups no orientation of the linking group is implied,
- Substituted alkyl and “substituted aryl” mean alkyl and aryl, respectively, in which one or more hydrogen atoms are each independently replaced with a subsiituent.
- Typical substiiuerrts include, but are not limited to, -X, -R, -O " , -OR, -SR, -S " , -NR 2 , -NR 3 ,
- each X is independently a halogen: -F, -CI, -Br, or -I; and each R. is independently -H, -C; ⁇ C 2 o alkyl, -
- R.G is a reactive group that contains a reactive site (RS) that is capable of forming a bond with either the components of the Linker unit (i.e., A, W, Y) or the Drug unit D.
- RS is the reactive site within a Reactive Group (RG).
- Reactive groups include sulfhydryj groups to form disulfide bonds or thioether bonds, aldehyde, ketone, or hydrazine groups to form hydrazone bonds, carboxylic or amino groups to form peptide bonds, carboxylic or hydroxy groups to form ester bonds, sulfonic acids to form sulfonamide bonds, alcohols to form carbamate bonds, and amines to form sulfonamide bonds or carbamate bonds.
- the following table is illustrative of Reactive Groups, Reactive Sites, and exemplary functional groups that can form after reaction of the reactive site. The table is not limiting.
- R' may represent one or more components of the self-stabilizing linker or optional secondary linker, as the case may be, and R" may represent one or more components of the optional secondary linker, Drug unit, Stability unit, or Detection unit, as the ease may be.
- the reactive site RS can form a new bond with components of the Linker unit or the Drug unit, as the case may be.
- the reactive site, RS, once linked to the remainder of the Linker unit has typically lost its reactivity,
- dibenzyl sulfonylurea refers to a cyclic amide that forms from a macro- cyclicization reaction with a thio-substituted succinimide and base present on the self-stabilizing linker assembly.
- Hydrolysis of a maieimide represents a nucieophi!ic addition reaction in which water, acting as the nucleophile, attacks one of the electrophi!ic carbonyl carbon atoms of the maieimide ring (or succinimide ring).
- the rate of this reaction is influenced by eleciroph iicity of the carbonyls, which can vary with the substitution of electron- donating or electron- withdrawing groups present on the nitrogen of the imide group.
- the rate of the hydrolysis reaction is also influenced by the pH of an aqueous solvent, which effectively increases the nucleopliilicity of water with increasing pH.
- the present invention provides, inter alia, N-substituted maleimides with hydrolysis rates that fall within a useful range wherein their reaction with thiols occurs mors quickly than their hydrolysis to the maieie acid derivative, but which yield thio-substituted succinimides with hydrolysis rates that are sufficiently rapid to achieve complete hydrolysis under gentle conditions that are very suitable for the manufacture of protein-based bioconjugates.
- the present invention is based, in part, on the discovery that a basic functional group proximal to a maleimide will catalyze the hydrolysis of a thio-substituted succinimide which is formed upon conjugation of the maleimide and a protein thiol leading to a stable bioeonjugate.
- a proximal basic group with an electron withdrawing group
- the rate of thio-substituted succinimide ring hydrolysis can be tuned to a desirable level.
- Design parameters that affect the rate of hydrolysis include the p a of the basic group, the strength of the electron withdrawing group when present, and the proximity of both groups to the maleimide carbonyl carbons.
- Design parameters that affect the percentage hydrolysis include the nature and proximity of the base to the maleimide carbonyl carbons.
- a Linker unit comprising a self-stabilizing linker assembly is referred to herein as a Self-Stabilizing Linker or Self-Stabilizing Linker unit.
- the Self-Stabilizing Linker prior to conjugation with the Ligand unit comprises a maleimide group.
- the Self-Stabilizing Linker is self-stabilizing by virtue of the proximity of the maleimide group to a base within the linker unit which catalyzes the hydrolysis of its own thio-substituted succinimide after conjugation to the Ligand unit. This is represented schematically below:
- Self-Stabilizing Linker refers to the Linker unit both prior to and post stabilization
- a Ligand-Functional Agent Conjugate comprising a Ligand unit and at least one Functional Agent selected from a. Drug unit, a Detection Unit, or a Stabilizing Unit, wherein the Ligand unit and each of the Functional Agent(s) are joined by a self-stabilizing linker assembly comprising a succinimide ring or a hydrolyzed succinimide ring directly conjugated to the Ligand unit via a thioether linkage; and a base and an electron withdrawing group (conjugated to the Ligand unit via the succinimide) operably linked to stabilize the conjugate in plasma relative to a ligand drug conjugate lacking the self-stabilizing linker assembly (i.e.
- the electron withdrawing group is positioned to increase the electrophilicity of the succinimide rendering it more reactive with water and the base is positioned to assist the hydrolysis of the succinimide ring (e.g., by an intramolecular base cataly sis mechanism).
- the succinimide ring in place of the succinimide ring is a dilactam formed when the base reacts with the succinimide ring.
- Functional Agent- Linker units are provided wherein the Linker portion comprises a self-stabilizing linker assembly
- Ligand-Linker conjugates are provided, wherein the Linker portion comprises a self-stabilizing linker assembly.
- the Linker portion further comprises an optional secondary linker assembly (L°).
- the Ligand-Functional Agent Conjugate is a Ligand-Drug Conjugate.
- the present invention provides in one group of embodiments, a Ligand-Drug Conjugate comprising a Ligand unit and at least one Drug unit, wherein the Ligand unit and each of the Drug unit(s) are joined by a self-stabilizing linker assembly comprising a succinimide ring or a hydrolyzed succinimide ring directly conjugated to the Ligand unit via a thioether linkage; and a base and an electron withdrawing group (conjugated to the Ligand unit via the succinimide ring) operably linked to stabilize the conjugate in plasma relative to a ligand drug conjugate lacking the self-stabilizing linker assembly (i.e.
- the electron withdrawing group is positioned to increase the electrophilicity of the succinimide rendering it more reactive with water and the base is positioned to assist the hydrolysis of the succinimide ring (e.g., by an intramolecular base catalysis mechanism), in some aspects, in place of the succinimide ring is a dilactam formed when the base reacts with the succinimide ring.
- Drug-Linker units are provided wherein the Linker portion comprises a self-stabilizing linker assembly.
- Ligand-Linker conjugates are provided, wherein the Linker portion comprises a self-stabilizing linker assembly, In some embodiments, the Linker portion further comprises an optional secondary linker assem bly (L°). In some embodiments, the secondary linker assembly is a releasabie linker assembly (L * ) which comprises a Cleavable unit and optionally one or more of a Stretcher and a Spacer unit. In some other embodiments, the secondary linker assembly is a non-releasable linker assembly (L N ) which comprises one or more of a Stretcher unit and a Spacer unit. In still other embodiments, the invention provides methods of treating cancer, immune disease, infectious diseases and other diseases and disorders using a Ligand-Drug Conjugate comprising a self-stabilizing linker assembly,
- the Linker unit of the Ligand-Functional Agent Conjugate can further comprise, in addition to a self-stabilizing linker assembly, an optional secondary linker assembly (L°) which joins each Functional Agent (or Drug unit) to the self-stabilizing linker assembly.
- the secondary linker assembly can be a releasabie linker assembly or a non- releasable linker assembly.
- Linker unit can be used herein to refer to the linker portion of the Ligand- Functional Agent Conjugate (or Ligand-Drug Conjugate) comprising the self-stabilizing linker assembly and optional secondary linker assembly.
- the Self-Stabilizing Linkers are designed such that the rate of the post-conjugation hydrolysis of the succinimide ring will be controllable and fall within a desired range.
- the limits of this range are typically dictated by issues which arise in the manufacture of ligand-drug conjugates.
- hydrolysis which is too slow would require unacceptable delays in the manufacturing process or aggressive conditions of pH and temperature which may induce damage to the protein backbone,
- a maleimide which is too reactive with water may be hydrolyzed to the corresponding maleic acid derivative before it can react with available protein thiols (see undesired pathway):
- maleic acid derivative (2 possible positional isomers)
- Such maleic acid derivatives are not reactive with thiols, and thus this reaction pathway does not result in a bioconjugate. Therefore, maleimides which undergo hydrolysis faster than thiol addition under applicable conditions are not useful reagents, in general, structural features which increase the hydrolysis rate of a thio-substituted succinimide will also increase the hydrolysis rate of the parent maleimide.
- the p a of the basic group, the strength of the electron withdrawing group(s), and the proximity of both groups to the maleimide are inter-related variables and will affect the hydrolysis rate of both the maleimide and corresponding thio-substituted succinimide product. Accordingly, positioning of the electron withdrawing group and base will be dependent upon the pKa of the base and the strength of the electron withdrawing group(s).
- the skilled artisan will understand that for particularly strong electron withdrawing groups such as fluoro,
- the group can be further from the maleimide.
- the hydrolysis reaction may compete with a macro-cyclization reaction such that the resultant conjugates comprise a heterogenous mixture of hydrolyzed thio-substituted succinimide conjugates and cyclized thio-substituted dilactam conjugates.
- a dilactam will not be formed.
- the Ligand-Functionai Agent Conjugate is represented by Formula 1:
- L is a Ligand unit
- D' is a Drug unit, a Detection unit, or a Stability unit:
- L° is the optional secondary linker assembly
- L ss is the self-stabilizing linker assembly, wherein
- M ! is a succinimide ring or a hydroiyzed succiniraide or together with BIJ forms a dilactam
- BU is a Basic unit
- HE is a hydrolysis enhancer comprising an electron withdrawing group
- the circle represents a scaffold that can be Ci -8 alkylene, C 1-8 heteroalkylene, Ce-io arylene, or Quo heteroarylene, and optionally comprises a reactive site suitable for attachment to the optional secondary linker assembly or D';
- the subscripts m, q and r are each 0 or 1 , and the sum of m + q + r is 0, 1 or 2 provided that if m + q + r is 0, the scaffold is a C 6- io arylene or C 4 _; 0 heteroarylene;
- r is zero, in some aspects, a is 1 and b is zero. In other aspects, a is zero and b is 1.
- the scaffold is a C 6 -io arylene or C4.10 heteroarylene and acts as the electron withdrawing group.
- exemplary aryls and heteroaryls include phenyl and pyridinyl,
- m + q + r is 1 or 2.
- the Conjugate is represented by Formula I or a sal t thereof wherein a is 1 and r is zero.
- the Conjugate is represented by Formula I or a salt thereof wherein L,° is present and is a releasable linker assembly
- the circle represents a scaffold that is Cj.g alkylene or Cj.g heteroalkylene (preferably C 1-4 alkylene or C1.4 heteroalkylene), a is 1, r is zero, and the sum of m+q is 1.
- the scaffold is Ci -3 alkylene or d-3 heteroalkylene.
- the alkylene is straight chain or branched.
- the Conjugate is represented by Formula I or a salt thereof wherein V " is present and is a releasable linker assembly, the circle represents a scaffold that is C 1-8 alkylene or Ci-8 heteroalkylene (preferably C].4 alkylene or C heteroalkylene), a is 1 , and m and r are zero.
- the scaffold is C 1 -3 alkylene or C1.3 heteroalkylene.
- the alkylene is straight chain or branched.
- the Conjugate is represented by Formula I or a salt thereof wherein L° is present and is a releasable linker assembly, the circle represents a scaffold that is Ci , C 2 , C3 or C4 straight or branched chain alkylene, a is i, r is zero, and the sum of m+q is 1.
- the Conjugate is represented by Formula 1 or a salt thereof wherein L° is present and is a releasable linker assembly, the circle represents a scaffold that is Q, C 2 , C 3 or Q straight or branched chain alkylene, a is 1 , and m and r are zero.
- the alkylene or heteroalkylene chain can be straight or branched, n some aspects, the alkylene or heteroalkylene chain will be a straight chain. In other aspects, it will be branched.
- p can range from 1 to 20, preferably 1 to 12, even more preferably i to 10, or 1 to 8.
- M 1 is preferably a succinimide ring (i.e., non- hydrolyzed) or a hydroiyzed succinimide ring (also referred to herein as hydroiyzed
- D' can be a Drug unit
- D and the Ligand-Functional Agent Conjugate can be a Ligand-Drug conjugate.
- th scaffold will comprise a reactive site suitable for attachment to the optional secondary linker assembly or D'.
- the self-stabilizing linker assembly (L 3 ⁇ 4 ) is represented by Formula ⁇ :
- M 1 represents a succinimide ring or a hydroiyzed succiniraide ring or a diiactam formed when the base reacts with the succinimide ring
- BU is a Basic unit
- HE is a hydrolysis enhancer comprising an electron withdrawing group
- the circle represents a scaffold that can be Ci.g alkylene, Cj.s heteroalkyiene, C& io arylene, or C4-10 heteroarylene, and optionally comprises a reactive site suitable for attachment to the optional secondary linker assembly, D !
- the subscripts m, q and r are each 0 or J , and the sum of m + q + r is 0, 1 or 2 provided that if m + q + r is 0, the scaffold is a C 6- ;o arylene or C4.10 heteroarylene.
- the self-stabilizing linker assembly is represented by Formula 11 wherein r is zero.
- m + q + r is 0.
- the Cg-jo arylene or C 4 .]o heteroarylene act as the electron withdrawing group.
- Exemplary aryls and heteroaryis include phenyl and pyridinyl.
- m + q + r is 1 or 2.
- the self-stabilizing linker assembly is represented by Formula 11 or a salt thereof wherein the circle represents a scaffold that is C f .g aikylene or Cj.g heteroalkylene (preferably C aikylene or heteroalkylene), r is zero, and the sum of m+q is i .
- the scaffold is C1.3 aikylene or Cj. 3 heteroalkylene.
- the aikylene is a straight chain or branched aikylene.
- the self-stabilizing linker assembly is represented by Formula II or a sait thereof wherein, the circle represents a scaffold that is C 1-8 aikylene or C]- heteroalkylene (preferably C aikylene or heteroalkylene) and m and r are zero.
- the scaffold is C1.3 aikylene or Cj.3 heteroalkylene.
- the aikylene is a straight chain or branched aikylene.
- the self-stabilizing linker assembly is represented by Formula II or a salt thereof wherein the circle represents a scaffold that is Ci , C 2 , C 3 . or C4 straight or branched chain aikylene, r is zero, and the sum of m+q is I .
- the self-stabilizing linker assembly is represented by Formula II or a salt thereof wherein the circle represents a scaffold that is C C 2 , C 3 , or C4 straight or branched chain aikylene, and m and r are zero.
- the aikylene or heteroalkylene chain will preferably be a straight or branched chain. In some aspects, the aikylene or heteroalkylene chain will be a straight chain. In other aspects, it will be a branched chain.
- M 1 is preferably a succinimide ring or a hydrolyzed succinimide ring.
- D' is preferably D, a Drug unit.
- the Ligand-Fursctional Agent Conjugate has the Formula (I);
- each of the scaffold, L, M ! , HE, BU, L°, D', and the subscripts p, m, q and r have the meanings provided above, selected embodiments include those wherein
- r is 1 , and m and q are 0;
- r is 1, m and q are 0, and a is 1 ;
- r is 1, m and q are 0, and D' is a i ug unit, D;
- the Basic unit comprises a primary, a secondary amine, or a tertiary amine.
- the Basic unit is selected from the group consisting of-(C(R )( R !
- the Basic unit is selected from the group consisting of -(CH 2 ) X NH 2 , -(CH 2 ) x NHR a , and -(CH 2 ) x NR a 2 , wherein x is an integer of from 0 to 6 (preferably 0 to 4, or 1 to 4) provided that if x is zero there are no less than 2 intervening atoms between the base of the Basic unit and the nitrogen atom of the succinimide (hydrolyzed or non-hydrolyzed) or dilactam, and each R a is independently selected from the group consisting of C 1-6 alkyl and C 1-6 haloaikyl, or two R a groups are combined with the nitrogen to which they are attached to form an azetidinyl, pyrrolidinyl or pipe
- x is an integer of from 1 to 4.
- the Basic unit is Ni k -CH 2 NH 2 , -CH 2 CH 2 NH 2 , - CH2CH2CH2 NH2, or -- 3 ⁇ 4CH 2 CH 2 CH 2 NH 2 provided that if the Basic unit is -NH 2 , there are no less than 2 intervening atoms between the base and the nitrogen atom of the succinimide (hydrolyzed or non-hydrolyzed) or dilactam.
- HE preferably comprises a carbonyl, sulfonyl or phosphoryl moiety.
- 1 is a succinimide ring or hydrolyzed succinimide.
- the circle represents a scaffold that is Cj -8 alkylene or Ci..g heteroalkylene (preferably Cj. 4 alkylene or C heteroalkylene).
- the alkylene is a straight or branched chain alkylene
- the Ligand-Functional Agent Conjugates have the formula
- each of the scaffold, L, M , HE, BIJ, L , D', and the subscript p has the meaning provided above, selected embodiments include those wherein: 1) the Basic unit (BU) comprises a primary, a secondary amine, or a tertiary amine, and D' is preferably a Drug unit D.
- BU Basic unit
- the Basic unit is selected from the group consisting of -(C(R 9 )( R. 1 )) X NH 2) -(C(R 9 )( R 10 )) x NHR a , and -(C(R 9 )( R 10 )) x NR a 2 , wherein x is an integer of from 0-4 (or 1-4) and each R a is independently selected from the group consisting of C 1-6 alk l and Q.6 haloalkyl, or two R a groups are combined with the nitrogen to which they are attached to form an azetidinyl, pyrrolidinyl or piperidinyl group, provided that if x is zero, there are no less than 2 intervening- atoms between the base of the Basic unit and the nitrogen atom of the succinimide (hydrolyzed or non-hydrolyzed) or dilactam, and R 9 and R lU are independently selected from H or C 1 .3 alky
- the Basic unit is selected from the group consisting of-(CH 2 ) X NH2, ⁇ (CH 2 ) X NHR ⁇ and - ⁇ (CH 2 ) x NR a 2 , wherein x is an integer of from 0 to 6 (preferably 0 to 4 or 1 to 4) provided that if x is zero, there are no less than 2 intervening atoms between the base of the Basic unit and the nitrogen atom of the succinimide (hydrolyzed or non-hydrolyzed) or dilactam, and each R a is independently selected from the group consisting of C e alkyl and .6 haloalkyl.
- R 8 groups are combined with the nitrogen to which they are attached to form an azetidinyl, pyrrolidinyl or piperidinyl group, and D' is preferably a Drug unit D.
- X is an integer of from 1 to 4.
- the Basic unit is -N3 ⁇ 4, -CH 2 N3 ⁇ 4 ⁇ CH 2 CH 2 NH 25 -C3 ⁇ 4CH 2 CH 2 NH 2 , or
- HE comprises a carbonyl, sulfonyl or phosphoryl moiety
- D' is preferably a Drug unit D.
- M 1 is a succinimide ring or hydrolyzed succinimide
- D' is preferably a Drug unit (D).
- the circle represents a scaffold that is Q-g alkylene or C-.-g heteroalkylene (preferably CM alkylene or C heteroalkylene), and D' is preferably a Drug unit (D).
- the alkylene is a straight chain or branched chain alkylene.
- HE is a carbonyl
- D' is preferably a Drug unit (D).
- H E is a carbonyl and the circle represents a scaffold that is a straight chain Ci-8 alkylene or C heteroalkylene (preferably CM alkylene or C heteroalkylene), and D' is preferably a Drug unit (D).
- H E is a carbonyl and the circle represents a scaffold that is a branched chain C i.g alkylene or Ci-8 heteroalkylene (preferably CM alkylene or CM heteroalkylene), and D' is preferably a Drug unit (D).
- Ligand-Drug Conj ugates have the formula:
- L° is a releasable linker assembly
- BU is (CI ! ; ⁇ ) v Nf -(CH 2 ) x NHR a , and ⁇ " ! h ), ⁇ ' R : ' 2 , wherein x is an integer of from 1-4 and each R a is independently selected from the group consisting of Q.
- L° is a releasable linker assembly
- BU is C! !-N! k -CH 2 CH 2 NH 2 , -CH 2 CH 2 CH 2 H 2 , or - CH2CH2CH 2 CH2 NH2.
- the Ab can be replaced by a non-antibody protein.
- M 1 is preferably a succinimide ring or a hydrolyzed succinimide ring.
- the Ligand-Drug Conjugates have the formula:
- L° is a releasable linker assembly
- BU is -(OL )xNH 2 , -(CH 2 ) NHR a , and -(Cl3 ⁇ 4 ) x NR a 2 , wherein x is an integer of from 1-4 and each R a is independently selected from the group consisting of Cj. 6 alkyl and C;.
- L° is a releasable linker assembly
- BU is -CH 2 NH 2 , -CH2CH 2 NH2, --CH 2 CH 2 CH 2 NH 2 , or -CH2CH2CH 2 CH2 H 2
- the Ab can be replaced by a non-antibody protein.
- M 1 is preferably a succinimide ring or a hydrolyzed succinimide ring.
- the Ligand-Drug Conjugates have the formula:
- L° is a releasable linker assembly
- BU is -(CH 2 ) X NH 2 , -(CH 2 ) x NHR a , and ⁇ (CH 2 ) x NR a 2 , wherein x is an integer of from 0-4 and each R a is independently selected from the group consisting of Cj.
- L° is a releasable linker assembly
- BU is -NH 2 , -CH 2 NH 2 , -CH 2 CH 2 NH 2 , ( ⁇ LCM K i h L. or -CH2CH 2 CH2CH 2 NH 2 .
- the Ab can be replaced by a non-antibody protein.
- M 1 is preferably a succinimide ring or a hydrolyzed succinimide ring.
- the present invention provides Fuctional Agent-Linker Conjugates (e.g., Drug-Linker Conjugates), Linkers, and Ligand-Linker assemblies.
- Fuctional Agent-Linker Conjugates e.g., Drug-Linker Conjugates
- Linkers e.g., Linkers, and Ligand-Linker assemblies.
- the present invention provides Functional Agent-Linker Conjugates (e.g., Drug-Linker Conjugates) having the formula:
- D' is a Drug unit, a Detection unit, or a Stability unit
- L° is an optional secondary linker assembly
- L ss is the self-stabilizing linker assembly, wherein BU is a Basic unit;
- HE is a hydrolysis enhancer comprising an electron withdrawing group
- the circle represents a scaffold that can be Ci_g alkylene, Cj.g heteroalkylene, C 6 -io arylene, or C,i.. ]0 heteroarylene, and optionally comprises a reactive site suitable for attachment to the optional secondary linker assembly or D';
- the subscripts rn, q and r are each 0 or 1 , and the sum of m + q + r is 0, 1 or 2 provided that if m + q + r is 0, the scaffold is a C 6 -io arylene or C4.10 heteroarylene, and the subscript a and b are each 0 or 1 , and the sum of a+b is 1.
- the Functional Agent-Linker Conjugate is represented by the formula:
- the Drug-Linker Conjugate is represented by the formulae:
- RG is a reactive group (comprising a reactive site) at the terminus of L°, suitable for attaching a Drug unit;
- L° is an optional secondary linker assembly that is present:
- L ss is the self-stabilizing linker assembly, wherein
- BU is a Basic unit
- HE is a hydrolysis enhancer comprising an electron withdrawing group
- the circle represents a scaffold that can be Ci-s alkyiene, C ⁇ .% heteroalkyiene, C 6- i 0 arylene, or C4.10 heteroarylene, and optionally comprises a reactive site suitable for attachment to the optional secondary linker assembly or Drug unit:
- the subscripts m, q and r are each 0 or 1 , and the sum of m + q + r is 0, 1 or 2 provided that if m + q + r is 0, the scaffold is a C&io arylene or Gno heteroarylene: and the subscript a and b are each 0 or 1, and the sum of a+b is 1 .
- RG is a reactive group that contains a reactive site that is capable of forming a bond with a Detection unit or a Stability unit instead of a Drug unit.
- the Linker is represented by the formula:
- Linker is represented by the formulae:
- Ligand-Linker Conjugates having the formula:
- L is a Ligand unit
- RG is a reactive group (comprising a reactive site) at the terminus of L° which is suitable for attaching a Drug unit;
- L u is an optional secondary linker assembly that is present
- L ss is a self-stabilizing linker assembly, wherein
- M is a succinimide ring or hydrolyzed succinimkle
- BU is a Basic unit
- HE is a hydrolysis enhancer comprising an electron withdrawing group
- the circle represents a scaffold that can be C 1-8 a!kylene, C].g heteroalkyiene, C 6 -io arylene, or C4.10 heteroaryiene, and optionally comprises a reactive site suitable for attachment to the optional secondary linker assembly or Drug unit;
- the subscripts m, q and r are each 0 or 1, and the sum of m + q + r is 0, 1 or 2 provided that if m + q + r is 0, the scaffold is a C 6 .io arylene or C -io heteroaryiene;
- RG is a reactive group that contains a reactive site that is capable of forming a bond with a Detection unit or a Stability unit instead of a Drug unit.
- the Ligand-Linker Conjugate is represented fay the formula:
- Ligand-Linker Conjugate is represented by the formula:
- L is an antibody (Ab).
- the circle, HE, M ⁇ BU, L° and RG have the meanings provided above. Additionally, each of the specifically recited selected embodiments for Ab, M ', BU, L° and RG (for any of the conjugates provided herein) are equally applicable to these Ligand-Linker conjugates.
- the self-stabilizing linker assembly instead of being represented by the structure for L ss is represented by L' 1 and has Formula (III):
- M 1 is a non-hydro lyzed or hydrolyzed succinimide or M 1 forms a dilactam with B (e.g., a dilactam is formed when B reacts with the succinimide ring), wherein the succinimide or dilactam is conjugated to the Ligand unit via a thioether linkage;
- V, Q, T, and G are independently selected from -(C(R 9 )( R 10 ))-;
- R 1 is H or C
- R 9 and R'°are in each occurrence, independently selected from H or C1.3 alkyl
- RS is a reactive site for conjugation to a component of the optional secondary linker assembly or Drug unit;
- g is 0 to 5;
- n 0 to 5;
- n 0 to 5;
- d is 0 or 1 ;
- x is 0 to 4, provided that when m is 0, x is 1 to 4;
- Ligand-Drug Conjugates have the formula:
- Drug-linkers have the formula:
- Ligand -Linker Conjugates have the formula:
- L if present, is a Ligand unit
- L° is an optional secondary linker assembly
- RG if present, is a reactive group (comprising a reactive site) at the terminus of L° which is suitable for attaching a Drug unit;
- M 1 if present, is a non-hydrolyzed or hydrolyzed succinimide or 1 forms a diiactam with B (e.g., a diiactam is formed when the base reacts with the succinimide ring), wherein the succinimide or diiactam is conjugated to the Ligand unit via a thioether linkage;
- V, Q, T, and G are independently selected from - ⁇ C(R 9 )( R 10 ))-;
- R' is H or Ci. 3 alkyl
- R 9 and R ! ° are, in each occurrence, independently selected from H or Cj. 3 aikyl;
- RS is a reactive site for conjugation to a component of the optional secondary linker assembly or Drug unit;
- g O to 5;
- n 0 to 5;
- x is 0 to 4, provided that when m is 0, x is 1 to 4;
- p if present, ranges from 1 to 20, preferably 1 to 12;
- the electron withdrawing group will either be represented by F (e.g., E 1 , E ⁇ or E : and E z" ) or by the reactive site RS.
- F e.g., E 1 , E ⁇ or E : and E z"
- the reactive site will act as an electron withdrawing group.
- n, d, and g are zero or m
- Exemplary embodiments wherein the Ligand-Drug Conjugates, Drug-Linkers, Linkers, or Ligand-Linker conjugates are represented by Formula III (or formulae I l ia, illb, Hie, or IIId, as the case may be) or pharmaceutically acceptable salts thereof, include those wherein m is zero; m is zero and n is zero, one, two, or three; x is I ; x is zero and n is zero, one, two, or three; and m is zero, n is zero, and x is 1.
- Exemplary embodiments include those described herein wherein wherein R and R 1 are hydrogen.
- E' and E" are independently selected from hydrogen, -CN, -N0 2 , -CX , and -X wherein is halogen or E ! and E: 2 together are (-O);
- R 3 , R 4 , R 5 , R 6 . R 7 and R 8 are endently selected from H or Cj-6 alkyl and e is 0 to 4;
- (xiv) B is ⁇ N(R 3 )(R 4 ), wherein R 3 and R 4 are independently selected from H or Ci-g aikyl;
- (xv) B is as in (xiii) or (xiv) and R 3 , R 4 , R R b , R 7 and R 8 are independently selected from H or Ci -3 alkyl;
- (xvi) B is as in (xiii) or (xiv) and R 3 , R 4 , R 5 , R B , R and R 8 are independently selected from 1 1 or methyl;
- (xvii) B is as in (xiii) or (xiv) or (xvi) and R 3 and R 4 are hydrogen;
- (xviii) B is as in (xiii) or (xiv) or (xvi) and at least one of R J and R 4 are hydrogen;
- (xix) B is as in (xiii) or (xiv) or (xvi) and at least one of R 3 and R 4 is not hydrogen;
- R ! , RQ, and R '° are independently selected from H or methyl;
- R ⁇ R Y , and R ! ° are independently selected from H or methyl;
- the cleavable unit is present and conjugated directly to the Drug unit via a cleavable peptide, disulfide, or hydrazone bond;
- the Drug is an auristatin
- M 1 is a hydrolyzed or non-hydrolyzed succinimide
- the Ligand unit is an antibody
- the Ligand unit is an antibody and is attached to the Linker unit though a cysteine residue of an interchain disulfide
- the Ligand unit is a monoclonal antibody; and any combinations or subcombinations of (i) througli (xxxvii) provided that the combinations or subcombinations do not conflict with each other (e.g., xxx and xxxi conflict because p cannot be both about 4 and about 8).
- m is zero, and n is zero, one, two, or three.
- m is zero, n is zero, and x is one.
- d can be one and g can be from 1 to 5 or d can be one and g can be from 2 to 5.
- one or more of (i), (iii) or (xi)-(xxxvi) can apply.
- the optional secondary linker assembly can be represented by the following formula: wherein -A- is an optional Stretcher unit, the subscript a' is 0 or I ;
- -W- is an optional Cleavable unit, the subscript v' is 0 or 1 ; and - ⁇ - is an optional Spacer unit, and the subscript y' is 0 or 1.
- V, T, B, I , Q, F, G, m, x, n, d, and g are as defined for formula III and RG is a reactive group comprising a reactive site, RS, for conjugation to the Drug unit D when the secondary linker assembly is absent or to a component of the secondary linker assembly wherein the secondary linker assembly secondary linker has the following formula: wherein -A- is an optional Stretcher unit, the subscript a' is 0 or 1 :
- -W- is an optional Cleavable unit, the subscript w' is 0 or 1 ; and -Y- is an optional Spacer unit, and the subscript y' is 0 or I .
- Exemplary self-stabilizing linker assemblies prior to conjugation with a Ligand and following conjugation and hydrolysis of the thio-substituted sueccinimide which is formed upon conjugation are as follows:
- V, Q, m. n, x, and B, are as defined above for Formula III or any other selected embodiment, c is from 1 to 4, and R' ' and R » 1 ! 2 are, at each occurrence, independently selected from H or Ci-C 6 alkyl, in an exemplary embodiment c is 1 or 4,
- the "S" of the hydrolyzed thio-succinimide represents a sulfur atom of the Ligand (e.g., antibody).
- the wavy line indicates linkage to the secondary linker assembly or Drug unit. In an exemplary embodiment, the wavy line indicates linkage to the following secondary linker assembly
- -A- is an optional Stretcher unit, the subscript a' is 0 or 1 ; -W- is an optional Cleavable unit, the subscript w ! is 0 or 1 ; and -Y- is an optional Spacer unit, and the subscript y' is 0 or 1 . It will be understood that more than one (e.g., 1 to 20) drug-linkers can be attached to each Ligand.
- a self-stabilizing linker assembly may undergo macro-cyclization to form a dilactam as follows wherein R represents the remainder of the conjugate:
- the optional secondary linker can comprise a variety of linking groups.
- L° can be present and have the formula: wherein
- -A- is an optional Stretcher unit, the subscript a' is 0 or 1 ;
- -W- is an optional Cleavable unit, the subscript v' is 0 or 1 ;
- -Y- is an optional Spacer unit, and the subscript y' is 0 or 1 ;
- the optional secondary linker assembly can be a releaseabie linker assembly, L R .
- w is I .
- the optional secondary linker assembly is a non-reieasable linker assembly.
- w is 0 and release of drug is via a total protein degradation pathway (i.e., non-cleavabie pathway).
- a Ligand Unit is present.
- the Ligand unit (L-) is a targeting agent that specifically binds to a target moiety.
- the Ligand can specifically bind to a cell component (a Cel l Binding Agent) or to other target molecules of interest.
- the Ligand unit acts to deliver the Drug unit to the particular target cell population with which the Ligand unit interacts.
- Ligands include, but are not limited to, proteins, polypeptides and peptides.
- Suitable Ligand units include, for example, antibodies, e.g., full-length antibodies and antigen binding fragments thereof, interferons, lymphokines, hormones, growth factors and colony-stimulating factors, vitamins, nutrient-transport molecules (such as, but not limited to, transferrin), or any other cell binding molecule or substance.
- the ligand is a non- antibody protein targeting agent.
- a Ltgand-Functional Agent is provided wherein D* is a Detection Unit or Stability unit and the Ligand unit is a protein (e.g., a non- antibody protein).
- a Ligand unit forms a bond with the maleirnide of the Self-Stabilizing Basic unit via a sulfhydryl group of the Ligand to form a thio-substituied succinimide.
- the su!fhydryi group can be present on the Ligand in the Ligand's natural state, for example a naturally-occurring residue, or can be introduced into the Ligand via chemical modification.
- the site of drug conj ugation can affect a number of parameters including ease of conjugation, drug-linker stability, effects on biophysical properties of the resulting bioconjugates, and in-vitro cytotoxicity.
- the site of conj ugation of a drug-linker to a ligand can affect the ability of the conjugated drug-linker to undergo an elimination reaction and for the drug linker to be transferred from the ligand of a bioconjugate to an aiternative reactive thiol present in the milieu of the bioconjugate, such as, for example, a reactive thiol in albumin, free cysteine, or glutathione when in plasma.
- Self-Stabilizing Linkers of the present invention is particularly beneficial when conjugated to thiol residues at sites that are susceptible to the elimination reaction and subsequent transfer of drug-linker if non-self-stabilizing alkyl maleimides are used (e.g., maleimido-eaproyi drug linker).
- sites include, for example, the interchain disulfides as well as select cysteine engineered sites,
- Use of the Self-Stabilizing Linkers of the present invention provides a stable linkage and ability to attach multiple drugs to each Ligand unit.
- the Ligand unit has one or more lysine residues that can be chemically modified to introduce one or more sulfhydryi groups.
- the reagents that can be used to modify lysines include, but ar not limited to, N-succinimidyl S-acetylthioacetate (SATA) and 2- Iminothiolane hydrochloride (Traut's Reagent).
- the Ligand unit can have one or more carbohydrate groups that can be chemically modified to have one or more sulfhydryi groups.
- the Ligand is an antibody and the sulfhydryi group is generated by reduction of an interchain disulfide. Accordingly, in some embodiments, the Linker unit is conjugated to a cysteine residue of the reduced interchain disulfides.
- the sulfhydryi group is chemically introduced into tire antibody, for example by introduction of a cysteine residue.
- the Linker unit is conjugated to an introduced cysteine residue.
- Useful non-immunoreactive protein, polypeptide, or peptide Ligands include, but are not limited to. transferrin, epidermal growth factors ("EGF”), bombesin, gastrin, gastrin- releasing peptide, platelet-derived growth factor, IL-2, IL-6, transforming growth factors ("TGF”), such as TGF-a and TGF- ⁇ , vaccinia growth factor (“VGF”), insulin and insuiin-like growth factors I and II, somatostatin, lectins and apoprotein from low density lipoprotein,
- EGF epidermal growth factors
- TGF transforming growth factors
- VGF vaccinia growth factor
- insulin and insuiin-like growth factors I and II somatostatin, lectins and apoprotein from low density lipoprotein
- Particularly preferred ligands are antibodies.
- Useful polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of immunized animals.
- Useful monoclonal antibodies are homogeneous populations of antibodies to a particular antigenic determinant (e.g. , a cancer cell antigen, a viral antigen, a microbial antigen, a protein, a peptide, a carbohydrate, a chemical, nucleic acid, or fragments thereof).
- a monoclonal antibody (mAb) to an antigen-of-interest can be prepared by using any technique known in the art which provides for the production of antibody molecules by continuous cell lines in culture.
- Useful monoclonal antibodies include, but are not limited to, human monoclonal antibodies, humanized monoclonal antibodies, or chimeric human-mouse (or other species) monoclonal antibodies.
- the antibodies include full-length antibodies and antigen binding fragments thereof.
- Human monoclonal antibodies may be made by any of numerous techniques known in the art (e.g., Teng et al., 1983, Proc. Natl. Acad. Sci. USA. 80:7308-7312: Kozbor et al, 1983, Immunology Today 4:72-79; and Olsson et al, 1982, Meth, Enzymol 92:3-16).
- the antibody can be a functionally active fragment, derivative or analog of an antibody that immunospecifically binds to target ceils (e.g., cancer cell antigens, viral antigens, or microbial antigens) or other antibodies bound to tumor cells or matrix.
- target ceils e.g., cancer cell antigens, viral antigens, or microbial antigens
- “functionally active” means that the fragment, derivative or analog is able to elicit anti-anii- idiotype antibodies that recognize the same antigen that the antibody from which the fragment, derivative or analog is derived.
- the antigenicity of the idiotype of the immunoglobulin molecule can be enhanced by deletion of framework and CDR sequences that are C-terminal to the CDR sequence thai specifically recognizes the antigen.
- synthetic peptides containing the CDR sequences can be used in binding assays with the antigen by any binding assay method known in the art (e.g., the BIA core assay) (See, e.g., Kabat et al., 1991, Sequences of Proteins of
- antibodies include fragments of antibodies such as, but not limited to, F(ab') 2 fragments, Fab fragments, Fvs, single chain antibodies, diabodies, tribodies, tetrabodies, scFv, scFv-FV, or any other molecule with the same specificity as the antibody.
- recombinant antibodies such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are useful antibodies.
- a chimeric antibody is a molecule in which different portions are derived from different animal species, such as for example, those having a variable region derived from a murine monoclonal and human immunoglobulin constant regions. (See, e.g., U.S. Patent No, 4,816,567; and U.S. Patent No.
- Humanized antibodies are antibody molecules from non- human species having one or more complementarity determining regions (CDRs) from the non- human species and a framework region from a human immunoglobulin molecule.
- CDRs complementarity determining regions
- Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in International Publication No. WO 87/02671 ; European Patent Publication No. 0 184 187; European Patent Publication No.
- Completely human antibodies are particularly desirable and can be produced using transgenic mice that are incapable of expressing endogenous immunoglobulin heavy and light chains genes, but which can express human heavy and light chain genes.
- Antibodies include analogs and derivatives that are either modified, i.e., by the covalent attachment of any type of molecule as long as such covalent attachment permits the antibody to retain its antigen binding immunospecificity.
- derivatives and analogs of the antibodies include those that have been further modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular antibody unit or other protein, etc.
- any of numerous chemical modifications can be carried out by known techniques including, but not limited to, specific chemical cleavage, acetylation, forrnylation, metabolic synthesis in the presence of tunicamycin, etc. Additionally, the analog or derivative can contain one or more unnatural amino acids.
- Antibodies can have modifications (e.g., substitutions, deletions or additions) in amino acid residues that interact with Fc receptors.
- antibodies can have modifications in amino acid residues identified as involved in the interaction between the anti-Fc domain and the FcRn receptor (see, e.g.. International Publication No. WO 97/34631, which Is incorporated herein by reference In its entirety ).
- Antibodies immunospecific for a cancer cell antigen can be obtained commercially or produced by any method known to one of skill in the art such as, e.g., chemical synthesis or recombinant expression techniques.
- immunospecific for a cancer cell antigen can be obtained, e.g., from the GenEiank database or a database like it, the literature publications, or by routine cloning and sequencing.
- antibodies for the treatment of cancer can be used.
- Antibodies immunospecific for a cancer cell antigen can be obtained commercially or produced by any method known to one of skill in the art such as, e.g., recombinant expression techniques.
- the nucleotide sequence encoding antibodies immunospecific for a cancer ceil antigen can be obtained, e.g., from the GenBank database or a database like it, the literature publications, or by routine cloning and sequencing.
- antibodies for the treatment of an autoimmune disease are used in accordance with the compositions and methods of the invention.
- Antibodies immunospecific for an antigen of a cell that is responsible for producing autoimmune antibodies can be obtained from any organization ⁇ e.g..
- useful antibodies are immunospecific for the treatment of autoimmune diseases incl ude, but are not limited to, anti-nuclear antibody; anti-ds DNA; Anti-ss DNA, anti-cardiolipin antibody igM, IgG; anti-phospholipid antibody IgM, IgG; anti-SM antibody; anti-mitochondrial antibody; thyroid antibody; microsomal antibody;
- thyroglobulin antibody anti-SCL-70 antibody; anti-Jo antibody; anti-U;RNP antibody;
- anti-La/SSB antibody anti-SSA
- anti-SSB antibody anti-perital ceils antibody
- anti-histones antibody anti-RNP antibody
- C-ANCA antibody C-ANCA antibody
- P-ANCA antibody anti-centromere antibody
- Anti-Fibriilarin antibody and anti-GBM antibody anti-La/SSB antibody
- anti-SSA anti-SSA
- anti-SSB antibody anti-perital ceils antibody
- anti-histones antibody anti-RNP antibody
- C-ANCA antibody C-ANCA antibody
- P-ANCA antibody anti-centromere antibody
- Anti-Fibriilarin antibody and anti-GBM antibody anti-GBM antibody
- useful antibodies can bind to a receptor or a receptor complex expressed on an activated lymphocyte.
- the receptor or receptor complex can comprise an immunoglobulin gene superfamily member, a TNF receptor superfamily member, an integrin, a cytokine receptor, a chemokine receptor, a major histocompatibility protein, a lectin, or a complement control protein.
- suitable immunoglobulin superfamily members are CD 2, CDS, CD4, CDS, CD 19, CD20, CD22, CD28, CD30, CD70, CD79, CD90, CD 152/CTLA-4, PD-1 , and 1COS.
- Non-limiting examples of suitable TNF receptor superfamily members are CD27, CD40, CD95/Fas, CD134/OX40, CD 137/4-1 BB, T F-R 1 , T F -2, RANK, TACI, BCMA, osteoprotegerin, Apo2/TRAIL-Rl, TRAIL-R2, TRAIL-R3, TRAIL-R4, and APO-3.
- Non-limiting examples of suitable integrins are CD1 l a, CD i lb, CD i lc, CD 18, CD29, CD41 , CD49a, CD49b, CD49c, CD49d, CD49e, C! ) 49f. ( 1 ) 1 03, and CD 104.
- Non- limiting examples of suitable lectins are C-type, S-type, and I-type lectin.
- the drug unit (D) can be any cytotoxic, cytostatic or immunosuppressive drug also referred to herein as a cytotoxic, cytostatic or immunosuppressive agent.
- the Drug unit has an atom that can form a bond with the Linker Unit, in some embodiments, the Drug unit D has a nitrogen atom that can form a bond with the Linker unit. In other embodiments, the Drug unit D has a carboxylic acid that can form a bond with the Linker unit. In other embodiments, the Drug unit D has a su!fhydryl group that can form a bond with the Linker unit . In other embodiments, the Drug unit D has a hydroxy! group or ketone that can form a bond with the Linker unit.
- cytotoxic or immunosuppressive agents include, for example, antitubulin agents, auristatins, DNA minor groove binders, DNA replication inhibitors, alkylating agents (e.g. , platinum complexes such as cis-platin, mono(p!atinum), bis(platinum) and tri-nuelear platinum complexes and carbopiatin), anthracyclin.es, antibiotics, antifolates-, antimetabolites, chemotherapy sensitizers, duocarmycins, etoposides, fluorinated pyrimidines, ionophores, lexitropsins, nitrosoureas, platinois, pre-formirsg compounds, purine antimetabolites, puromycins, radiation sensitizers, steroids, taxanes, topoisornerase inhibitors, vinca alkaloids, or the like.
- alkylating agents e.g. , platinum complexes such as cis-platin, mono
- cytotoxic agents include, for example, DNA minor groove binders, DNA alkylating agents, and tubulin inhibitors.
- cytotoxic agents include, for example, auristatins, camptothecins, duocarmycins, etoposides, maytansines and maytansinoids (e.g., DM! and DM4), taxanes, benzodiazepines (e.g.,
- PBDs pyrrolo [1 ,4] benzodiazepines
- oxazolidinobenzodiazepines oxazolidinobenzodiazepines
- vinca alkaloids oxazolidinobenzodiazepines
- Select benzodiazepine containing drugs are described in WO 2010/091 150, WO 2012/1 12708, WO 2007/085930, and WO 201 1/023883.
- Individual cytotoxic or immunosuppressive agents include, for example, an androgen, antbramycin (AMC), asparaginase, 5-azacytidine, azathioprine, bleomycin, busuJfan, buthionine sulfoximine, calicheamicin, camptothecin, carbopiatin, carmustine (BSNU), CC-1065, chlorambucil, cisplatin, colchicine, cyclophosphamide, cytarabine, cytidine arabinoside, cytochalasin B, dacarbazine, dactinomycin (formerly actinomycin).
- AMC antbramycin
- asparaginase 5-azacytidine
- azathioprine 5-azacytidine
- azathioprine 5-azacytidine
- azathioprine 5-azacytidine
- azathioprine 5-azacytidine
- azathioprine
- suitable cytotoxic agents include, for example, DNA minor groove binders (e.g., enediynes and ⁇ exitropsins, a CBI compound; see also U.S. Patent No. 6,130,237), duocarmycras (see U.S. Publication No.
- taxanes e.g., paclitaxei and docetaxel
- puromycins e.g., vinca alkaloids, CC-1065, SN-38, topotecan, morpholino- doxorubicin, rhizoxin, cyanomorpholino-doxorubicin, echinomvcin, combretastatin, netropsin, epothilone A and B, estramustine, cryptophysins, cemadotin, maytansinoids, discodermoiide, eleutherobin, and mitoxantrone.
- taxanes e.g., paclitaxei and docetaxel
- puromycins e.g., vinca alkaloids, CC-1065, SN-38, topotecan, morpholino- doxorubicin, rhizoxin, cyanomorpholino-doxorubicin, echinomvcin, comb
- the Drug unit is an anti-tubulin agent.
- anti-tubulin agents include, but are not limited to, taxanes (e.g., Taxol® (paclitaxei), Taxotere ⁇ (docetaxel)), T67 (Tularik) and vinca alkyloids (e.g., vincristine, vinblastine, vindesme, and vinorelbine).
- antitubulin agents include, for example, baccatin derivatives, taxane analogs (e.g., epothilone A and B), nocodazole, colchicine and colcimid, estramustine, cryptophysins, cemadotin, maytansinoids, combretastatins, discodermoiide, and eleutherobin.
- the cytotoxic agent is maytansine or a maytansinoid, another group of anti-tubulin agents.
- ImmunoGen, Inc. see also Chari et ah, 1992, Cancer Res. 52:127- 131 and U.S. Patent No. 8,163,888).
- the Drug unit is an auristatin.
- Auristatins include, but are not limited to, AE, AFP, AEB, AEVB, MMAF, and MMAE.
- the synthesis and structure of auristatins are described in U.S. Patent Application Publication Nos. 2003-0083263, 2005- 0238649 2005-0009751 , 2009-01 1 1756, and 201 1 -0020343: International Patent Publication No. WO 04/010957, international Patent Publication No. WO 02/088172, and U.S. Patent Nos. 7,659,241 and 8,343,928; each of which is incorporated by reference in its entirety and for all purposes.
- Exemplary auristatins of the present invention bind tubulin and exert a cytotoxic or cytostatic effect on the desired cell line.
- Exemplary auristatin Drug units have the following formula or a pharmaceutically acceptable sal t thereof wherein the wavy line indicates site of attachment to the linker unit:
- the Drug is a benzodiazepine (including benzodiazepine containing drugs e.g., pyrrolo[l ,4]benzodiazepiries (PBDs), indolinobenzodiazepines, and oxazo!idino benzodiazepines) .
- benzodiazepine including drugs e.g., pyrrolo[l ,4]benzodiazepiries (PBDs), indolinobenzodiazepines, and oxazo!idino benzodiazepines.
- PBDs are of the general structure:
- PBDs to form an adduct in the minor groove enables them to interfere with DNA processing, hence their use as antitumour agents.
- the biological activity of these molecules can be potentiated by, for example, joining two PBD units together through their C8/C -hydroxy! functionalities via a flexible alkylene linker.
- the PBD dimers are thought to form sequence-selective DNA lesions such as the palindromic 5'-Pu-GATC-Py-3' interstrand cross-link which is thought to be mainly responsible for their biological activity.
- [0J 4] There are a number of different assays that can be used for determining whether a Ligand-Drug Conjugate exerts a cytostatic or cytotoxic effect on a cell line. In one example for determining whether a Ligand-Drug Conjugate exerts a cytostatic or cytotoxic effect on a ceil line, a thymidine incorporation assay is used.
- Ligand- Drug Conj ugate has a cytostatic or cytotoxic effect on the cell line if the cells of the culture have reduced ⁇ -thymidine incorporation compared to cells of the same cell hne cultured under the same conditions but not contacted with the Ligand-Drug Conjugate.
- cell viability is measured by determining in a cell the uptake of a dye such as neutral red, trypan blue, or ALAMAR.TM blue ⁇ see, e.g.. Page et l. t 1993, Intl. J. of Oncology 3:473-476).
- a dye such as neutral red, trypan blue, or ALAMAR.TM blue
- the cells are incubated in media containing the dye, the cells are washed, and the remaining dye, reflecting cellular uptake of the dye, is measured spectrophotometrically.
- Preferred Ligand-Drug Conjugates include those with an IC50 value (defined as the mAB concentration that gives 50% cell kill) of less than 1000 ng/ml, preferably less than 500 ng/ml, more preferably less than 100 ng ml, even most preferably less than 50 or even less than 10 ng/rnl on the cell line,
- a non-hydrolyzed succinimide (also referred to herein as a succinimide ring) conjugated to the Ligand unit via a thioether linkage can be represented as follows wherein R represents the remainder of the Linker unit optionally conjugated to a Drug unit, Detection unit or Stability unit:
- a hydrolyzed succinimide (also referred to herein as a hydrolyzed succinimide ring) conjugated to the Ligand unit via a thioether linkage can be represented as one of its two positional isomers as follows wherein R represents the remainder of the Linker unit optionally conjugated to a Drug unit, Detection unit or Stability unit:
- the non-hydrolyzed succinimides and hydrolyzed succinimide representations there can be from 1 to 20, preferably 1 to 12, 1 to 10 or 1 to 8 self-stabilizing linkers conjugated to each Ligand. In some aspects, there are from I to 20, preferably 1 to 12, 1 to 10 or 1 to 8 drug-linkers conjugated to each Ligand. Additionally, for the conjugates described herein where a Ligand is not attached, the succinimide is in an unsaturated form as a maieimide (capable of reactive with a thiol or the Ligand).
- the Basic unit can be essentially any base capable of facilitating a hydroxide ion (or vvaier) attack to hydrolyze a nearby succinimide group.
- BU represents any "base” but is typically a group comprising a tethered amine or nitrogen containing heterocycle; the amine or nitrogen containing heterocycle acting as the base of the Basic unit.
- R epresentative amines include ⁇ N(R 3 )(R 4 ) wherein R 3 and R 4 are independently selected from H or Ci ⁇ alkyl, preferably H or methyl.
- R 5 , R 6 , R 7 and R 8 are, at each occurrence, independently selected from hydrogen or Ci ⁇ alkyl, preferably H or methyl, and e is 0-4.
- the wavy line indicates the point of attachment to a tethering group (typically an aikylene linker - ⁇ (C(R )( R 1,J )) ⁇ wherein the subscript x is an integer of from 0 to 6 (or 1 to 6 ) provided that if x is 0 there are no less than 2 intervening atoms between the base of the Basic unit and the nitrogen atom of the succinimide (hydrolyzed or non-hydroiyzed) or diiactam and R.
- y and R'° are independently selected from H or C: .3 a!kyi.
- the aikylene linker is -(CH 2 ) x - wherein the subscript x is an integer of from 0 to 6 (or 1 to 6) provided that if x is 0 there are no less than 2 intervening atoms between the base of the Basic unit and the nitrogen atom of the succinimide (hydrolyzed or non- hydroiyzed) or diiactam.
- the subscript x is preferably 0 to 4, 1 to 4, or from 1 to 3, or from 2 to
- the Basic unit will in some embodiments, be selected from the group consisting of -( €3 ⁇ 4 ) X NH 2 , -( 3 ⁇ 4 ) x NHR a , and --( €3 ⁇ 4 ) X NR " 2, wherein x i s an integer of from 0 to 4, 1 to 4 , or from 1 to 3, or from 2 to 3 , or from 2 to
- each R a is independently seiected from the group consisting of Cue alkyl and Q.6 haloalkyl, or two R a groups are combined with the nitrogen to which they are attached to form an azetidinyl, pyrrolidinyl or piperidinyl group.
- the base of the Basic unit will be a nitrogenous base.
- the hydrolysis enhancers (HE) of Formula I, as well as the other formulae comprising a self-stabilizing linker (L Ss> ), can be essentially any electron-withdrawing group capable of facilitating the hydrolysis of a nearby succinimide group,
- the hydrolysis is further facilitated by the Basic unit (BU) assisting a hydroxide ion (or water) attack to hydrolyze a nearby succinimide group; or to render the nearby succinimide group more susceptible to hydrolysis.
- HE can include a functional group that draws electrons away from a reaction center.
- Exemplary electron withdrawing groups include, but are not limited to, -C( :::: 0), ( () ⁇ .
- -C -NO?, -CX 3 , - X, -COOR, -CONR2, -COR, -COX, -SO2R, -SO2OR, -SO2NHR, -SO2NR2, -PO3R2, - P(0)(CH 3 )NHR, NO, - R f .
- -CR CR 2 , and -C ⁇ CR wherein X is F, Br, CI or ⁇ , and R is, at each occurrence, independently selected from the group consisting of hydrogen and C h alky!.
- Exemplary electron withdrawing groups can also include aryl groups (e.g., phenyl) and certain heteroaryl groups (e.g., pyridine).
- electron withdrawing groups includes aryls or heteroaryls further substitued with electron withdrawing groups.
- HE comprises a carbony], sulfonyl or phosphoryl moiety.
- HE will comprise a reactive site suitable for attachment to the optional secondary linker assembly or Drug unit.
- the optional secondary linker assembly can be represented by the formula: wherein - A- is an optional Stretcher unit, the subscrip a' is 0 or 1 ; -W- is an optional Cleavable unit, the subscript w' is 0 or 1 ; and ⁇ Y- Is an optional Spacer unit, and the subscript y' is 0 or 1.
- Hie wavy line adjacent to the optional Stretcher unit indicates the site of attachment to the self- stabilizing linker assembly and the wavy line adjacent, to the optional Spacer unit indicates the site of attachment to the Drue unit.
- Monomethyi auristatin E is conjugated tbrough a protease cleavable peptide linker to an antibody
- monomethyi auristatin F is conjugated directly to an antibody through
- DM1 is conjugated through a disulfide or directly through the heterobifunctional SMCC linker
- DM4 is conjugated through a disulfide linker.
- linker systems can be adapted for use with a self-stabilizing linker assembly or modified to include a basic component and/or electron withdrawing group using the teachings described herein and provide release of drug by a cleavable or non-cleavable system depending on the linker system used.
- Disulfide, thioether, peptide, hydrazine, ester, or carbamate bonds are all examples of bonds that can be used to connect a Drug Unit to a Linker Unit. Stretcher units, Cleavable units, and Spacer units are described in more detail below.
- the Stretcher unit is designed in such a way to allo branching within the Linker unit, e.g., the attachment of more than one Drug unit or Detection unit or Stability unit to each self-stabilizing linker assembly, as represented by the following formula:
- -W- is an optional Cleavable unit, the subscript vv' is 0 or 1 ; -Y- is an optional Spacer unit, the subscript y' is 0 or 1 , u is from 2 to 20 (preferably from 2 to 10);
- A is a Stretcher unit, A' is an optional Stretcher unit component at the terminus of A; and a' is 0 or 1 .
- Each A', W, Y, and D' can be the same or different.
- Each Cleavable unit can be attached to the Stretcher unit (either A or A') through the same or different functional group on the Stretcher unit.
- D' is a Drug unit D.
- Ligand-Functional Agent Conjugates or Ligand-Drug Conjugates having either branched or non-branched linkers have the following formulae:
- D is a Drug unit
- the circle represents a scaffold that can be C !-8 alkylene, Ci.g heteroalkylene, C 6 -io arylene, or C4.10 heteroarylene, and optionally comprises a reactive site suitable for attachment to A, W, Y or D' (or D as the case may be);
- -W- is an optional Cleavable unit, the subscript W is 0 or 1 ;
- -Y- is an optional Spacer unit, the subscript y' is 0 or 1, A is a.
- A' is an optional Stretcher unit component at the terminus of A: a' is 0 or I ; and u is from i to 20 (preferably from I to 10) wherein when u is from 2 to 20 A is present and when u is 1, A can be present or absent.
- Each A', W, Y, and D' (or D as the case may be) can be the same or different.
- Each Cleavable unit can be attached to the Stretcher unit (either A or A') through the same or different functional group on the Stretcher unit.
- w' is 1.
- w' is 1 and a' is 0.
- the circle can represent a scaffold that is Ci.g alkyiene or Q-g heteroalkyiene (preferably C alkyiene or C heteroalkyiene) or C-..3 alkyiene or C1.3 heteroalkyiene.
- the alkyiene is straight chain or branched
- Ligand-Functional Agent Conjugates having either branched or non-branched linkers can be represented by the following formulas:
- the circle represents a scaffold that can be C;.g alkyiene, C 1-8 heteroalkylene, C 6-1 o aryiene, or C4.10 heteroarylene, and optionally comprises a reactive site suitable for attachment to A, W, Y or D', -W- is an optional Cieavable unit, the subscript w' is 0 or 1; -Y- is an optional Spacer unit, the subscript y' is 0 or 1 , A is a Stretcher unit, A' is an optional Stretcher unit component at the terminus of A; a' is 0 or 1 ; and 11 is from 1 to 20 (preferably from 1 to 10), wherein when u is from 2 to 20 A is present and when u is 1 , A can be present or absent.
- a scaffold that can be C;.g alkyiene, C 1-8 heteroalkylene, C 6-1 o aryiene, or C4.10 heteroarylene, and optionally comprises a reactive site suitable for attachment to A, W, Y or D',
- Each A', W, Y, and D' can be the same or different.
- Each Cieavable unit can be attached to the Stretcher unit (either A or A') through the same or different functional group on the Stretcher unit, in some aspects, ' is 1.
- w' is I and a' is 0.
- the linker isn't branched u is 1
- a' is 0, and A can be present or absent.
- the linker is branched u is from 2 to 20 (preferably from 2 to 10).
- BU is selected from the group consisting of -(CH 2 ) X N!3 ⁇ 4, -iC3 ⁇ 4 ) x NHR a , and
- x is an integer of from 0-4 and each R a is independently selected from the group consisting of Q -6 alkyl and C 1-6 haloalkyl, or two R a groups are combined with the nitrogen to which they are attached to form an azetidinyl, pyrrolidinyl or piperidiny) group, provided that there are no less than 2 intervening atoms between the base of the Basic unit and the nitrogen atom of the succinimide (hydrolyzed or non-hydrol zed).
- X is 0-4 and each R a is Ci. 6 alkyl.
- Ligand-Drug Conjugates having either branched or non-branched linkers can be represented by the following formulas:
- D is a Drug unit
- the circle represents a scaffold that can be Ct-g alkylene, C 1-8 heteroalkylene, C io arylene, or C4.10 heteroaryiene, and optionally comprises a reactive site suitable for attachment to A, W, Y or D
- -W- is an optional Cleavable unit
- the subscript W is 0 or 1
- -Y- is an optional Spacer unit
- the subscript y' is 0 or 1
- A is a Stretcher unit
- A' is an optional Stretcher unit component at the terminus of A
- a' is 0 or 3
- u is from 3 to 20 (preferably from 1 to 10), wherein when u is from 2 to 20 A is present and when u is 1 , A can be present or absent.
- Each A', W. Y, and D can be th same or different.
- Each Cleavable unit can be attached to the Stretcher unit (either A or A') through the same or different functional group on the Stretcher unit.
- w' is 1.
- w ! is 1 and a' is 0.
- the linker isn't branched u is 1
- a' is 0, and A can be present or absent.
- the linker is branched u is from 2 to 20 (preferably from 2 to 10).
- BU is selected from the group consisting of --(CHb ) ⁇ ⁇ 2 .
- x is an integer of from 0-4 and each R a is independently selected from the group consisting of Cj.. 6 alky! and haloalkyl, or two R a groups are combined with the nitrogen to which they are aitached to form an azetidinyi, pyrrol idinyl or piperidinyl group, provided that there are no less than 2 intervening atoms between the base of the Basic unit and the nitrogen atom of the succinimide (hydro !yzed or non-hydrolyzed).
- X is 0-4 and each R a is C 1-6 alkyl.
- the circle represents a scaffold that can be Ci-g alkyiene, C 1-8 heteroalkylene, C 6- J O arylene, or C4.10 heteroarylene, and optionally comprises a reactive site suitable for attachment to A, W, Y or D';
- W- is an optional Cleavable unit, the subscript w* is 0 or 1 ;
- -Y- is an optional Spacer unit, the subscript y !
- A is 0 or 1
- A is a Stretcher unit
- A' is an optional Stretcher unit component at the terminus of A
- a' is 0 or 1
- u is from 1 to 20 (preferably from 1 to 10, wherein when u is from 2 to 20, A is present and when u is 1, A can he present or absent.
- Each A', W, Y, and D ! can be the same or different.
- Each Cleavable unit can be attached to the Stretcher unit (either A or A') through the same or different functional group on the Stretcher unit, in some aspects, w' is 1 . in some aspects, w' is i and a' is 0.
- the linker isn't branched u is 1, a' is 0, and A can be present or absent.
- the linker is branched u is from 2 to 20 (preferably from 2 to 10)
- the circle can represent a scaffold that is Q.g alkylene or Q.g heteroalkylene (preferably CM alkylene or C heteroalkylene) or Q.3 alkylene or C1..3 heteroalkylene.
- the alkylene is straight chain or branched.
- D' can he D.
- D' is D.
- BU is selected from the group consisting of -(CH 2 ) X NH 2 , ---(CH 2 ) x NHR , and -(CH 2 ) x NR a 2, wherein x is an integer of from 0- 4 and each R a is independently selected from the group consisting of Cj-e alkyl and Ci-g haloa!kyl, or two R 3 groups are combined with the nitrogen to which they are attached to form an azetidinyl, pyrrolidinyl or piperidinyl group, provided that there are no less than 2 intervening atoms between the base of the Basic unit and the nitrogen atom of the succinimide (hydrolyzed or non-hydrolyzed).
- X is 0-4 and each R a is C 1-6 alkyl.
- Ligand-Linker Conjugates having either branched or non-branched linkers can be represented by the following formulas:
- the circle represents a scaffold that can be C 1-8 alkylene.
- RG is a reactive group (comprising a reactive site) at
- W- is an optional Cleavable unit, the subscript w' is 0 or 1 ; -Y- is an optional Spacer unit, the subscript y* is 0 or 1 ,
- A is a Stretcher unit, A' is an optional Stretcher unit component at the terminus of A; a' is 0 or 1 ; and u is from 1 to 20 (preferably from 1 to 10) wherein when u is from 2 to 20, A is present and when u is 1, A can be present or absent.
- Each A', W, Y, and D can be the same or different.
- Each Cleavable unit can be attached to the Stretcher unit (either A or A') through the same or different functional group on the Stretcher unit.
- W is 1 .
- w' is 1 and a' is 0.
- the linker isn't branched u is I , a! is 0, and A can be present or absent.
- the linker is branched u is from 2 to 20 (preferably from 2 to 10).
- the circl can represnet a scaffold that is C .$ alkylene or Ci dem heteroalkylene (preferably C
- BU is selected from the group consisting of - ⁇ €3 ⁇ 4 ) X NH 2 , - (CH 2 ) X NHR ⁇ and -(CH 2 ) x NR a 2 , wherein x is an integer of from 0-4 and each R a is
- Ci -6 alkyl and C 1-6 haloalkyl independently selected from the group consisting of Ci -6 alkyl and C 1-6 haloalkyl, or two R a groups are combined with the nitrogen to which they are attached to form an azetidinyl, pyrrolidinyl or piperidinyi group, provided that there are no less than 2 intervening atoms between the base of the Basic unit and the nitrogen atom of the succinimide (hydrolyzed or non- bydrolyzed).
- X is 0-4 and each R R is Ci -6 alkyl.
- Branched or non-branched Linkers can be represented by the following formulas:
- each of the scaffold, HE, BU, and the subscripts a, b, m, q, and r have the meanings provided for Formula ⁇ and any of the selected embodiments for Formula I, the circle represents a scaffold that can be d. « alkylene, Ci-8 heteroalkylene, C 6- i 0 arylene, or C4.10 heteroarylene, and optionally comprises a reactive site- suitable for attachment to A, W, Y or D; RG is a reactive group (comprising a reactive site) at
- W- is an optional Cleavable unit
- the subscript w' is 0 or 1 :
- - Y- is an optional Spacer unit, the subscript y' is 0 or 1
- A is a Stretcher unit, A' is an optional Stretcher unit component at the terminus of A; a' is 0 or 1 ; and
- u is from 3 to 20
- each Cleavable unit can be attached to the Stretcher unit (either A or A') through the same or different functional group on the Stretcher unit, in some aspects, w' is 3. In some aspects, w' is 1 and a' is 0. In aspects wherein the linker isn't branched u is 1 , a' is 0, and A can be present or absent, h other aspects, wherein the linker is branched u is from 2 to 20 (preferably from 2 to 10).
- the circle can represent a scaffold that is Cj.8 alkylene or Ci.g
- heteroalkylene preferably C alkylene or Q.4 heteroalkylene
- heteroalkylene In some such aspects, the alkylene is straight chain or branched. 1.85] In some aspects j s represented
- BU is selected from the group consisting of --(C3 ⁇ 4 ) X NH 2 , - (CH 2 ) x NHR a , and (CI 1 2 ) x ' NR a 2 , wherein x is an integer of from 0-4 and each R a is independently selected from the group consisting of C f .g alkyl and Q-e haioalkyl, or two R a groups are combined with the nitrogen to which they are attached to form an azetidinyl, pyrroiidinyl or piperidinyl group, provided that there are no less than 2 intervening atoms between the base of the Basic unit and the nitrogen atom of the suceinimide (hydrolyzed or non- hydrolyzed),
- X is 0-4 and each R a is Ci-6 alkyl.
- exemplary Ligand-Drug Conjugates having either branched or non-branched linkers have the following formulae:
- L is a Ligand unit
- W- is an optional Cleavable unit
- the subscript w' is 0 or 1
- -Y- is an optional Spacer unit
- the subscript y' is 0 or 1
- A is a Stretcher unit.
- A' is an optional Stretcher unit component at the terminus of A; a' is 0 or 1; and u is from 1 to 20 (preferably from 1 to 10) wherein when u is from 2 to 20, A is present and when u is 1 , A can be present or absent.
- Each A', W, Y. and D can be the same or different.
- Each Cleavable unit can be attached to the Stretcher unit (either A or A') through the same or different functional group on the Stretcher unit, in some aspects, w' is 1. in some aspects, w' is 1 and a' is 0. In aspects wherein the linker isn't branched u is 1, a' is 0, and A can be present or absent, in other aspects, wherein the linker is branched u is from 2 to 20 (preferably from 2 to 10).
- Stretcher units Cleavable units, and Spacer units are described in more detail below.
- a Stretcher unit is capable of linking the self-stabilizing linker assembly to the Cleavable unit when the Cleavable unit is present, the self-stabilizing linker assembly to the Spacer unit when the Cleavable unit is absent but the Spacer unit is present and the self-stabilizing linker assembly to the Drug unit when both the Cleavable unit and the Spacer unit are absent.
- a Stretcher unit is capable of attaching to more than one Cleavable unit, Spacer unit, and/or Drug unit.
- the Stretcher unit can also act to alter the physiochemical properties of the Drug- Linker depending on components of the Stretcher unit, in some aspects, the Stretcher unit will be added in order to increase the solubility of the Drug-Linker and will comprise one or multiple solubility-enhancing groups such as ionic groups or water-soluble polymers.
- Water-soluble typically includes any segment or polymer that is soluble in water at room temperature and includes poly(ethylene)g!yeol groups as well as other polymers such as polyethyleneimines.
- a Stretcher unit can comprise one or multiple stretcher groups.
- Exemplary stretcher groups include, for example, -NH-C
- a representative stretcher group having a carbonyl group for linkage to the remainder of the Linker unit or the Drug unit is as follow: wherein R !
- j is -Ci-Cio alkylene-, -C 3 -Cgcarbocyclo-, -aryiene-, -Ci-Cjoheteroalkylene-, -C 3 - Cgheterocyclo-, -Cj -Chalky lene-arylene-.
- R 13 is -Ci-Cio alkylene- or -C j -C 3 oheteroalkylene-.
- R 13 is -Ci ⁇ Ci 0 alkylene-, -(CH 2 CH 2 O) 1-10 (-CH 2 )i -3 -, or
- R is -Ci-Cio alkylene- polyethyleneglycol, or polyethyjeneimine.
- Non-cleavable drug release systems are known in the art and can be adapted for use with the self-stabilizing linker assemblies of the present invention as Stretcher units and/or Spacer units.
- a non-cleavab!e linker in capable of Unking a Drug unit to a Ligand in a generally- stable and covalent manner and is substantially resistant to acid-induced cleavage, light-induced cleavage, peptidase- or esterase-induced cleavage, and disulfide bond cleavage.
- Drug is released from Ligand Drug Conjugates containing non-cieavable linkers via alternative mechanisms, such as proteolytic ligand degradation.
- Cross-linking reagents that form non-cleavable linkers between maytansinoid drugs and ligands are well known in the art and can adapted for use herein.
- Exemplary cross-linking reagants that form non-cleavable linkers between the maytansinoid drugs and ligands comprise a maleimido or haloacetyl-based moiety.
- the Cleavable unit (- W-), when present, is capable of linking the self-stabilizing linker assembly to the Spacer unit when the Spacer unit is present or the self-stabilizing linker assembly to the Drug unit when the Spacer unit is absent.
- the linkage from the self-stabilizing linker assembly to the Spacer unit or to the Drug unit can be directly from the self-stabilizing linker assembly when the Stretcher unit is absent or via the Stretcher unit if the Stretcher unit is present.
- the Cleavable unit will be directly conjugated to the self- stabilizing linker assembly on one end and to the Drug unit on the other end. in other embodiments, the Cleavable unit will be directly conjugated to the Stretcher unit on one end and to the Drug unit on the other end. In yet other embodiments, the Cleavable unit will be directl conjugated to the Stretcher unit on one end and to the Spacer unit on the other end. in even yet other embodiments, the Cleavable unit will be directly conjugated to the self-stabilizing linker assembly on one end and to the Spacer unit on the other end. Any of specifically described self- stabilizing linker assemblies described herein can be used in these embodiments.
- the Cleavable unit is capable of forming a cleavable bond with a Drug unit or a Spacer unit.
- Reactive groups for forming cleavable bonds can include, for example, sulfhydryi groups to form disulfide bonds, aldehyde, ketone, or hydrazine groups to form hydrazone bonds, carboxylic or amino groups to form peptide bonds, and carboxylic or hydroxy groups to form ester bonds.
- cleavable linkers include disulfide containing linkers that are cleavable through disulfide exchange, acid-labile linkers that are cleavable at acidic pH, and linkers that are cleavable by hydrolases, peptidases, esterases, and glucuronidases.
- the structure and sequence of the Cleavable unit is such that the unit is cleaved by the action of enzymes present at the target site.
- the Cleavable unit can be cleavable by other mechanisms.
- the Cleavable unit can comprise one or multiple cleavage sites.
- the Cleavable unit will comprise one amino acid or one or more sequences of amino acids.
- the Cleavable unit can comprise, for example, a monopeptide, a dipeptide, tripeptide, tetrapeptide, pentapeptide, hexapeptide, heptapeptide, octapeptide, nonapeptide, decapeptide, undecapeptide or dodecapeptide unit.
- each amino acid can be natural or unnatural and/or a D- or L-isomer pro vided of course that there is a cleavable bond, in some embodiments, the Cleavable unit will comprise only natural amino acids. In some aspects, the Cleavable unit will comprise 1 to 12 amino acids in contiguous sequence.
- each amino acid is Independently selected from the group consisting of alanine, arginine, asparlic acid, asparagine, histidme, glycine, glutamic acid, glutamine, phenylalanine, lysine, leucine, serine, tyrosine, threonine, isoleucine, proline, tryptophan, valine, cysteine, methionine, selenocysteine, ornithine, penicillamine, ⁇ -alanine, aminoalkanoic acid, aminoalkynoic acid, aminoalkanedioic acid, arainobenzoic acid, amino- heterocyclo-alkanoic acid, heterocycio-carboxyiic acid, citrulline, statine, diaminoalkanoic acid, and derivatives thereof.
- each amino acid is independently selected from the group consisting of alanine, arginine. asparlic acid, asparagine, hisiidine, glycine, glutamic acid, glutamine, phenylalanine, lysine, leucine, serine, tyrosine, threonine, isoleucine, proline, tryptophan, valine, cysteine, methionine, and selenocysteine.
- each amino acid is independently selected from the group consisting of alanine, arginine, aspartic acid, asparagine, histidme, glycine, glutamic acid, glutamine, phenylalanine, lysine, leucine, serine, tyrosine, threonine, isoleucine, proline, tryptophan, and valine, in some embodiments, each amino acid is selected from the proteinogenic or the non-proteinogenic amino acids.
- each amino acid is independently selected from the group consisting of the following L-(natural) amino acids: alanine, arginine, aspartic acid, asparagine, histidine, glycine, glutamic acid, glutamine, phenylalanine, lysine, leucine, serine, tyrosine, threonine, isoleucine, tryptophan and valine.
- each amino acid is independently selected from the group consisting of the following D-isomers of these natural amino acids: alanine, arginine, aspartic acid, asparagine, histidine, glycine, glutamic acid, glutamine, phenylalanine, lysine, leucine, serine, tyrosine, threonine, isoleucine, tryptophan and valine.
- the bond between the Cleavable unit and the Drug unit can be enzymaticaliy cleaved b one or more enzymes, including a tumor-associated protease, to liberate the Drug unit (-D), which in one embodiment is protonated in vivo upon release to provide a Drug (D).
- Useful Cleavable units can be designed and optimized in their selectivity for enzymatic cleavage by a particular enzyme, for example, a tumor-associated protease.
- a linkage (or bond) between the Cleavable unit and the Drug unit or Spacer unit is that which cleavage is catalyzed by cathepsin B, C and D, or a plasmin protease.
- the Cleavable unit can comprise only natural amino acids. In other embodiments, the Cleavable unit can comprise only non-natural amino acids. In some embodiments, the Cleavable unit can comprise a natural amino acid linked to a non-natural amino acid. In some embodiments, the Cleavable unit can comprise a natural amino acid linked to a D ⁇ isomer of a natural amino acid.
- An exemplary Cleavable unit is the dipeptide -Val-Cit-, -Phe-Lys- or -Val-Ala.
- the Cleavable unit will comprises a peptide and will comprise from 1 to 22 amino acids.
- the peptide will be conjugated directly to the Drug unit and the Spacer unit will be absent.
- the Stretcher unit and Spacer unit will be absent.
- the peptide will be a dipeptide.
- the Cleavable unit -TMW W - will be represented by -(- ⁇ ) ⁇ .. ⁇ 2-, or (- ⁇ ) ⁇ .. ⁇ wherein AA is at each occurrence independently selected from natural or non- natural amino acids, in one aspect, AA is at each occurrence independently selected from natural amino acids.
- amino acids are typically linked to the Drug unit or Spacer unit through functional units present in the amino acid, e.g., its earboxylie acid or amino termini.
- the Ligand Drug Conjugates and Drug-Linkers are represented by the following formulae or salts thereof wherein L, L bS , L 1 r A, a', AA, Y, y', D, and p are as defined in any of the embodiments described herein and f is an integer from 1 to 12:
- the Cieavable unit will comprise a glucoronide unit, preferably 1 or 2 glucoronide units.
- the Glucuronide unit comprises a sugar moiety (Su) linked via a glycoside bond (- ( )'-) to a self-immolative Spacer:
- glycosidic bond ( ⁇ 0' ⁇ ) is typically a ⁇ -glucuronidase-cleavage site, such as a bond cieavable by human, lysosomal ⁇ -glucuronidase,
- Su is a Sugar moiety,_-0'- represents a glycosidic bond; each R is independently hydrogen, a halogen, -CN, or -N0 2 ; wherein the wavy bond adjacent to the nitrogen atom indicates covalent attachment to the Stretcher unit or to the Ligand and the wavy bond adjacent to the oxygen indicates covalent attachment to the Spacer unit or to the Drug unit.
- An exemplary Linker unit comprising a glucoronide prior to conjugation to an antibody and post conjugation is as follows wherein the wavy line indicates attachment to a Drug unit or Spacer unit and Ab represents an antibody and S is a sulfur atom of the antibody, It will be understood that more than one self-stabilizing assembly can be attached to each antibody:
- the Cleavable unit itself will comprise a sulfur atom that is capable of forming a bond with a sulfur atom of a Spacer unit or Drug unit to form a disulfide or hindered disulfide. Cleavage occurs between the two sulfur atoms of the disulfide.
- one of the sulfur atoms is cleaved from the Drug unit and, provided there is no further release mechanism, the other sulfur atom remains attached to the Drug unit.
- a Linker unit comprising a Cleavable unit having a sulfur atom is capable of forming a bond with a sulfur atom of a Spacer unit or Drug unit to form a disulfide or hindered disulfide
- Exemplary linkers include, for example, the following Drug-Linker wherein the wavy line indicates the site of attachment to the remainder of the Linker unit, D is a mavtansinoid drug, and R a and 3 ⁇ 4 are independently selected from H or meth l.
- a variety of disulfide linkers are known in the art and can adapted for use in the present invention, including, for example, those that can be formed using SATA (N-succirdraidyl-S- aeetyithioacetaie), SPDP (N-succinimidyl-3-(2-pyridyldithio)propionate) > SPDB (N- succinimidyl-3-(2 ⁇ pyridyldithio)butyrate), SMPT (N-succiniraidyl-oxycarbonyl-alpha-methyl- alpha-(2-pyridyl-dithio)toluene), and SPP (N-succinimidyl 4-(2-pyridyIdithio)pentanoate).
- SATA N-succirdraidyl-S- aeetyithioacetaie
- SPDP N-succinimidyl-3-
- the cleavable linker is pH-sensitive and will comprise, for example, an acid-labile linker that is hydrolyzable in the iysosome (e.g., a hydrazone, seraicarbazone, thiosemicarbazone, cis-aconitic amide, orthoester, acetai, or ketal group) can be used.
- an acid-labile linker that is hydrolyzable in the iysosome
- Such linkers are relatively stable under neutral pH conditions, such as those in the blood, but are unstable at below pH 5.5 or 5.0, the approximate pH of the Iysosome.
- the Cleavable unit will be conjugated directly to the Drug unit and the Spacer unit will be absent and the Cleavable unit will be linked to the Drug unit via a cleavable peptide, disulfide, or hydrazone bond.
- the Spacer unit when present, links a Cleavable unit to the Drug unit or a Stretcher unit to the Drug unit or a self-stabilizing linker assembly to a Drug unit.
- the Spacer unit when present can act to extend the framework of the Linker unit.
- the Spacer unit can comprise multiple self-immolative or non-self immolative groups.
- the Spacer unit comprises one or more self-immolative groups, in this context, the term "self-immolative group” refers to a Afunctional chemical moiety that is capable of covalentiy linking together two spaced chemical moieties into a normally stable tripartite molecule.
- the Spacer unit is not self-imraolative. In these embodiments, part, or all of the Spacer unit remains attached to the Drug unit.
- -Y - is a self-immolative group and is linked to a Cleavable unit via the methylene carbon atom of the self-immolative group, and linked connected directly to the Drug unit via a carbonate, carbamate or eiher group.
- -Yy- is a p-aminobenzyl alcohol (PAB) unit whose phenylene portion is optionally substituted with -C]-Cg alkyl, -0-(C t ⁇ Cg alkyl), -halogen,- nitro or -cyano.
- PAB p-aminobenzyl alcohol
- -Yy- can be a carbonate group.
- An unsubstituted PAB unit is as follows:
- self-immolative groups include, but are not limited to, aromatic compounds that are electronically similar to the PAB group such as 2-arainoitnidazol-5-methanol derivatives (see, e.g., Hay et ah, 1999, Bioorg. Med. Chem, Lett. 9:2237) and ortho or para- arninobenzyiaeetals.
- Spacers can be used that undergo cyclization upon amide bond hydrolysis, such as substituted and unsubstituted 4-aminobutyric acid amides (see, e.g., Rodrigues et ah, 1995, Chemistry Biology 2:223), appropriately substituted bicyclo[2.2.1] and bicyclo[2.2.2] ring systems (s e, e.g.. Storm et ah, 1972, J. Amer. Chem. Soc. 94:5815) and 2-arninophenylpropionic acid amides (see, e.g., Amsberry et ah, 1990, J. Org. Chem. 55:5867).
- Elimination of amine- containing drugs that are substituted at the a-position of glycine are also examples of self-immolative groups.
- the optional Secondary Linker Assembly will typically be absent.
- the Stretcher unit will generally be present but the Cleavable unit and the Spacer unit will be absent.
- the Stretcher unit will extend the framework of the Linker unit to provide more distance between the self- stabilizing assembly and the Detection unit or Stability unit, in such aspects, the Stretcher unit is capable of linking the self-stabilizing linker assembly to the Detection unit or the Stability unit.
- the number of self-stabilizing linkers per Ligand is represented by p.
- p represents the number of drug-linker molecules (or detection-linker or stability-linker molecules) per Ligand molecule (e.g., antibody).
- p can represent the average number of self-stabilizing linkers per Ligand (or in embodiments where the linkers are not branched, the average number of drug-linker molecules (or detection-linker or stability-linker molecules) per Ligand (e.g., antibody)).
- the variable p ranges from 1 to 20, typically 1 to 12, 1 to 10 and is preferably from 1 to 8.
- p when p represents the average, number of self-stabilizing linkers per antibody, p ranges from about 2 to about 5. in some embodiments, p is about 2, about 4, or about 8. in some preferred embodiments, when p represents the average number of drug-linker molecules per antibody, p ranges from about 2 to about 5. In some embodiments, p is about 2, about 4, or about 8.
- the number of D' per self-stabilizing linkers is represented by u. u ranges from 1 to 10.
- the average number of Drugs units per Ligand unit in a preparation from a conjugation reaction may be characterized by conventional means such as mass spectroscopy, ELISA assay, HiC and HPLC.
- the quantitative distribution of Drug-Linker-Ligand conjugates in terms of p may also be determined.
- separation, purification, and characterization of homogeneous Ligand-Drug Conjugates, where p is a certain value from Ligand -Drug Conj gate with other drug loadings may be achieved by means such as reverse phase HPLC or
- the Self-Stabilizing linker assembly links the Ligand unit to a Stretcher unit if the Stretcher unit is present, links the Ligand unit to a Cleavabie unit if the Stretcher unit is absent and a Cleavabie unit is present, links the Ligand unit to a Spacer unit if the Stretcher unit and the Cleavabie unit are absent and the Spacer unit is present, or links the Ligand Unit to D' (e.g., a Drug Unit) if the Stretcher unit. Cleavabie unit and Spacer unit are absent.
- D' e.g., a Drug Unit
- the Stretcher unit, Cleavabie unit, and Spacer unit will be absent and the self- stabilizing linker assembly will be conjugated directly to D' (e.g., a Drug Unit). In other embodiments, one or more of the Stretcher unit, Cleavabie unit, and Spacer unit will be present.
- tl/2 of hydrolysis refers to the time taken for half of the compound of interest to hydrolyze, i.e., undergo a ring opening, under stated conditions (e.g., pH 7.4 and 22°C).
- the tl/2 of hydrolysis of the thio-substituted succinimide of the Self-Stabilizing Linker unit is less than 4 hours, preferably less than 3 hours, even more preferably, less than 2 hours, less than 1 hour, less than 45 minutes, less than 30 minutes, less than 15 minutes using the following assay and sta ed conditions.
- the hydrolysis reaction rates of maleimido drug linkers following conjugation to antibody cysteines can be determined by mass spectrometry, as the hydrolyzed product has a molecular weight 18 daltons greater than the unhydrolyzed conj ugate. Reduction of the interchain disulfides of a human IgGl creates a single reduced cysteine on the light chain and three reduced cysteines on the heavy chain.
- the self-stabilizing raaleimide drug-linker can then be conjugated to the reduced antibody at pH 7,4 and 22°C and introduced to a high-resolution electrospray mass spectrometer via a reversed-phase HPLC column which separates the conjugated light and heavy chains.
- the masses of the conjugated light and heavy chains can thus be measured, and the peak intensities determined by standard mass spectrometry data processing software (e.g., MassLynx).
- standard mass spectrometry data processing software e.g., MassLynx
- the disappearance of the peak corresponding to the mass of the original, unhydrolyzed conjugate and the appearance of the peak corresponding to the mass of the hydrolyzed conjugate can be monitored, the intensities of the peaks determined, and the percentage of hydrolyzed conjugate calculated at each timepoint.
- a curve is generated (e.g., using PRISM) which can be fit to a standard equation for exponential phenomena which includes a parameter for tl/2.
- the Self-Stabilizing Linker will be designed such that the maleimide component of the Self-Stabilizing Linker does not substantially undergo hydrolysis prior to conjugation to the Ligand unit,
- the tl 12 of hydrolysis of the thio- substituted succinimide of the Self-Stabilizing Linker is from about 5 or about 10 minutes to about 24 hours, preferably from about 5 or about 10 minutes to about 12 hours, more preferably from about 5 or about 10 minutes to about 5 hours, more preferably from about 5 or about 10 minutes to about 2.5 hours, even more preferably from about 5 or about 10 minutes to about 1 hour, even more preferably from about 5 or about 10 minutes to about 30 minutes, even more preferably from about 5 or about 10 minutes to about 20 minutes, and even more preferably from about 10 minutes to about 15 minutes at a ⁇ of about 7 to about 7.5 (e.g., 7.4) and a temperature of about 22°C,
- the hydrolysis goes to completion. Complete hydrolysis is considered to be achieved if 90% of the thio-substiiuted succinimide hydroiyzes. Preferably, 95% or greater, 96%. 97%, 98%, 99% or 100% hydrolysis will be achieved.
- the hydrolysis reaction will compete with a dilactam formation and will not achieve completion.
- at least 90% of the reaction product will be a combination of either a hydrolyzed thio-substituted succinimide Ligand-Drug Conjugate or a thio-substituted dilactam Ligand-Drug Conjugate.
- the reaction product will be a combination of either a hydrolyzed thio-substituted Ligand-Drug Conjugate or a thio- substituted dilactam Ligand-Drug Conjugate.
- the percentage of hydrolysis can be calculated from the mass spectrometrie data of the conjugate at the final timepoint by determining the intensity of the peak corresponding to the mass of the original, unhydrolyzed conjugate and the intensity of the peak corresponding to the mass of the hydrolyzed conjugate, and using the sum of the peak intensities to determine the percentage hydrolyzed and percentage unhydrolyzed,
- the stability of the Ligand-Drug Conjugate can he characterized by the ability of the Ligand-Drug Conjugate to undergo an elimination reaction and for the Drug-Linker to be transferred from the Ligand unit to a alternative reactive thiol present in the milieu of the Ligand-Drug Conjugate, in some embodiments, the Drug-Linker will exhibit no or substantially no disassociation from the Ligand under the following assay and stated conditions.
- substantially no disassociation from the Ligand is considered to be achieved if less than 40%, preferably less than 20%, even more preferably less than 10%, or even more preferably less than 5% or less than 2% of the Drug-Linker in a sample disassociates from the L gand.
- the elimination of a drug-linker containing an enzyme-cleavable linker from an antibody can be measured in ex vivo plasma by the following method.
- the conjugate is placed in sterile plasma and incubated at 37°C.
- an aliquot is removed at fro/en at -80°C.
- the samples are passed over a protein A affinity resin to capture the antibody, the resin is washed with buffer, and then drug is released from the captured antibody by treatment with an appropriate enzyme (e.g. papain or proteinase K for peptide-based cleavable linkers).
- an appropriate enzyme e.g. papain or proteinase K for peptide-based cleavable linkers.
- the released drug can then be quantified by standard LC-MS methodology, and the quantity of drug measured at each timepoint divided by the q uantity of drug measured for the pre-incubation aliquot to determine the percentage of drug remaining conjugated to the antibody at each timepoint.
- the precision of this assay can be improved by including an internal standard antibody-drug conjugate which is prepared using an isotopically labeled version of the same drug-linker, such that the drug which is released from it can be detected independently in the LC-MS assay from the drug released from the test drug-linker by virtue of its mass difference.
- This isotopically labeled internal standard antibody-drug conjugate is added to each sample in equal amounts immediately prior to the protein A capture step.
- An alternative method for evaluating the elimination of a maieimide drug-linker from an antibody (or other ligand) is to incubate the conjugate in buffer (e.g., phosphate-buffered saline) at slightly elevated pH (e.g., pH 8.0) in the presence of a large excess of a small-molecule thiol (e.g., N-acetyl cysteine, NAC) which will react with any maleimide that eliminates from the parent conjugate.
- buffer e.g., phosphate-buffered saline
- slightly elevated pH e.g., pH 8.0
- a small-molecule thiol e.g., N-acetyl cysteine, NAC
- LC-MS assays can be performed to detect and quantify the drag-linker conjugated to NAC, or the parent !igand-eonjugate. In the latter case, the ratio of the ligatid- conjugate to unconjugated ligand can be measured and will remain constant over time if the ligand-conjugate is stable. Additional methods are provided in the examples section.
- the Ligand-Drug Conjugates are useful for inhibiting the multiplication of a tumor ceil or cancer cell, causing apoptosis in a tumor or cancer ceil, or for treating cancer in a patient.
- the Ligand-Drug Conjugates can be used accordingly in a variety of settings for the treatment of cancers.
- the Ligand-Drug Conjugates can be used to deliver a drug to a tumor cell or cancer cell.
- the Ligand unit of a Ligand-Drug Conjugate binds to or associates with a cancer-ceil or a tumor-cell-associated antigen, and the Ligand-Drug Conjugate can be taken up (internalized) inside a tumor cell or cancer cell through receptor-mediated endocytosis or other internalization mechanism.
- the antigen can be attached to a tumor cell or cancer cell or can be an extracellular matrix protein associated with the tumor cell or cancer cell.
- the drug is released within the cell, in an alternative embodiment, the Drug or Drug unit is cleaved from the Ligand-Drug Conjugate outside the tumor ceil or cancer cell, and the Drug or Drug unit subsequently penetrates the cell,
- the Ligand-Drug Conjugates can provide conjugation-specific tumor or cancer drug targeting, thus reducing genera! toxicity of the drug.
- the Linker units stabilize the Ligand-Drug Conjugates in blood, yet are capable of liberating drug once inside the cell.
- the Ligand unit binds to the tumor cell or cancer cell.
- the Ligand unit binds to a tumor cell or cancer cell antigen which is on the surface of the tumor eel! or cancer cell.
- the Ligand unit binds to a tumor cell or cancer cell antigen which is an extracellular matrix protein associated with the tumor cell or cancer cell.
- the specificity of the Ligand unit for a particular tumor cell or cancer cell can be important for determining those tumors or cancers that are most effectively treated.
- a ligand drug conjugate haying a BR96 Ligand unit can be useful for treating antigen positive carcinomas including those of the lung, breast colon, ovaries, and pancreas.
- Ligand- Drug Conjugates having an anti-CD30 or an anti-CD70 binding Ligand unit can be useful for treating hematologic malignancies,
- Solid tumors including but not limited to: fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangtosarcoma, lymphangioendotheliosareoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon cancer, colorectal cancer, kidney cancer, pancreatic cancer, bone cancer, breast cancer, ovarian cancer, prostate cancer, esophogeal cancer, stomach cancer, oral cancer, nasal cancer, throat cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papil lary adenocarcinomas, cystadenocarcinoma, medullary carcinoma,
- ALL acute lymphoblastic leukemia
- B-eell leukemia acute lymphoblastic B-eell leukemia
- T-ceil leukemia acute myeloblasts leukemia
- AML acute myeloblasts leukemia
- APL ac promyelocyte leukemia
- APL acute monoblastic leukemia
- acute erythroleukeraic leukemia acute megakaryoblastic leukemia
- acute myeiomonocytic leukemia acute nonlymphocyctic leukemia
- acute undifferentiated leukemia chronic myelocytic leukemia "CML”
- chronic lymphocytic leukemia chronic lymphocytic leukemia
- hairy ceil leukemia multiple myeloma acute and chronic leukemias:
- lymphoblastic, myelogenous, lyraphocytic, myelocytic leukemias Lymphomas
- Cancers including, but not limited to, a tumor, metastasis, or other disease or disorder characterized by uncontrolled cell growth, can be treated or inhibited by administration of a Ligand-Drug Conjugate.
- methods for treating cancer including
- a Ligand-Drug Conjugate administering to a patient in need thereof an effective amount of a Ligand-Drug Conjugate and a. chemotherapeutic agent.
- the chemotherapeutic agent is that with which treatment of the cancer has not been found to be refractory, In another embodiment, the chemotherapeutic agent is that with which the treatment of cancer has been found to be refractory.
- the Ligand-Drug Conjugates can be administered to a patient that has also undergone surgery as treatment for the cancer. [0247] in some embodiments, the patient also receives an additional treatment, such as radiation therapy.
- the Ligand-Drug Conjugate is administered concurrently with the chemotherapeutic agent or with radiation therapy, In another specific embodiment, the chemotherapeutic agent or radiation therapy is administered prior or subsequent to administration of a ligand drug conjugate,
- a chemotherapeutic agent can be administered over a series of sessions. Any one or a combination of the chemotherapeutic agents, such a standard of care chemotherapeutic agent(s), can be administered,
- methods of treatment of cancer with a Ligand-Drug Conj ugate are provided as an alternative to chemotherapy or radiation therapy where the chemotherapy or the radiation therapy has proven or can prove too toxic, e.g., results in unacceptable or unbearable side effects, for the subject being treated.
- the patient being treated can, optionally, be treated with another cancer treatment such as surgery, radiation therapy or chemotherapy, depending on which treatment is found to be acceptable or bearable.
- the Ligand-Drug Conjugates are useful for killing or inhibiting the replication of a cell that produces an autoimmune disease or for treating an autoimmune disease.
- the Ligand-Drug Conjugates can be used accordingly in a variety of settings for the tTeatment of an autoimmune disease in a patient.
- the Ligand-Drug Conjugates can be used to deliver a drug to a target ceil.
- the Ligand-Drug Conjugate associates with an antigen on the surface of a target cell, and the ligand drug conjugate is then taken up inside a target-cell through receptor-mediated endocytosis.
- the Linker unit binds to an autoimmune antigen.
- the antigen is on the surface of a ceSi involved in an autoimmune condition.
- the Ligand unit binds to an autoimmune antigen which is on the surface of a cell.
- the Ligand unit binds to activated lymphocytes that are associated with the autoimmune disease state.
- the Ligand-Drug Conjugate kills or inhibit the multiplication of cells that produce an autoimmune antibody associated with a particular autoimmune disease.
- Th2 lymphocyte related disorders e.g., atopic dermatitis, atopic asthma, rhinocorijunctivitis, allergic rhinitis, Omenn's syndrome, systemic sclerosis, and graft versus host disease
- Thl lymphocyte-related disorders e.g., rheumatoid arthritis, multiple sclerosis, psoriasis, Sjorgren's syndrome, Hashimoto's thyroiditis, Grave ' s disease, primary biliary cirrhosis, Wegener's granulomatosis, and tuberculosis
- activated B lymphocyte-related disorders e.g., systemic lupus erythematosus, Goodpasture's syndrome, rheumatoid arthritis, and type 1 diabetes
- Polyglandular Syndromes Presenile Dementia, Primary Agammaglobulinemia, Primary Biliary Cirrhosis, Psoriasis, Psoriatic Arthritis, Raynauds Phenomenon, Recurrent Abortion, Reiter's Syndrome, Rheumatic Fever, Rheumatoid Arthritis, Sampter's Syndrome, Schistosomiasis, Schmidt's Syndrome, Scleroderma, Shulman's Syndrome, Sjorgen's Syndrome, Stiff-Man Syndrome, Sympathetic Ophthalmia, Systemic Lupus Erythematosus, Takayasu's Arteritis, Temporal Arteritis, Thyroiditis, Thrombocytopenia, Thyrotoxicosis, Toxic Epidermal Necrolysis, Type B insulin Resistance, Type I Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vitiligo, Waldenstrom's Macroglobulemia, Wegener's
- Methods for treating an autoimmune disease including administering to a patient in need thereof an effective amount of a Ligand-Drug Conjugate and another therapeutic agent known for the treatment of an autoimmune disease.
- the Ligand-Drug Conjugates are useful for killing or inhibiting the multiplication of a cell that produces an infectious disease or for treating an infectious disease.
- the Ligand-Drug Conjugates can be used accordingly in a variety of settings for the treatment of an infectious disease in a patient.
- the Ligand-Drug Conjugates can be used to deliver a drug to a target cell.
- the Ligand unit binds to the infectious disease cell.
- the conjugates kill or inhibit the multiplication of cells that produce a particular infectious disease.
- Particular types of infectious diseases that can be treated with the Ligand-Drug Conjugates include, but are not limited to, those disclosed in Table 3.
- Measles, Subacute sclerosing panencephalitis Common Cold, Mumps, Rubella, Roseola, Fifth Disease, Chickenpox, Respiratory syncytial virus infection, Croup, Bronchiolitis, infectious Mononucleosis, Poliomyelitis, Herpangina, Hand-Foot- and-Mouth Disease, Bornholm Disease, Genital Herpes, Genital Warts, Aseptic Meningitis, Myocarditis, Pericarditis. Gastroenteritis, Acquired
- AIDS immunodeficiency Syndrome
- HSV Human Immunodeficiency Virus
- Reye's Syndrome Kawasaki Syndrome
- influenza Bronchitis
- Viral "Walking" Pneumonia Acute Febrile Respiratory Disease
- Acute pharyngoconj uncti val fever Epidemic keratoconjunctivitis
- Herpes Simplex Virus i HSV-1
- Herpes Simplex Virus 2 HSV-2
- Shingles Cytomegalic Inclusion Disease
- Rabies Progressive Multifocal Leukoencephalopathy
- Kuru Fatal Familial Insomnia
- Creutzfeldt- Jakob Disease Gerstraann-Straussler-Scheinker Disease
- Tropical Spastic Paraparesis Western Equine Encephalitis, California Encephalitis, St.
- Methods for treating an Infectious disease including administering to a patient in need thereof a Ligand-Drug Conjugate and another therapeutic agent that is an anti- infectious disease agent.
- a Ligand-Drug Conjugate and another therapeutic agent that is an anti- infectious disease agent.
- the present invention provides pharmaceutical compositions comprising the Ligand- Drug Conjugates described herein and a pharmaceutically acceptable carrier.
- the Ligand-Drug Conjugates can be in any form that allows for the compound to be administered to a patient for treatment of a disorder associated with expression of the antigen to which the Ligand unit binds.
- the conjugates can be in the form of a liquid or solid.
- the preferred route of administration is parenteral. Parenteral administration includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques.
- the compositions are administered parenterally.
- the compounds are administered intravenously.
- the present invention also provides pharmaceutical compositions comprising the Ligand-Functional Agent Conjugates described herein and a pharmaceutically acceptable carrier.
- the Ligand-Drug Conjugates can be in any form that allows for the compound to be
- compositions can be formulated so as to allow a compound to be bioavailable upon administration of the compositi on to a patient.
- Compositions can take the form of one or more dosage units, where for example, a tablet can be a single dosage unit.
- compositions can be non-toxic in the amounts used. It will be evident to those of ordinary skill in the art that the optimal dosage of the active ingredient(s) in the pharmaceutical composition will depend on a variety of factors. Relevant factors include, without limitation, the type of animal (e.g., human), the particular form of the compound, the manner of administration, and the composition employed.
- the composition can be, for example, in the form of a liquid.
- the liquid can be useful for delivery by injection, in a composition for administration by injection, one or more of a surfactant, preservative, wetting agent, dispersing agent, suspending agent, buffer, stabilizer and isotonic agent can also be included.
- the liquid compositions can also include one or more of the following: sterile diluents such as water for injection, saline solution, preferably physiological saline, Ringer's solution, isotonic sodium chloride, fixed oils such as synthetic mono or digyleerides which can serve as the solvent or suspending medium, polyethylene glycols, glycerin, cyclodextrin, propylene glycol or other solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as amino acids, acetates, citrates or phosphates; detergents, such as nonionic surfactants, polyols; and agents for the adjustment of tonicity such as sodium chloride or dextrose.
- sterile diluents such as water for injection, saline solution, preferably physiological saline, Ringer's solution
- a parenteral composition can be enclosed in ampoule, a disposable syringe or a mul tiple-dose vial made of glass, plastic or other material.
- Physiological saline is an exemplary adjuvant.
- An injectable composition is preferably sterile.
- the amount of the conjugate that is effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques, in addition, in vitro or in vivo assays can optionally be employed to help identify optimal dosage ranges,
- the precise dose to be employed in the compositions will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances.
- compositions comprise an effective amount of a compound such that a suitable dosage will be obtained. Typically, this amount is at least about 0.01% of a compound by weight of the composition.
- the composition can comprise from about 0.01 to about 100 mg of a Ligand-Drug Conjugate per kg of the animal's body weight, in one aspect, the composition can include from about I to about 100 mg of a Ligand-Drug Conjugate per kg of the animal's body weight, in another aspect, the amount administered will be in the range from about 0.1 to about 25 mg/kg of body weight of a compound.
- the dosage of a compound administered to a patient is typically about 0.01 mg/kg to about 100 mg/kg of the subject's body weight. In some embodiments, the dosage administered to a patient is between about 0.01 mg/kg to about 35 mg/kg of the subject's body- weight. In some embodiments, the dosage administered to a patient is between about 0.1 mg/kg and about 15 mg/kg of the subject's body weight. In some embodiments, the dosage
- the administered to a patient is between about 0.1 mg/kg and about 20 mg/kg of the subject's body weight. In some embodiments, the dosage administered is between about 0.1 mg/kg io about 5 mg/kg or about 0.1 mg/kg to about 10 mg/kg of the subject's body weight. In some
- the dosage administered is between about 1 mg/kg to about 15 mg/kg of the subject's body weight. In some embodiments, the dosage administered is between about 1 mg/kg to about 10 mg/kg of the subject's body weight. In some embodiments, the dosage administered is between about 0.1 to 4 mg/kg, even more preferably 0.1 to 3.2 mg/kg, or even more preferably 0.1 to 2.7 mg/kg of the subject's body weight over a treatment cycle.
- Ligand-Functional Agent Conjugates e.g., Ligand-Drug Conjugates
- the Ligand-Functional Agent Conjugates can be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g. , oral mucosa, rectal and intestinal mucosa). Administration can be systemic or local.
- Various delivery systems are known, e.g.,
- encapsulation in liposomes, microparticles, microcapsules, capsules can be used to administer a compound.
- more than one compounds or composition is administered to a patient,
- carrier refers to a diluent, adjuvant or excipient, with which a compound is administered.
- Such pharmaceutical carriers can be liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil.
- the carriers can be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea,.
- auxiliary, stabilizing, thickening, lubricating and coloring agents can be used.
- the compound or compositions and pharmaceutically acceptable carriers when administered to a patient, are sterile. Water is an exemplary carrier when the compounds are administered intravenously.
- Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
- suitable pharmaceutical carriers also include excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanoi.
- the present compositions if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
- the conjugates are formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to animals, particularly human beings.
- the carriers or vehicles for intravenous administration are sterile isotonic aqueous buffer solutions.
- the compositions can also include a solubilizing agent.
- Compositions for intravenous administration can optionally comprise a local anesthetic such as lignocaine to ease pain at the site of the injection.
- the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent.
- a conjugate is to be administered by infusion, it can be dispensed, for example, with an infusion bottle containing sterile pharmaceuticaf grade water or saline.
- an ampoule of sterile water for injection or saline can be provided so that the ingredients can be mixed prior to administration.
- compositions are generally formulated as sterile, substantially isotonic and in full compliance with all Good Manufacturing Practice (GMP) regulations of the U.S. Food and Drug Administration.
- GMP Good Manufacturing Practice
- compositions of the present invention comprise the Ligand Drug Conjugates of the present invention and a pharmaceutically acceptable carrier.
- all, or substantially ail. or more than 50% of the Ligand Drug Conjugates present in the pharmaceutical composition comprises a hydrolyzed thio-substituted succinimide.
- more than 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98%, or 99% of the Ligand Drug Conjugates present in the pharmaceutical composition comprises a hydrolyzed thio-substituted succinimide.
- the present invention provides methods of preparing Ligand- Drug Conjugates or Ligand-Functional Agent Conjugates comprising a Self-Stabilizing Linker.
- methods of the present invention comprise the steps of providing a Drug-Linker or Linker unit as described herein, conj gating said Drug-Linker or Linker unit to a sulfhydryl group of a Ligand unit to form a conjugate, allowing the resultant conjugate to undergo a hydrolysis reaction to form a Ligand-Drug conjugate comprising a thio- substituted hydrolyzed succinirnide.
- the rate of the ihio-substitued succinirnide hydrolysis can be manipulated by adjusting the reaction conditions following conjugation of the Drug-Linker to the Ligand, e.g., by adjusting the pH or temperature.
- all, substantially all, or at least 50%, 60%, 70%, 80%, 85%, 90% or even 95% of the thio- substituted succinirnide is hydrolyzed without manipulation of the reaction conditions, i.e., the hydrolysis reaction occurs under the same reaction conditions as the conjugation reaction.
- the conjugation conditions are pH of about 7.4 and a temperature of about 22° C,
- methods for preparing a Ligand-Drug Conjugate comprises the steps of providing a Drug-Linker or Linker unit comprising a Self-Stabilizing Linker;
- a Ligand- Drug Conjugate conjugate comprising a non-hydrolyzed thio-substituted succinirnide; al lowing the non-hydrolyzed thio-substituted succinirnide to undergo a hydrolysis reaction, wherein all, substantially all, or at least 50%, 60%, 70%, 80% or even 85% of the succinirnide is hydrolyzed from 10 minutes to 4 hour's following conjugation.
- all, substantially all, or at least 50%, 60%, 70%, 80%, 85%, 90% or even 95 % of the succinirnide is hydrolyzed by 10 minutes, by 20 minutes, 40 minutes 60 minutes, 90 minutes or 120 minutes following conjugation.
- the hydrolysis reaction occurs under the same reaction conditions as the conjugation reaction.
- the conjugation conditions are pH of about 7.4 and a temperature of about 22° C.
- the present invention provides, inter alia, Self-Stabilizing Linkers. Methods of preparing Self-Stabilizing Linker units are encompassed within the scope of the present invention.
- Maleimide compounds are typically prepared from corresponding amines by reaction of the primary amine with maleic anhydride followed by cyclodehydration of the maleamic acid. The overall scheme for the preparation of maleimde compounds is shown in the scheme below.
- the first step of maleimide preparation the formation of the maleamic acid is very facile and can be usually accomplished in good yield by slow addition of the amine to a suspension containing a stoichiometric excess of the maleic anhydride.
- the second step, cyclodehydration of the maleamic acid can be accomplished in a number of ways known to skilled in the art.
- the use of chemical dehydrating agents has been a well established method for accomplishing this step.
- Carbodiimides in combination with isomerizing alcohols, for example: DCC/HOBt have been used to effect, cyclodehydration of amic acids to maleimides.
- Thermal cyclodehydration with use of azeotropic distillation in the presence of acid catalyst is another well known method to generate maleimides.
- the use of an azeotropic solvent permits the efficient removal of the water co-product as it forms, thereby driving reaction to maleimide.
- Suitable azeotropic solvents include cyclohexane, benzene, toluene, ethylbensene, mesitylene, and the like. Toluene is considered to be the most desirable since it boils at 1 10 °C at atmospheric pressure. Boiling temperatures below 200 °C are preferable to minimize possible thermal isomerization of maleamic acid to the more thermodynamically stable trans (fumaramic acid) structure.
- the use of polar aprotic co-solvents can be beneficial for overall yield improvement as well as reducing time of cyciodehydration.
- Several polar aprotic solvents including
- dimethy!formamide dimethylacetamide, acetonitrile, N-methylpyrrolidone, dimethylsulfoxide, arid sulfonate have been claimed to be useful.
- the most useful polar aprotic solvent is dimethylformamide.
- maleimide compounds can be generated from maleimide and appropriate alcohol using, for example, Mitsunobu reaction conditions as shown in the scheme below (M.A. Walker, Tetrahedron Letters, 1994, v. 35, n 5, pp. 665-668),
- the self-stabilizing linker assembly of the present invention are linked to the Stretcher unit, Cleavable unit, Spacer unit, or Drug unit using the teachings described herein in
- Linkers and Drug-Linkers are conj gated to Ligand units using teachings described herein in combination with methods known in the art.
- an antibody ca be treated with a reducing agent, such as dithiothreitol (DTT) to reduce some or all of the interchain disulfide cysteine residues to form highly nucleophilic cysteine thiol groups.
- DTT dithiothreitol
- the full reduced antibody or partially reduced antibody can be subsequently conjugated to the maleimide of the Linker Unit.
- conjugation conditions are gentle ones, pH of about 7 and a temperature of about 22 °C.
- the present invention provides intermediates for use in making Self-Stabilizirig Linkers. Intermediates include the following wherein T, c, R 31 and R 12 are as previously described.
- self-stabilizing linkers for increasing the hydrolysis rates of mono thio-substituted succinimides, self-stabilizing linkers can also be used to increase the hydrolysis rate of mono-thio-substituted maleimides, di-thio-substituted maleimides, or di-thio- substituted succinimides.
- a Ligand-Functionai Agent Conjugate comprising a Ligand unit and at least one Functional Agent selected from a Drug unit, a Detection unit, or a Stability unit, wherein the Ligand unit and each of the Functional Agent(s) are joined by a self-stabilizing linker assembly comprising a succinimide ring, a maleimide ring, a hydrolyzed succinimide ring or a hydrolyzed maleimide ring wherein the succinimide ring, maleimide ring, hydrolyzed succinimide ring or hydrolyzed maleimide ring is directly conjugated to the Ligand unit via one or two thioether linkages; and a base and an electron withdrawing group operabiy linked to stabilize the conjugate in plasma relative to a Ligand-Functionai Agent Conjugate lacking the self-stabilizing Sinker assembly (i.e.
- the electron withdrawing group is positioned to increase the electrophilicity of the succinimide or maleimide rendering it more reactive with water and the base is positioned to assist the hydrolysis of the succinimide or maleimide ring (e.g., by an intramolecular base catalysis mechanism),
- the Ligand-Functionai Agent Conjugates are represented by- Formula IV or IVa:
- L is a Ligand unit
- LL is a Ligand unit that can be present or absent, wherein L and LL can be the same or different Ligand units;
- D ! is a Drug unit, a Detection unit, or a Stability unit
- L° is an optional secondary linker assembly
- * is a maleimide ring, a hydrolyzed maieimide, a succinimide ring, or a hydrolyzed succinimide conjugated to at least one of L or L ⁇ via a thioether linkage;
- BU is a Basic unit
- HE is a hydrolysis enhancer comprising an electron withdrawing group
- the circle represents a scaffold that can be C; -8 alkylene, Cj. 3 heteroalkylene, aryiene, or C 4-1 o heteroarylene, and optionally comprises a reactive site suitable for attachment to L°, A, W, Y or D';
- the subscripts m, q and r are each 0 or 1 , and the sum of m + q + r is 0, 1 or 2 provided that if m + q + r is 0.
- the scaffold is a Ce- ⁇ aryiene or C4.10 heteroarylene;
- the subscript w' is 0 or 1 ;
- -A- is an optional Stretcher unit
- -A'- is an optional Stretcher unit component at the terminus of A
- a' is 0 or i ;
- u is from 1 to 20, with the proviso that when u is from 2 to 20, A is present, and when u is L A can be present or absent.
- L, HE and BU, L°, A, W, and Y have the meanings provided for the Ligand-Drug Conjugates. Additionally each of the specifically recited selected embodiments for the circle, L, HE, BU, L°, A, W, and Y are equally applicable to these Conjugates.
- L and L L can be different Ligand units or the same Ligand unit, In embodiments, wherein L and L t , are the same Ligand unit, the succinimide or maleimide can be conjugated to the Ligand unit on the same or different polypeptide chains of the Ligand unit.
- m + q + r is 0, 1 or 2
- r is zero.
- the Ligand-Funciional Agent Conjugate is represented by Formula IV or IVa or a salt thereof wherein r and m are zero and q is one.
- the Ligand-Functional Agent Conjugate is represented by Formula IV or IVa or a salt thereof wherein the circle represents a scaffold that is C 1-g alkylene or Cj-g heteroalkylene (preferably C 1 .4 alkylene or C heteroalkylene), r is zero, and the sum ofm+q is 1.
- the scaffold is Q. 3 alkylene or Q.3 heteroalkylene. in some such aspects, the alkylene is straight chain or branched.
- the Ligand-Functional Agent Conjugate is represented by Formula IV or I Va or a salt thereof wherein the circle represents a scaffold that is C 1-8 alkylene or Ci-s heteroalkylene (preferably C alkylene or C].. 4 heteroalkylene), and m and r are zero.
- the scaffold is C 1 .3 alkylene or C1.3 heteroalkylene.
- the alkylene is straight chain or branched.
- the Ligand-Functional Agent Conjugate is represented by Formula IV or IVa or a salt thereof wherein the circle represents a scaffold that is Q, C 2 , C3 or C4 straight or branched chain alkylene, r is zero, and the sum of m+q is 1.
- the Ligand-Functional Agent Conjugate is represented by Formula IV or IVa or a salt thereof wherein the circle represents a scaffold that is Ci , C 2s C 3 or straight or branched chain alkyiene, and m and r are zero.
- n and r are zero and is represented by
- M" is a succinimide ring or hydrolyzed succinimide and Lj_, is present.
- M 2 is a succinimide ring or hydrolyzed succinimide and LL is absent.
- M is a maleimide ring or hydrolyzed maleimide and L L is present.
- M is a maleimide ring or hydrolyzed maleimide and LL is absent.
- when M 2 is a maleimide ring or hydrolyzed maleimide LL is present or absent and when M 2 is a succinimide ring or hydrolyzed succinimide LL is present.
- L and L L when L and L L are present, L and L L can be the same Ligand unit or different Ligand units. In some aspects wherein L and LL are present and are the same Ligand unit, the maleimide or succinimide can be conjugated to the ligand unit on the same or different polypeptide chains of the Ligand unit.
- the alkyiene or heteroaikylene chain can be straight or branched, in some aspects, the alkyiene or heteroaikylene chain will be a straight chain. In other aspects, it will be branched.
- p can range from 1 to 20, preferably 1 to 12, even more 1 to 10 or 1 to 8.
- the scaffold in some aspects wherein the scaffold itself is directly linked to the optional secondary linker assembly or D', (for example, in select embodiments when q is zero or when q is zero and r is zero), the scaffold will comprise a reactive site suitable for attachment to A or D'.
- the maleimide ring can be conjugated to the Ligand unit via one or two thioether linkages as illustrated below both in non-hydrolyzed and hydrolyzed form and the succinimi.
- de ring can be conjugated to the Ligand unit via two thioether linkages as illustrated below in both non-hydrolyzed and hydrolyzed form wherein the wavy line indicates the point of attachment to the remainder of the linker conj ugate or linker-functional agent, conjugate:
- p typically ranges from 3 to 30, or 1 to 8, or 1 to 4 and the maleimide or succinimide can be conjugated to the same or different polypeptide chains of the Ligand.
- the Ligand is an antibody. In other aspects, the Ligand is a non-antibody protein.
- D' is a Drug unit, a Detection unit, or a Stability unit
- L° is an optional secondary linker assembly
- Q and Z are hydrogen or halogen wherein at least one of Q and Z are halogen:
- BU is a Basic unit
- HE is a hydrolysis enhancer comprising an electron withdrawing group
- the circle represents a scaffold that can be Ci.g alkylene, Ci.g heteroalkylene, C$.10 arylene, or C4-S 0 heteroarylene, and optionally comprises a reactive site suitable for attachment to L°, A, W, Y or D';
- the subscripts m, q and r are each 0 or 1 , and the sum of m + q + r is 0, 1 or 2 provided that if m + q + r is 0, the scaffold is a C-6-10 arylene or C4.10 heteroarylene;
- W- is an optional Cleavable unit, the subscript w' is 0 or 1 ; -Y- is an optional Spacer unit, the subscript y' is 0 or i. ,
- A is an optional Stretcher unit
- A' is an optional Stretcher unit component at the terminus of A; a' is 0 or 1 ; and u is from 1 to 20, with the proviso that when u is from 2 to 20, A is present and when u is 1 , A can be present or absent
- the halogen is bromine
- HE and BU, L°, A, W, and Y have the meanings provided for the Drag-Linker Conjugates. Additionally each of the specifically recited selected embodiments for the circle, HE, BU, L°. A, W, and Y are equally applicable to these Conjugates.
- n and r are zero and is represented by
- Ligand-Linker Conjugates having either branched or non-branched linkers can be represented by the following formulas:
- L is a Ligand unit
- LL is a Ligand unit that can be present or absent, wherein L and L
- RG is a reactive group (comprising a reactive site) at the terminus of L° or is suitable for attaching a Drug unit, Detection unit or Stability unit;
- L° is an optional secondary linker assembly that is present
- M 1 is a maleimide ring, a hydrolyzed ma!eirmde, a succinimide ring, or a hydrolyzed succinimide conjugated to at least one of L or LL via a thioether linkage;
- BU is a Basic unit
- HE is a hydrolysis enhancer comprising an electron withdrawing group
- the circle represents a scaffold that can be Cj -8 alkylene, Ci. heteroalkylene, C 6- jo aryiene, or C4.10 heteroarvlene, and optionally comprises a reactive site suitable for attachment to L°, A, W, Y or FA;
- the subscripts m, q and r are each 0 or 1 , and the sum of m + q + r is 0, 1 or 2 provided that if m + q + r is 0, the scaffold is a Q.
- I G aryiene or C4. 10 heteroarylene;
- the subscript p ranges from 1 to 20.
- W- is an optional Cleavable unit, the subscript w ! is 0 or 1 ;
- -Y- is an optional Spacer unit, the subscript y' is 0 or 1 ,
- A is an optional Stretcher unit
- A' is an optional Stretcher unit component at the terminus of A; a' is 0 or 1 ; and u is from 1 to 20, with the proviso that when u is from 2 to 20, A is present and when u is 3 , A can be present or absent.
- L, HE and BU, L°, A, W, and Y have the meanings provided for the Ligand-Drug Conjugates. Additionally each of the specifically recited selected embodiments for the circle, L, HE, BU, L°, A, W, and Y are equally applicable to these Conjugates.
- r and m are zero and is represented by:
- Branched or non-branched Linkers can be represented by the following formulas:
- RG is a reactive group (comprising a reactive site) at the terminus of L
- L is an optional secondary linker assembly that is present:
- Q and Z are hydrogen or halogen wherein at least one of Q and Z are halogen;
- BU is a Basic unit
- HE is a hydrolysis enhancer comprising an electron withdrawing group
- the circle represents a scaffold that can be Ciippog alkyfene, C;_g heteroalkyiene, C 6- io arylene, or C4- 1 0 heteroarylene, and optionally comprises a reactive site suitable for attachment to L°, A, W, Y or RG;
- the subscripts m, q and r are each 0 or 1, and the sum of m + q + r is 0, 1 or 2 provided that if m + q + r is 0, the scaffold is a -io arylene or C 4 . 1 0 heteroarylene;
- W ⁇ is an optional Cleavable unit, the subscript w' is 0 or i ;
- -Y- is an optional Spacer unit.
- the subscript y' is 0 or 1 ,
- A is an optional Stretcher unit
- A' is an optional Stretcher unit component at the terminus of A; a' is 0 or 1 ; and u is from 1 to 20, with the proviso that when u is from 2 to 20, A is present and when u is 1 , A can be present or absent.
- HE and BU, L°, A, W, and Y have the meanings provided for the Ligand-Drug Conjugates. Additionally each of the specifically recited selected embodiments for the circle, HE, BU, L°, A, W, and Y are equally applicable to these Conjugates.
- r and m are zero and is represented by:
- [0331 j mDPR-Val-Cit-PAB- MAE was prepared by coupling Boc-protected mDPR to Val- Cit-PAB-MMAE using standard methods for peptide coupling. The Boe group was removed in the final step.
- MMAE (5.34g, 6,94 mmol), Fmoc-Val-Cit-PAB-OCO-pNP (5.0g, 6.94 mmol) and HOBi (1.4 mmol) were charged to a 250 mi round bottom flask purged with N2 and dissolved in 15 ml of DMA. DIPEA (2.44 ml, 14 mmol) was then added, and the solution was stirred overnight at room temperature under inert atmosphere. The product was isolated by preparative HPLC, using a linear gradient from 30% MeCN (0.05%TFA) to 100% MeCN (0.05% TFA) over 40 min. Fractions containing product were concentrated on the rotovap to a white powder, affording 3.2 g (34%)
- MMAE 100 mg, 0.089 mmol
- HATU 41 mg, 0.107 mmol
- DIPEA 34 uL
- the reaction mixture was diluted with 1 ml DMSO and the product was isolated by preparative HPLC. (70 mg, 56%)
- Y is the observed percent hydrolysis at time t
- Ymax is the asymptotic maximal % hydrolysis
- K is the hydrolysis rate constant.
- Example 5 Evaluating spacing between the maleimide and basic group of the self-stabilizing linker assembly
- an antibody conjugate would have to be held at pH 8 and 37 °C for approximately 5 hours to achieve complete hydrolysis (about 5 half-lives). Exposure of an antibody or other protein to such conditions for extended periods can potentially result in covalent modifications and misfolding events, and so raaleimides with even faster hydrolysis rates were sought.
- This phenomenon may arise from a competing reaction such as direct nucleophilic attack of the primary amine on the succinimide ring, or may be due to an isomeric impurity in the maleimide which leads to biphasic hydrolysis kinetics.
- Example 7 Evaluating spacing between the maleimide and carboxamide group of the self- stabilizing linker assembly
- Both DPR maleimides possess a basic primary amine which is separated from the maleiraido nitrogen by two carbon atoms. Both also possess an electron withdrawing carboxamide group, however the distance from the maleimido nitrogen the carboxaraide varies from 1 to 2 carbon units (a. and ⁇ , respectively). Finajly, the separation between the basic amine and the carboxamide also varies from 1 to 2 carbon units ( ⁇ and a, respectively).
- a self-stabilizing maleimido-drug-iinker was prepared.
- This drug-linker contains the maleimido-DPR group coupled to the cytotoxic agent MMAE via a protease- cleavable val-cit PAB self-imrnolative group (referred to herein as maleimido-DPR-val-cit-PAB- MMAE).
- a non self-stabilizing drug-linker was used (referred to herein as maleimido-caproyl-val-cit-PAB-MMAE).
- the maleimide units of these drug-linkers can be prepared using maleic anhydride and mono -protected diaminopropionic acid and aminocaproic acid, respectively
- DPR diamine roprionyl
- ADCs were prepared with 8 drugs per antibody of either maleimido-DPR-val-cit-PAB-MMAE or maleimido-caproyi-val-cit-PAB-MMAE using a fully reduced humanized IgGl .
- Drug loading was confirmed by reversed-phase HPLC on a polymeric PLRP-S column as described previously (Sun 2005). Complete succinimide hydrolysis of the self-stabilizing linker was also confirmed by electrospray mass spectrometry.
- the ADC prepared with the self-stabilizing DPR maleimido drug-linker exhibited minimal loss of drug over this tirnecourse (from 8.0 to 7.9 drugs per antibody over 14 days), while the ADC prepared with the caproyl maleimido drug-linker lost approximately half of its drug load (from 8.0 to 3.9 drugs per antibody over 14 days) under these conditions.
- ADCs were prepared with 8 drugs per antibody of either maleimido-DPR-val-eit-PAB-M AE or raaleimido-caproyl-vai-cit-PAB-MMAE using a fully reduced human IgGl. These ADCs (0.25 mg/mL) were incubated in sterile rat plasma for 7 days at 37 °C.
- a second assay format was utilized to assess ADC stability in rat and human plasma ex vivo.
- ADCs were prepared with 4 drugs per antibody of either maleimido-DPR-val-cit-PAB- MMAE or maleimido-caproyl-val-cit-PAB-MMAE using a human IgGl partially reduced to a level of 4 thiols per antibody (resulting in an ADC with 4 drugs per antibody).
- These two ADCs were spiked into rat and human plasma and incubated at 37 °C for 7 days. At seven timepoints during this incubation, aliquots were removed and frozen at -80 °C until completion of the timecourse.
- ADCs were then isolated from each sample and MMAE released proteolytically from the isolated ADCs as described previously (Sanderson 2005), The released MMAE was then quantified by LC-MS/MS and normalized to the initial value for each ADC ( Figure 9).
- the ADC prepared with a self- stabilizing maleimide lost little or no drug under these conditions, while approximately half of the drug was lost from a ma!eimido- caproyi ADC.
- the drug:antibody ratio can be measured for ADCs in rat plasma by reversed-phase HPLC analysis following purification with IgSeiect resin. This method was applied to samples derived from an in vivo pharmacokinetic experiment in rats. ADCs were prepared with 4 drugs per antibody of either maleimido-DPR-val-cit-PAB-MMAE or maleimido-caproyl-vai-cit-PAB-MMAE using a humanized IgGl partially reduced to an average of 4 thiols per antibody (resulting in drug : antibody ratio of 4).
- ADCs were further purified as described previously (Sanderson 2005) by hydrophobic interaction chromatography to isolate the species containing 4 drugs per antibody. These ADCs were dosed intravenously at 10 nig/kg in Sprague-Dawley rats. At five timepoints, three animals from each dosing group were sacrificed and the collected blood was processed to plasma and frozen at. -80 °C. Upon completion of the study, all samples were processed by the IgSeiect resin method described above, except that the sample volume, varied. The drug : antibody ratio at each timepoint in this study are plotted in Figure 10.
- the ADC prepared with a self-stabilizing maleimide exhibits minimal loss of drug in vivo, dropping from an initial value of 4.3 drugs per antibody to a value of 3.6 drugs per antibody ( 12% reduction) after 7 days.
- the drug : antibody ratio of an ADC prepared with a maleimido-caproyl linker dropped from an initial value of 3.9 to a value of 1.5 (61 % reduction). This illustrates that the increased stability of a self-stabilizing drug-linker that is observed ex vivo translates into an in vivo setting.
- Example 12 Pharmacokinetics
- maleimido-caproyl ADCs are prone to loss of drug through raaleirnide elimination whereas self-stabilizing maleimide ADCs are not, it is reasonable to predict that exposure to antibody-conjugated drug will be greater following equivalent doses of the two ADCs.
- ADCs were prepared with 4 drugs per antibody of either ma!eimido-DPR-vai-cit-PAB-MMAE or raaleimido-caproyl-val-cit-PAB-MMAE using a human IgG l partially reduced to an average of 4 thiols per antibody (resulting in drug : antibody ratio of 4).
- ADCs were prepared with 4 drugs per antibody of either maleimido-DPR-val-cit-PAB-MMAE or maleimido-caproyl- val-cit-PAB-MMAE using a humanized IgGl (which has no known binding to any rat antigen) partially reduced to an average of 4 thiols per antibody (resulting in an average drug : antibody ratio of 4).
- ADCs w r ere dosed intravenously in female CD®IGS rats (Charles River Laboratories) at 10 mg/kg (6 rats per test article plus 6 rats receiving vehicle only).
- conjugates were prepared with the anti-CD30 antibody cAC iO using drug-sinkers containing the val-cit-PAB-MMAE cytotoxic pay load linked to the antibody via either a maleimido-caproyl group or a self-stabilizing maleimido-DPR group.
- ADCs were evaluated in two separate murine xenograft models of CD30+ human malignancies. In the first mode!
- L428 human Hodgkin Lymphoma cells were implanted subcutaneousiy in female NSG mice and tumors were allowed to grow a volume of approximately 100 mm 3 before dosing at 1 mg kg ever four days for four doses (six mice per dose group).
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Insulating Materials (AREA)
- External Artificial Organs (AREA)
Abstract
Description
Claims
Priority Applications (22)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2014013807A MX368678B (en) | 2012-05-15 | 2013-05-14 | Self-stabilizing linker conjugates. |
SG11201406252WA SG11201406252WA (en) | 2012-05-15 | 2013-05-14 | Self-stabilizing linker conjugates |
NZ630870A NZ630870A (en) | 2012-05-15 | 2013-05-14 | Self-stabilizing linker conjugates |
KR1020237024059A KR20230113821A (en) | 2012-05-15 | 2013-05-14 | Self-stabilizing linker conjugates |
KR1020227042635A KR102557309B1 (en) | 2012-05-15 | 2013-05-14 | Self-stabilizing linker conjugates |
CN201380025771.XA CN104822656B (en) | 2012-05-15 | 2013-05-14 | Self-stabilization linker conjugate |
EP13791383.6A EP2850094B1 (en) | 2012-05-15 | 2013-05-14 | Self-stabilizing linker conjugates |
BR112014028222A BR112014028222A2 (en) | 2012-05-15 | 2013-05-14 | self-stabilizing binding conjugates. |
KR1020217023061A KR102475777B1 (en) | 2012-05-15 | 2013-05-14 | Self-stabilizing linker conjugates |
KR1020207022850A KR102433686B1 (en) | 2012-05-15 | 2013-05-14 | Self-stabilizing linker conjugates |
KR1020147034652A KR102144069B1 (en) | 2012-05-15 | 2013-05-14 | Self-stabilizing linker conjugates |
JP2015512756A JP6423340B2 (en) | 2012-05-15 | 2013-05-14 | Self-stabilizing linker conjugate |
EA201401254A EA037203B1 (en) | 2012-05-15 | 2013-05-14 | Antibody-drug conjugates with self-stabilizing linkers |
CN201810349815.9A CN108465112B (en) | 2012-05-15 | 2013-05-14 | Self-stabilizing linker conjugates |
AU2013263002A AU2013263002C1 (en) | 2012-05-15 | 2013-05-14 | Self-stabilizing linker conjugates |
CA2869777A CA2869777C (en) | 2012-05-15 | 2013-05-14 | Self-stabilizing linker conjugates |
ZA2014/07369A ZA201407369B (en) | 2012-05-15 | 2014-10-10 | Self-stabilizing linker conjugates |
HK15108030.8A HK1207388A1 (en) | 2012-05-15 | 2015-08-19 | Self-stabilizing linker conjugates |
AU2018201190A AU2018201190B2 (en) | 2012-05-15 | 2018-02-19 | Self-stabilizing linker conjugates |
AU2020202805A AU2020202805B2 (en) | 2012-05-15 | 2020-04-28 | Self-stabilizing linker conjugates |
AU2021201636A AU2021201636B2 (en) | 2012-05-15 | 2021-03-16 | Self-stabilizing linker conjugates |
AU2023203005A AU2023203005A1 (en) | 2012-05-15 | 2023-05-15 | Self-stabilizing linker conjugates |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261647373P | 2012-05-15 | 2012-05-15 | |
US61/647,373 | 2012-05-15 | ||
US201361770983P | 2013-02-28 | 2013-02-28 | |
US61/770,983 | 2013-02-28 | ||
US201361773067P | 2013-03-05 | 2013-03-05 | |
US61/773,067 | 2013-03-05 | ||
US13/799,244 US9504756B2 (en) | 2012-05-15 | 2013-03-13 | Self-stabilizing linker conjugates |
US13/799,244 | 2013-03-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013173337A2 true WO2013173337A2 (en) | 2013-11-21 |
WO2013173337A3 WO2013173337A3 (en) | 2015-06-11 |
Family
ID=49584442
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/040951 WO2013173337A2 (en) | 2012-05-15 | 2013-05-14 | Self-stabilizing linker conjugates |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP2850094B1 (en) |
JP (5) | JP6423340B2 (en) |
KR (5) | KR102475777B1 (en) |
CN (2) | CN108465112B (en) |
AU (5) | AU2013263002C1 (en) |
BR (1) | BR112014028222A2 (en) |
CA (2) | CA2869777C (en) |
EA (1) | EA037203B1 (en) |
HK (1) | HK1207388A1 (en) |
MX (2) | MX368678B (en) |
NZ (3) | NZ741211A (en) |
SG (2) | SG11201406252WA (en) |
WO (1) | WO2013173337A2 (en) |
ZA (1) | ZA201407369B (en) |
Cited By (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9144615B2 (en) | 2011-06-10 | 2015-09-29 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
US9254339B2 (en) | 2011-06-10 | 2016-02-09 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
WO2016040684A1 (en) | 2014-09-11 | 2016-03-17 | Seattle Genetics, Inc | Targeted delivery of tertiary amine-containing drug substances |
WO2016054315A1 (en) | 2014-10-01 | 2016-04-07 | Medimmune, Llc | Method of conjugating a polypeptide |
US20160310612A1 (en) * | 2013-10-15 | 2016-10-27 | Seattle Genetics, Inc. | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
WO2016192528A1 (en) | 2015-05-29 | 2016-12-08 | Newbio Therapeutics, Inc. | Trimaleimide Linkers and Uses Thereof |
JP2017531027A (en) * | 2014-07-16 | 2017-10-19 | メドシャイン ディスカバリー インク | Linker and its application to ADC |
WO2017214301A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-egfr antibody drug conjugates |
WO2017214282A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-egfr antibody drug conjugates |
WO2017214339A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
WO2017214335A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
WO2017214233A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-egfr antibody drug conjugates |
WO2017214458A2 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
WO2017214456A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
WO2017214462A2 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
US9849191B2 (en) | 2013-10-11 | 2017-12-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
WO2018031690A1 (en) | 2016-08-09 | 2018-02-15 | Seattle Genetics, Inc. | Drug conjugates with self-stabilizing linkers having improved physiochemical properties |
JP2018507168A (en) * | 2014-12-03 | 2018-03-15 | ジェネンテック, インコーポレイテッド | Quaternary amine compounds and antibody-drug conjugates thereof |
WO2018075692A2 (en) | 2016-10-19 | 2018-04-26 | Invenra Inc. | Antibody constructs |
EP3210623A4 (en) * | 2014-10-24 | 2018-07-04 | NOF Corporation | Antibody-drug complex having cyclic benzylidene acetal linker |
EP3270965A4 (en) * | 2015-03-18 | 2018-09-05 | Seattle Genetics, Inc. | Cd48 antibodies and conjugates thereof |
WO2019033773A1 (en) | 2017-08-14 | 2019-02-21 | Newbio Therapeutics, Inc. | Tetramaleimide linkers and use thereof |
US10316080B2 (en) | 2013-10-11 | 2019-06-11 | Asana Biosciences, Llc | Protein-polymer-drug conjugates |
WO2019236954A1 (en) | 2018-06-07 | 2019-12-12 | Seattle Genetics, Inc. | Camptothecin conjugates |
WO2019234136A1 (en) | 2018-06-05 | 2019-12-12 | King's College London | Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system |
US10689458B2 (en) | 2015-11-30 | 2020-06-23 | Pfizer Inc. | Site specific HER2 antibody drug conjugates |
CN111533778A (en) * | 2015-07-28 | 2020-08-14 | 上海皓元生物医药科技有限公司 | Industrial production method of antibody-conjugated drug linker |
JP2020128378A (en) * | 2014-12-09 | 2020-08-27 | アッヴィ・インコーポレイテッド | Bcl-xl inhibitory compounds and antibody drug conjugates including the same |
JP2020143062A (en) * | 2014-12-09 | 2020-09-10 | アッヴィ・インコーポレイテッド | Bcl-xL INHIBITORY COMPOUNDS HAVING LOW CELL PERMEABILITY AND ANTIBODY DRUG CONJUGATES INCLUDING THE SAME |
WO2021067861A1 (en) | 2019-10-04 | 2021-04-08 | Seagen Inc. | Camptothecin peptide conjugates |
US11091498B2 (en) | 2016-04-04 | 2021-08-17 | Rutgers, The State University Of New Jersey | Topoisomerase poisons |
US11116847B2 (en) | 2013-12-19 | 2021-09-14 | Seagen Inc. | Methylene carbamate linkers for use with targeted-drug conjugates |
US11147852B2 (en) | 2011-12-23 | 2021-10-19 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
WO2021226454A1 (en) * | 2020-05-08 | 2021-11-11 | Mpeg La, L.L.C. | Linker compounds |
US11174318B2 (en) | 2016-12-22 | 2021-11-16 | Università Degli Studi Magna Graecia Catanzaro | Monoclonal antibody targeting a unique sialoglycosylated cancer-associated epitope of CD43 |
US11229708B2 (en) | 2015-12-04 | 2022-01-25 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
US11364303B2 (en) | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
US11389543B2 (en) | 2017-09-08 | 2022-07-19 | Seagen Inc. | Process for the preparation of tubulysins and intermediates thereof |
US11541128B2 (en) | 2016-12-14 | 2023-01-03 | Seagen Inc. | Multi-drug antibody drug conjugates |
WO2023280227A2 (en) | 2021-07-06 | 2023-01-12 | Profoundbio Us Co. | Linkers, drug linkers and conjugates thereof and methods of using the same |
WO2023033129A1 (en) | 2021-09-03 | 2023-03-09 | 東レ株式会社 | Pharmaceutical composition for treating and/or preventing cancer |
EP3991754A4 (en) * | 2019-06-28 | 2023-05-17 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Antibody-drug conjugate, intermediate thereof, preparation method therefor and application thereof |
RU2800137C1 (en) * | 2019-06-28 | 2023-07-19 | Шанхай Фудань-Чжанцзян Био-Фармасьютикал Ко., Лтд. | Antibody-drug conjugate, intermediate for its production, method of its production and its use |
US11730822B2 (en) | 2017-03-24 | 2023-08-22 | Seagen Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
US11759527B2 (en) | 2021-01-20 | 2023-09-19 | Abbvie Inc. | Anti-EGFR antibody-drug conjugates |
WO2023178289A2 (en) | 2022-03-17 | 2023-09-21 | Seagen Inc. | Camptothecin conjugates |
US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
US11844839B2 (en) | 2016-03-25 | 2023-12-19 | Seagen Inc. | Process for the preparation of pegylated drug-linkers and intermediates thereof |
EP4321522A1 (en) | 2022-08-12 | 2024-02-14 | Seagen Inc. | Cytotoxic compounds and conjugates thereof |
WO2024092219A1 (en) * | 2022-10-28 | 2024-05-02 | Eli Lilly And Company | Self-hydrolyzing maleimides for bioconjugation |
WO2024108053A1 (en) | 2022-11-17 | 2024-05-23 | Sanofi | Ceacam5 antibody-drug conjugates and methods of use thereof |
WO2024129756A1 (en) | 2022-12-13 | 2024-06-20 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
US12036286B2 (en) | 2021-03-18 | 2024-07-16 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
WO2024165045A1 (en) * | 2023-02-09 | 2024-08-15 | Beigene, Ltd. | Self-stabilizing linker conjugates |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA037203B1 (en) * | 2012-05-15 | 2021-02-18 | Сиэтл Джинетикс, Инк. | Antibody-drug conjugates with self-stabilizing linkers |
CN109069665A (en) * | 2016-05-10 | 2018-12-21 | 百时美施贵宝公司 | The antibody-drug conjugates of the tubulysin analog of stability with enhancing |
SG11202106122QA (en) * | 2018-12-21 | 2021-07-29 | Seagen Inc | Adcs with thiol multiplex linkers |
CN114306633A (en) * | 2020-09-29 | 2022-04-12 | 迈威(上海)生物科技股份有限公司 | Preparation method of disubstituted bridging antibody coupling drug |
Citations (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0012023A1 (en) | 1978-12-05 | 1980-06-11 | Claude Peter Windsor-Smith | Change speed gear |
EP0171496A2 (en) | 1984-08-15 | 1986-02-19 | Research Development Corporation of Japan | Process for the production of a chimera monoclonal antibody |
EP0173494A2 (en) | 1984-08-27 | 1986-03-05 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by DNA splicing and expression |
WO1986001533A1 (en) | 1984-09-03 | 1986-03-13 | Celltech Limited | Production of chimeric antibodies |
EP0184187A2 (en) | 1984-12-04 | 1986-06-11 | Teijin Limited | Mouse-human chimaeric immunoglobulin heavy chain, and chimaeric DNA encoding it |
WO1987002671A1 (en) | 1985-11-01 | 1987-05-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
US4816397A (en) | 1983-03-25 | 1989-03-28 | Celltech, Limited | Multichain polypeptides or proteins and processes for their production |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
EP0446071A2 (en) | 1990-03-09 | 1991-09-11 | Hybritech Incorporated | Tris-maleimido compounds as intermediates in trifunctional antibody synthesis |
US5122368A (en) | 1988-02-11 | 1992-06-16 | Bristol-Myers Squibb Company | Anthracycline conjugates having a novel linker and methods for their production |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5585089A (en) | 1988-12-28 | 1996-12-17 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US5824805A (en) | 1995-12-22 | 1998-10-20 | King; Dalton | Branched hydrazone linkers |
US5973166A (en) | 1998-03-02 | 1999-10-26 | The Dexter Corporation | Method for the preparation of maleimides |
US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
WO2002088172A2 (en) | 2001-04-30 | 2002-11-07 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
WO2004010957A2 (en) | 2002-07-31 | 2004-02-05 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US20050238649A1 (en) | 2003-11-06 | 2005-10-27 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
WO2005112919A2 (en) | 2004-05-19 | 2005-12-01 | Medarex, Inc. | Self-immolative linkers and drug conjugates |
US20060024317A1 (en) | 2004-05-19 | 2006-02-02 | Medarex, Inc | Chemical linkers and conjugates thereof |
WO2007038658A2 (en) | 2005-09-26 | 2007-04-05 | Medarex, Inc. | Antibody-drug conjugates and methods of use |
WO2007085930A1 (en) | 2006-01-25 | 2007-08-02 | Sanofi-Aventis | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use |
US20090018086A1 (en) | 2005-07-07 | 2009-01-15 | Seattle Genetics, Inc. | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus |
US20090111756A1 (en) | 2005-07-07 | 2009-04-30 | Seattle Genectics, Inc. | Monomethylvaline Compounds Having Phenylalanine Carboxy Modifications at the C-Terminus |
US20090274713A1 (en) | 2008-04-30 | 2009-11-05 | Immunogen Inc. | Cross-linkers and their uses |
WO2010091150A1 (en) | 2009-02-05 | 2010-08-12 | Immunogen, Inc. | Novel benzodiazepine derivatives |
US20110020343A1 (en) | 2008-03-18 | 2011-01-27 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
WO2011023883A1 (en) | 2009-08-25 | 2011-03-03 | Sanofi-Aventis | Conjugates of pyrrolo[1,4]benzodiazepine dimers as anticancer agents |
US7968687B2 (en) | 2007-10-19 | 2011-06-28 | Seattle Genetics, Inc. | CD19 binding agents and uses thereof |
US20110256157A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
US8142784B2 (en) | 2004-06-01 | 2012-03-27 | Genentech, Inc. | Antibody-drug conjugates and methods |
US8163888B2 (en) | 2003-10-10 | 2012-04-24 | Immunogen, Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates |
WO2012112708A1 (en) | 2011-02-15 | 2012-08-23 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and methods of preparation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07508550A (en) * | 1992-07-01 | 1995-09-21 | アクゾ ノーベル ナムローゼ フェンノートシャップ | Method of modifying polyphenylene ether resin composition |
US8877901B2 (en) * | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
US7432331B2 (en) * | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
US20110288011A1 (en) * | 2008-12-05 | 2011-11-24 | Jean-Paul Castaigne | Peptide therapeutic conjugates and uses thereof |
PL3903829T3 (en) * | 2009-02-13 | 2023-08-14 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
EP2629801B3 (en) * | 2010-10-22 | 2019-11-27 | Seattle Genetics, Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway |
EA037203B1 (en) | 2012-05-15 | 2021-02-18 | Сиэтл Джинетикс, Инк. | Antibody-drug conjugates with self-stabilizing linkers |
EP2968591A1 (en) * | 2013-03-15 | 2016-01-20 | Novartis AG | Cell proliferation inhibitors and conjugates thereof |
-
2013
- 2013-05-14 EA EA201401254A patent/EA037203B1/en unknown
- 2013-05-14 CA CA2869777A patent/CA2869777C/en active Active
- 2013-05-14 KR KR1020217023061A patent/KR102475777B1/en active IP Right Grant
- 2013-05-14 KR KR1020207022850A patent/KR102433686B1/en active IP Right Grant
- 2013-05-14 JP JP2015512756A patent/JP6423340B2/en active Active
- 2013-05-14 SG SG11201406252WA patent/SG11201406252WA/en unknown
- 2013-05-14 NZ NZ74121113A patent/NZ741211A/en unknown
- 2013-05-14 BR BR112014028222A patent/BR112014028222A2/en not_active Application Discontinuation
- 2013-05-14 CN CN201810349815.9A patent/CN108465112B/en active Active
- 2013-05-14 SG SG10201608904YA patent/SG10201608904YA/en unknown
- 2013-05-14 NZ NZ630870A patent/NZ630870A/en unknown
- 2013-05-14 KR KR1020227042635A patent/KR102557309B1/en active IP Right Grant
- 2013-05-14 AU AU2013263002A patent/AU2013263002C1/en active Active
- 2013-05-14 WO PCT/US2013/040951 patent/WO2013173337A2/en active Application Filing
- 2013-05-14 CN CN201380025771.XA patent/CN104822656B/en active Active
- 2013-05-14 NZ NZ724892A patent/NZ724892A/en unknown
- 2013-05-14 MX MX2014013807A patent/MX368678B/en active IP Right Grant
- 2013-05-14 EP EP13791383.6A patent/EP2850094B1/en active Active
- 2013-05-14 KR KR1020147034652A patent/KR102144069B1/en active Application Filing
- 2013-05-14 CA CA3131619A patent/CA3131619A1/en not_active Abandoned
- 2013-05-14 KR KR1020237024059A patent/KR20230113821A/en not_active Application Discontinuation
-
2014
- 2014-10-10 ZA ZA2014/07369A patent/ZA201407369B/en unknown
- 2014-11-13 MX MX2019012201A patent/MX2019012201A/en unknown
-
2015
- 2015-08-19 HK HK15108030.8A patent/HK1207388A1/en unknown
-
2018
- 2018-02-19 AU AU2018201190A patent/AU2018201190B2/en active Active
- 2018-05-21 JP JP2018097123A patent/JP6709247B2/en active Active
-
2020
- 2020-04-28 AU AU2020202805A patent/AU2020202805B2/en active Active
- 2020-05-22 JP JP2020089453A patent/JP7014856B2/en active Active
-
2021
- 2021-03-16 AU AU2021201636A patent/AU2021201636B2/en active Active
-
2022
- 2022-01-20 JP JP2022007056A patent/JP7431261B2/en active Active
-
2023
- 2023-05-15 AU AU2023203005A patent/AU2023203005A1/en active Pending
-
2024
- 2024-02-01 JP JP2024014096A patent/JP2024032941A/en active Pending
Patent Citations (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0012023A1 (en) | 1978-12-05 | 1980-06-11 | Claude Peter Windsor-Smith | Change speed gear |
US4816397A (en) | 1983-03-25 | 1989-03-28 | Celltech, Limited | Multichain polypeptides or proteins and processes for their production |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0171496A2 (en) | 1984-08-15 | 1986-02-19 | Research Development Corporation of Japan | Process for the production of a chimera monoclonal antibody |
EP0173494A2 (en) | 1984-08-27 | 1986-03-05 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by DNA splicing and expression |
WO1986001533A1 (en) | 1984-09-03 | 1986-03-13 | Celltech Limited | Production of chimeric antibodies |
EP0184187A2 (en) | 1984-12-04 | 1986-06-11 | Teijin Limited | Mouse-human chimaeric immunoglobulin heavy chain, and chimaeric DNA encoding it |
WO1987002671A1 (en) | 1985-11-01 | 1987-05-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
US5122368A (en) | 1988-02-11 | 1992-06-16 | Bristol-Myers Squibb Company | Anthracycline conjugates having a novel linker and methods for their production |
US5585089A (en) | 1988-12-28 | 1996-12-17 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0446071A2 (en) | 1990-03-09 | 1991-09-11 | Hybritech Incorporated | Tris-maleimido compounds as intermediates in trifunctional antibody synthesis |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US5824805A (en) | 1995-12-22 | 1998-10-20 | King; Dalton | Branched hydrazone linkers |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
US5973166A (en) | 1998-03-02 | 1999-10-26 | The Dexter Corporation | Method for the preparation of maleimides |
US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
WO2002088172A2 (en) | 2001-04-30 | 2002-11-07 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US20050009751A1 (en) | 2001-04-30 | 2005-01-13 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
WO2004010957A2 (en) | 2002-07-31 | 2004-02-05 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US7659241B2 (en) | 2002-07-31 | 2010-02-09 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US8163888B2 (en) | 2003-10-10 | 2012-04-24 | Immunogen, Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates |
US20050238649A1 (en) | 2003-11-06 | 2005-10-27 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
WO2005112919A2 (en) | 2004-05-19 | 2005-12-01 | Medarex, Inc. | Self-immolative linkers and drug conjugates |
US20060024317A1 (en) | 2004-05-19 | 2006-02-02 | Medarex, Inc | Chemical linkers and conjugates thereof |
US8142784B2 (en) | 2004-06-01 | 2012-03-27 | Genentech, Inc. | Antibody-drug conjugates and methods |
US20090111756A1 (en) | 2005-07-07 | 2009-04-30 | Seattle Genectics, Inc. | Monomethylvaline Compounds Having Phenylalanine Carboxy Modifications at the C-Terminus |
US20090018086A1 (en) | 2005-07-07 | 2009-01-15 | Seattle Genetics, Inc. | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus |
US8343928B2 (en) | 2005-07-07 | 2013-01-01 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus |
WO2007038658A2 (en) | 2005-09-26 | 2007-04-05 | Medarex, Inc. | Antibody-drug conjugates and methods of use |
WO2007085930A1 (en) | 2006-01-25 | 2007-08-02 | Sanofi-Aventis | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use |
US7968687B2 (en) | 2007-10-19 | 2011-06-28 | Seattle Genetics, Inc. | CD19 binding agents and uses thereof |
US20110020343A1 (en) | 2008-03-18 | 2011-01-27 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
US20090274713A1 (en) | 2008-04-30 | 2009-11-05 | Immunogen Inc. | Cross-linkers and their uses |
WO2010091150A1 (en) | 2009-02-05 | 2010-08-12 | Immunogen, Inc. | Novel benzodiazepine derivatives |
WO2011023883A1 (en) | 2009-08-25 | 2011-03-03 | Sanofi-Aventis | Conjugates of pyrrolo[1,4]benzodiazepine dimers as anticancer agents |
US20110256157A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
WO2012112708A1 (en) | 2011-02-15 | 2012-08-23 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and methods of preparation |
Non-Patent Citations (35)
Title |
---|
ALLEY ET AL., BIOCONJUGATE CHEM, vol. 19, 2008, pages 759 - 765 |
AMSBERRY ET AL., J. ORG. CHEM., vol. 55, 1990, pages 5867 |
BEIDLER ET AL., J. IMMUNOL., vol. 141, 1988, pages 4053 - 4060 |
CHARI ET AL., CANCER RES., vol. 52, 1992, pages 127 - 131 |
DUBOWCHIKWALKER, PHARM. THERAPEUTICS, vol. 83, 1999, pages 67 - 123 |
H. N. BORAH ET AL., J. CHEM. RESEARCH (S, 1998, pages 272 - 272 |
HAY ET AL., BIOORG. MED. CHEM. LETT., vol. 9, 1999, pages 2237 |
JONES ET AL., NATURE, vol. 321, 1986, pages 552 - 525 |
KABAT E ET AL., J. IMMUNOLOGY, vol. 125, no. 3, 1980, pages 961 - 969 |
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, NATIONAL INSTITUTE OF HEALTH |
KINGSBURY ET AL., J. MED. CHEM., vol. 27, 1984, pages 1447 |
KOZBOR ET AL., IMMUNOLOGY TODAY, vol. 4, 1983, pages 72 - 79 |
LIU ET AL., J. IMMUNOL., vol. 139, 1987, pages 3521 - 3526 |
M.A. WALKER, TETRAHEDRON LETTERS, vol. 35, no. 5, 1994, pages 665 - 668 |
MORRISON, SCIENCE, vol. 229, 1985, pages 1202 - 1207 |
NEVILLE ET AL., BIOL. CHEM., vol. 264, 1989, pages 14653 - 14661 |
NISHIMURA ET AL., CANCER. RES., vol. 47, 1987, pages 999 - 1005 |
OI ET AL., BIOTECHNIQUES, vol. 4, 1986, pages 214 |
OLSSON ET AL., METH. ENZYMOL., vol. 92, 1982, pages 3 - 16 |
PAGE ET AL., INTL. J. OF ONCOLOGY, vol. 3, 1993, pages 473 - 476 |
RODRIGUES ET AL., CHEMISTRY BIOLOGY, vol. 2, 1995, pages 223 |
RYAN ET AL., CHEM. COMMUN., vol. 47, 2011, pages 5452 - 5454 |
SHAW ET AL., J. NATL. CANCER INST., vol. 80, 1988, pages 1553 - 1559 |
SHEN ET AL., NATURE BIOTECH, vol. 30, no. 2, 2012, pages 184 - 9 |
SKEHAN ET AL., J. NAT'L CANCER INST., vol. 82, 1990, pages 1107 - 12 |
SMITH ET AL., J. AM. CHEM. SOC., vol. 132, no. 6, 2010, pages 1960 - 1965 |
STEPHEN C. ALLEY ET AL., BIOCONJUGATE CHEMISTRY, vol. 19, no. 3, 1 March 2008 (2008-03-01), pages 759 - 765 |
STORM ET AL., J. AMER. CHEM. SOC., vol. 94, 1972, pages 5815 |
SUN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 3439 - 3443 |
TENG ET AL., PROC. NATL. ACAD. SCI. USA., vol. 80, 1983, pages 7308 - 7312 |
THORPE ET AL., CANCER RES., vol. 47, 1987, pages 5924 - 5931 |
V. ONDRUS, ARKIVOC, vol. 60-67, 2001 |
VERHOEYAN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1043 |
WAWRZYNCZAK ET AL.: "Immunoconjugates: Antibody Conjugates in Radioimagery and Therapy of Cancer", 1987, OXFORD U. PRESS |
WOOD ET AL., NATURE, vol. 314, 1985, pages 446 - 449 |
Cited By (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9770519B2 (en) | 2011-06-10 | 2017-09-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
US9254339B2 (en) | 2011-06-10 | 2016-02-09 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
US10603386B2 (en) | 2011-06-10 | 2020-03-31 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
US10537645B2 (en) | 2011-06-10 | 2020-01-21 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
US9943609B2 (en) | 2011-06-10 | 2018-04-17 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
US9144615B2 (en) | 2011-06-10 | 2015-09-29 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
US11147852B2 (en) | 2011-12-23 | 2021-10-19 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
US10316080B2 (en) | 2013-10-11 | 2019-06-11 | Asana Biosciences, Llc | Protein-polymer-drug conjugates |
US11434278B2 (en) | 2013-10-11 | 2022-09-06 | Asana Biosciences, Llc | Protein-polymer-drug conjugates |
US9849191B2 (en) | 2013-10-11 | 2017-12-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
US11103593B2 (en) | 2013-10-15 | 2021-08-31 | Seagen Inc. | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
EP3057585B1 (en) | 2013-10-15 | 2020-07-22 | Seattle Genetics, Inc. | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
US20160310612A1 (en) * | 2013-10-15 | 2016-10-27 | Seattle Genetics, Inc. | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
US11116847B2 (en) | 2013-12-19 | 2021-09-14 | Seagen Inc. | Methylene carbamate linkers for use with targeted-drug conjugates |
JP2017531027A (en) * | 2014-07-16 | 2017-10-19 | メドシャイン ディスカバリー インク | Linker and its application to ADC |
JP2020079251A (en) * | 2014-07-16 | 2020-05-28 | メドシャイン ディスカバリー インク | Linker and its application to ADC |
JP7042291B2 (en) | 2014-07-16 | 2022-03-25 | メドシャイン ディスカバリー インク | Its application to linkers and ADCs |
TWI701049B (en) * | 2014-09-11 | 2020-08-11 | 美商西雅圖遺傳學公司 | Targeted delivery of tertiary amine-containing drug substances |
TWI813394B (en) * | 2014-09-11 | 2023-08-21 | 美商思進公司 | Targeted delivery of tertiary amine-containing drug substances |
CN114732916A (en) * | 2014-09-11 | 2022-07-12 | 西雅图基因公司 | Targeted delivery of tertiary amine-containing drug substances |
EP3191502A4 (en) * | 2014-09-11 | 2018-04-25 | Seattle Genetics, Inc. | Targeted delivery of tertiary amine-containing drug substances |
TWI794617B (en) * | 2014-09-11 | 2023-03-01 | 美商西雅圖遺傳學公司 | Targeted delivery of tertiary amine-containing drug substances |
WO2016040684A1 (en) | 2014-09-11 | 2016-03-17 | Seattle Genetics, Inc | Targeted delivery of tertiary amine-containing drug substances |
CN114732916B (en) * | 2014-09-11 | 2023-12-19 | 西雅图基因公司 | Targeted delivery of tertiary amine-containing drug substances |
EP3900742A1 (en) * | 2014-09-11 | 2021-10-27 | Seagen Inc. | Targeted delivery of tertiary amine-containing drug substances |
TWI769478B (en) * | 2014-09-11 | 2022-07-01 | 美商西雅圖遺傳學公司 | Targeted delivery of tertiary amine-containing drug substances |
WO2016054315A1 (en) | 2014-10-01 | 2016-04-07 | Medimmune, Llc | Method of conjugating a polypeptide |
US10377837B2 (en) | 2014-10-24 | 2019-08-13 | Nof Corporation | Antibody-drug conjugate having cyclic benzylidene acetal linker |
US10808050B2 (en) | 2014-10-24 | 2020-10-20 | Nof Corporation | Antibody-drug conjugate having cyclic benzylidene acetal linker |
EP3210623A4 (en) * | 2014-10-24 | 2018-07-04 | NOF Corporation | Antibody-drug complex having cyclic benzylidene acetal linker |
JP2018507168A (en) * | 2014-12-03 | 2018-03-15 | ジェネンテック, インコーポレイテッド | Quaternary amine compounds and antibody-drug conjugates thereof |
JP2020143062A (en) * | 2014-12-09 | 2020-09-10 | アッヴィ・インコーポレイテッド | Bcl-xL INHIBITORY COMPOUNDS HAVING LOW CELL PERMEABILITY AND ANTIBODY DRUG CONJUGATES INCLUDING THE SAME |
JP2020128378A (en) * | 2014-12-09 | 2020-08-27 | アッヴィ・インコーポレイテッド | Bcl-xl inhibitory compounds and antibody drug conjugates including the same |
EP3662933A1 (en) * | 2015-03-18 | 2020-06-10 | Seattle Genetics, Inc. | Cd48 antibodies and conjugates thereof |
US10722592B2 (en) | 2015-03-18 | 2020-07-28 | Seattle Genetics, Inc. | CD48 antibodies and conjugates thereof |
EP3270965A4 (en) * | 2015-03-18 | 2018-09-05 | Seattle Genetics, Inc. | Cd48 antibodies and conjugates thereof |
WO2016192528A1 (en) | 2015-05-29 | 2016-12-08 | Newbio Therapeutics, Inc. | Trimaleimide Linkers and Uses Thereof |
CN111533778B (en) * | 2015-07-28 | 2023-04-25 | 上海皓元生物医药科技有限公司 | Industrial production method of antibody-coupled drug connector |
CN111533778A (en) * | 2015-07-28 | 2020-08-14 | 上海皓元生物医药科技有限公司 | Industrial production method of antibody-conjugated drug linker |
US10689458B2 (en) | 2015-11-30 | 2020-06-23 | Pfizer Inc. | Site specific HER2 antibody drug conjugates |
US11229708B2 (en) | 2015-12-04 | 2022-01-25 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
US11844839B2 (en) | 2016-03-25 | 2023-12-19 | Seagen Inc. | Process for the preparation of pegylated drug-linkers and intermediates thereof |
US11091498B2 (en) | 2016-04-04 | 2021-08-17 | Rutgers, The State University Of New Jersey | Topoisomerase poisons |
WO2017214335A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
WO2017214301A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-egfr antibody drug conjugates |
WO2017214282A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-egfr antibody drug conjugates |
EP3888689A1 (en) | 2016-06-08 | 2021-10-06 | AbbVie Inc. | Anti-egfr antibody drug conjugates |
WO2017214462A2 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
WO2017214456A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
EP4104865A1 (en) | 2016-06-08 | 2022-12-21 | AbbVie Inc. | Anti-egfr antibody drug conjugates |
WO2017214339A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
EP4364754A2 (en) | 2016-06-08 | 2024-05-08 | AbbVie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
WO2017214458A2 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
US10640563B2 (en) | 2016-06-08 | 2020-05-05 | Abbvie Inc. | Anti-B7-H3 antibodies and antibody drug conjugates |
WO2017214233A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-egfr antibody drug conjugates |
AU2017310436B2 (en) * | 2016-08-09 | 2022-08-25 | Seagen Inc. | Drug conjugates with self-stabilizing linkers having improved physiochemical properties |
WO2018031690A1 (en) | 2016-08-09 | 2018-02-15 | Seattle Genetics, Inc. | Drug conjugates with self-stabilizing linkers having improved physiochemical properties |
EP3496747A4 (en) * | 2016-08-09 | 2020-04-15 | Seattle Genetics, Inc. | Drug conjugates with self-stabilizing linkers having improved physiochemical properties |
US11944689B2 (en) | 2016-08-09 | 2024-04-02 | Seagen Inc. | Drug conjugates with self-stabilizing linkers having improved physiochemical properties |
WO2018075692A2 (en) | 2016-10-19 | 2018-04-26 | Invenra Inc. | Antibody constructs |
US11541128B2 (en) | 2016-12-14 | 2023-01-03 | Seagen Inc. | Multi-drug antibody drug conjugates |
US11174318B2 (en) | 2016-12-22 | 2021-11-16 | Università Degli Studi Magna Graecia Catanzaro | Monoclonal antibody targeting a unique sialoglycosylated cancer-associated epitope of CD43 |
US11965033B2 (en) | 2016-12-22 | 2024-04-23 | Università Degli Studi Magna Graecia Catanzaro | Monoclonal antibody targeting a unique sialoglycosylated cancer-associated epitope of CD43 |
US11730822B2 (en) | 2017-03-24 | 2023-08-22 | Seagen Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
WO2019033773A1 (en) | 2017-08-14 | 2019-02-21 | Newbio Therapeutics, Inc. | Tetramaleimide linkers and use thereof |
US11389543B2 (en) | 2017-09-08 | 2022-07-19 | Seagen Inc. | Process for the preparation of tubulysins and intermediates thereof |
US11364303B2 (en) | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
WO2019234136A1 (en) | 2018-06-05 | 2019-12-12 | King's College London | Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system |
WO2019236954A1 (en) | 2018-06-07 | 2019-12-12 | Seattle Genetics, Inc. | Camptothecin conjugates |
RU2800137C1 (en) * | 2019-06-28 | 2023-07-19 | Шанхай Фудань-Чжанцзян Био-Фармасьютикал Ко., Лтд. | Antibody-drug conjugate, intermediate for its production, method of its production and its use |
EP3991754A4 (en) * | 2019-06-28 | 2023-05-17 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Antibody-drug conjugate, intermediate thereof, preparation method therefor and application thereof |
WO2021067861A1 (en) | 2019-10-04 | 2021-04-08 | Seagen Inc. | Camptothecin peptide conjugates |
WO2021226454A1 (en) * | 2020-05-08 | 2021-11-11 | Mpeg La, L.L.C. | Linker compounds |
US11759527B2 (en) | 2021-01-20 | 2023-09-19 | Abbvie Inc. | Anti-EGFR antibody-drug conjugates |
US12036286B2 (en) | 2021-03-18 | 2024-07-16 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
WO2023280227A2 (en) | 2021-07-06 | 2023-01-12 | Profoundbio Us Co. | Linkers, drug linkers and conjugates thereof and methods of using the same |
US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
WO2023033129A1 (en) | 2021-09-03 | 2023-03-09 | 東レ株式会社 | Pharmaceutical composition for treating and/or preventing cancer |
WO2023178289A2 (en) | 2022-03-17 | 2023-09-21 | Seagen Inc. | Camptothecin conjugates |
EP4321522A1 (en) | 2022-08-12 | 2024-02-14 | Seagen Inc. | Cytotoxic compounds and conjugates thereof |
WO2024092219A1 (en) * | 2022-10-28 | 2024-05-02 | Eli Lilly And Company | Self-hydrolyzing maleimides for bioconjugation |
WO2024108053A1 (en) | 2022-11-17 | 2024-05-23 | Sanofi | Ceacam5 antibody-drug conjugates and methods of use thereof |
WO2024129756A1 (en) | 2022-12-13 | 2024-06-20 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
WO2024165045A1 (en) * | 2023-02-09 | 2024-08-15 | Beigene, Ltd. | Self-stabilizing linker conjugates |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020202805B2 (en) | Self-stabilizing linker conjugates | |
US20210300867A1 (en) | Self-stabilizing linker conjugates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13791383 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2013263002 Country of ref document: AU Date of ref document: 20130514 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2869777 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 122022019441 Country of ref document: BR Ref document number: 2013791383 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2015512756 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2014/013807 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20147034652 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201401254 Country of ref document: EA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014028222 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014028222 Country of ref document: BR Kind code of ref document: A2 Effective date: 20141112 |